

10/574,087

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1611bxv

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS	3	AUG 06	FSTA enhanced with new thesaurus edition
NEWS	4	AUG 13	CA/CAPplus enhanced with additional kind codes for granted patents
NEWS	5	AUG 20	CA/CAPplus enhanced with CAS indexing in pre-1907 records
NEWS	6	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS	7	AUG 27	USPATOLD now available on STN
NEWS	8	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS	9	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS	10	SEP 13	FORIS renamed to SOFIS
NEWS	11	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS	12	SEP 17	CA/CAPplus enhanced with printed CA page images from 1967-1998
NEWS	13	SEP 17	CAPplus coverage extended to include traditional medicine patents
NEWS	14	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	15	OCT 02	CA/CAPplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS	16	OCT 19	BEILSTEIN updated with new compounds
NEWS	17	NOV 15	Derwent Indian patent publication number format enhanced
NEWS	18	NOV 19	WPIX enhanced with XML display format
NEWS	19	NOV 30	ICSD reloaded with enhancements
NEWS	20	DEC 04	LINPADOCDB now available on STN
NEWS	21	DEC 14	BEILSTEIN pricing structure to change
NEWS	22	DEC 17	USPATOLD added to additional database clusters
NEWS	23	DEC 17	IMSDRUGCONF removed from database clusters and STN
NEWS	24	DEC 17	DGENE now includes more than 10 million sequences
NEWS	25	DEC 17	TOXCENTER enhanced with 2008 MeSH vocabulary in MEDLINE segment
NEWS	26	DEC 17	MEDLINE and LMEMLINE updated with 2008 MeSH vocabulary
NEWS	27	DEC 17	CA/CAPplus enhanced with new custom IPC display formats
NEWS	28	DEC 17	STN Viewer enhanced with full-text patent content from USPATOLD
NEWS	29	JAN 02	STN pricing information for 2008 now available
NEWS	30	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

10/574,087

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 09:41:35 ON 21 JAN 2008

```
=> file reg
COST IN U.S. DOLLARS                SINCE FILE      TOTAL
                                     ENTRY      SESSION
FULL ESTIMATED COST                0.21          0.21
```

FILE 'REGISTRY' ENTERED AT 09:41:50 ON 21 JAN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 20 JAN 2008 HIGHEST RN 1000368-36-4
DICTIONARY FILE UPDATES: 20 JAN 2008 HIGHEST RN 1000368-36-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>
Uploading C:\Program Files\Stnexp\Queries\10574087.str

10/574,087



chain nodes :
18 19 20 21
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
chain bonds :
5-7 10-13 18-19 20-21
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-17
14-15 15-16 16-17
exact/norm bonds :
5-7 7-8 7-12 8-9 9-10 10-11 10-13 11-12 13-14 13-17 14-15 15-16 16-17
18-19 20-21
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 : 7 : 13 :

G1:CH2, [*1], [*2]

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS 19:CLASS
20:CLASS 21:CLASS



10/574,087

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 CH2, [01], [02]

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 09:42:13 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 3648 TO ITERATE

54.8% PROCESSED 2000 ITERATIONS

33 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 69338 TO 76582


PROJECTED ANSWERS: 738 TO 1668

L2 33 SEA SSS SAM L1

=> d scan

10/574,087

L2 33 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Methanone, [4-amino-2-[[4-(3-hydroxy[1,4'-bipiperidin]-1'-yl)phenyl]amino]-
5-thiazolyl](3-fluorophenyl)-
MF C26 H30 F N5 O2 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):32

10/574,087

L2 33 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1,4'-Bipiperidine, 4-[(2,5-difluorophenyl)methyl]-1'-(3-fluoro-4-methoxyphenyl)-
MF C24 H29 F3 N2 O




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/574,087

L2 33 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Benzamide, N-[2-[[(3R)-1-[1-(4-cyanophenyl)-4-piperidinyl]-3-pyrrolidinyl]amino]-2-oxoethyl]-3-(trifluoromethyl)-
MF C26 H28 F3 N5 O2

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/574,087

L2 33 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Benzeneacetamide, 3,4-difluoro-N-[(3R)-1-[1-(2-nitrophenyl)-4-piperidinyl]-
3-pyrrolidinyl]-
MF C23 H26 F2 N4 O3
CI COM

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/574,087

L2 33 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Thieno[2,3-b]pyridine-5-carboxamide, N-[(3S)-1-[1-(4-fluorophenyl)-4-
piperidinyl]-3-pyrrolidinyl]-4-methoxy-2-methyl-
MF C25 H29 F N4 O2 S


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/574,087


L2 33 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Methanone, [4-amino-2-[[4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]amino]-
5-thiazolyl](4-nitrophenyl)-
MF C25 H28 N6 O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/574,087

L2 33 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1,4'-Bipiperidine, 4-[(2-bromo-5-fluorophenyl)methyl]-1'-(3-fluoro-4-methoxyphenyl)-
MF C24 H29 Br F2 N2 O




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/574,087

L2 33 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Benzamide, N-[2-[[(3R)-1-[1-(2-methoxyphenyl)-4-piperidinyl]-3-pyrrolidinyl]amino]-2-oxoethyl]-3-(trifluoromethyl)-
MF C26 H31 F3 N4 O3


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/574,087

L2 33 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Benzenesulfonamide, 2-[[2-[(4-[1,4'-bipiperidin]-1'-yl-2-ethoxyphenyl)amino]-5-chloro-4-pyrimidinyl]amino]-N-(cyclopropylmethyl)-
MF C32 H42 Cl N7 O3 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/574,087

L2 33 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 5-Pyrimidinecarboxylic acid, 1-[[[1'-(2-cyanophenyl)[1,4'-bipiperidin]-4-yl]methyl]amino]carbonyl]-6-(3,4-difluorophenyl)-1,2,3,6-tetrahydro-4-(methoxymethyl)-2-oxo-, methyl ester, (6S)-
MF C33 H38 F2 N6 O5
CI COM


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/574,087


L2 33 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Methanone, [4-amino-2-[(4-[1,4'-bipiperidin]-1'-ylphenyl)amino]-5-
thiazolyl](4-chloro-3-nitrophenyl)-
MF C26 H29 Cl N6 O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/574,087

L2 33 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1,4'-Bipiperidine, 4-[(2-chlorophenyl)methyl]-1'-(2,3-dimethoxyphenyl)-
MF C25 H33 Cl N2 O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/574,087

L2 33 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1H-Benzimidazole-2-acetamide, N-[(3R)-1-[1-(4-fluorophenyl)-4-piperidinyl]-
3-pyrrolidinyl]-7-(trifluoromethyl)-
MF C25 H27 F4 N5 O


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/574,087


L2 33 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Benzenesulfonamide, 2-[[2-[[4-[1,4'-bipiperidin]-1'-yl]-2-(
(cyclopropylmethoxy)phenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-methyl-
MF C31 H40 Cl N7 O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/574,087


L2 33 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Benzonitrile, 2-[3-(hydroxymethyl)[1,4'-bipiperidin]-1'-yl]-
MF C18 H25 N3 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/574,087


L2 33 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Methanone, [4-amino-2-[[4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]amino]-
5-thiazolyl](4-fluorophenyl)-
MF C25 H28 F N5 O S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/574,087

L2 33 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Benzonitrile, 3-[4-[(3-methoxyphenyl)methyl][1,4'-bipiperidin]-1'-yl]-
MF C25 H31 N3 O




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/574,087

L2 33 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Benzamide, N-[2-[[(3R)-1-[1-(2-methylphenyl)-4-piperidinyl]-3-
pyrrolidinyl]amino]-2-oxoethyl]-3-(trifluoromethyl)-
MF C26 H31 F3 N4 O2


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/574,087

L2 33 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Benzamide, 2-[[2-[[4-[1,4'-bipiperidin]-1'-yl]-2-(trifluoromethyl)phenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-ethyl-
MF C30 H35 Cl F3 N7 O




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/574,087

L2 33 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-Oxazolidinecarboxamide, N-[[1'-(2-cyanophenyl)[1,4'-bipiperidin]-4-yl]methyl]-4-(3,4-difluorophenyl)-2-oxo-, (4S)-
MF C28 H31 F2 N5 O3
CI COM


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/574,087


L2 33 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Methanone, [4-amino-2-[[4-(3-hydroxy[1,4'-bipiperidin]-1'-yl)phenyl]amino]-
5-thiazolyl](3,4-dichlorophenyl)-
MF C26 H29 Cl2 N5 O2 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/574,087

L2 33 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1,4'-Bipiperidine, 4-[(2,5-dichlorophenyl)methyl]-1'-(4,5-dimethoxy-2-methylphenyl)-
MF C26 H34 Cl2 N2 O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/574,087

L2 33 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1,3(2H,4H)-Isoquinolinedione, 4-[[[3-fluoro-4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]amino]methylene]-6-(3-thienyl)-, (4Z)-
MF C29 H29 F N4 O2 S


Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/574,087

L2 33 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Benzamide, 4-[1,4'-bipiperidin]-1'-yl-N-methyl-N-[1-(2-pyrimidinyl)-4-
piperidinyl]-
MF C27 H38 N6 O




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/574,087

L2 33 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-Oxazolidinecarboxamide, N-[[1-[1-(2-cyanophenyl)-4-piperidinyl]-3-pyrrolidinyl]methyl]-4-(3,4-difluorophenyl)-2-oxo-, (4S)-
MF C27 H29 F2 N5 O3


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/574,087


L2 33 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Methanone, [4-amino-2-[[4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]amino]-
5-thiazolyl](3-ethoxyphenyl)-
MF C27 H33 N5 O2 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/574,087


L2 33 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1H-Indole-5-carbonitrile, 3-[1'-(2,6-dimethoxyphenyl)[1,4'-bipiperidin]-4-yl]-
MF C27 H32 N4 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/574,087


L2 33 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Pyrrolidinecarboxamide, 1-[2-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-
piperidinyl]-
MF C22 H24 Cl3 N3 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/574,087


L2 33 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN [1,4'-Bipiperidin]-3-ol, 1'-(4-aminophenyl)-
MF C16 H25 N3 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/574,087


L2 33 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2H-Pyran-4-carboxamide, 4-[(4-[1,4'-bipiperidin]-1'-
ylphenyl)sulfonyl]tetrahydro-N-hydroxy-
MF C22 H33 N3 O5 S
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/574,087


L2 33 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1H-Isoindol-1-one, 7-[[2-[(4-[1,4'-bipiperidin]-1'-yl)-2-methoxyphenyl)amino]-5-chloro-4-pyrimidinyl]amino]-2,3-dihydro-2-methyl-
MF C30 H36 Cl N7 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/574,087


L2 33 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 5-Pyrimidinecarboxamide, 2-[[4-[3-(hydroxymethyl)[1,4'-bipiperidin]-1'-yl]phenyl]amino]-4-[[[(2,3,6-trifluorophenyl)methyl]amino]-, dihydrochloride (9CI)
MF C29 H34 F3 N7 O2 . 2 Cl H



● 2 HCl

10/574,087

L2 33 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1,4'-Bipiperidine, 1'-(4-chlorophenyl)-4-phenyl-
MF C22 H27 Cl N2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

10/574,087

=> s l1 sss ful
FULL SEARCH INITIATED 09:42:59 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 72544 TO ITERATE

100.0% PROCESSED 72544 ITERATIONS 726 ANSWERS
SEARCH TIME: 00.00.01

L3 726 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 178.82 179.03

FILE 'CAPLUS' ENTERED AT 09:43:06 ON 21 JAN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 21 Jan 2008 VOL 148 ISS 4
FILE LAST UPDATED: 20 Jan 2008 (20080120/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l3
L4 123 L3

=> d l4 1-124 bib hit str
'STR' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS ----- GI and AB
ALL ----- BIB, AB, IND, RE
APPS ----- AI, PRAI
BIB ----- AN, plus Bibliographic Data and PI table (default)
CAN ----- List of CA abstract numbers without answer numbers
CBIB ----- AN, plus Compressed Bibliographic Data
CLASS ----- IPC, NCL, ECLA, FTERM
DALL ----- ALL, delimited (end of each field identified)
DMAX ----- MAX, delimited for post-processing
FAM ----- AN, PI and PRAI in table, plus Patent Family data
FBIB ----- AN, BIB, plus Patent FAM
IND ----- Indexing data
IPC ----- International Patent Classifications
MAX ----- ALL, plus Patent FAM, RE

10/574,087

PATS ----- PI, SO
SAM ----- CC, SX, TI, ST, IT
SCAN ----- CC, SX, TI, ST, IT (random display, no answer numbers;
SCAN must be entered on the same line as the DISPLAY,
e.g., D SCAN or DISPLAY SCAN)
STD ----- BIB, CLASS

IABS ----- ABS, indented with text labels
IALL ----- ALL, indented with text labels
IBIB ----- BIB, indented with text labels
IMAX ----- MAX, indented with text labels
ISTD ----- STD, indented with text labels

OBIB ----- AN, plus Bibliographic Data (original)
OIBIB ----- OBIB, indented with text labels

SBIB ----- BIB, no citations
SIBIB ----- IBIB, no citations

HIT ----- Fields containing hit terms
HITIND ----- IC, ICA, ICI, NCL, CC and index field (ST and IT)
containing hit terms
HITRN ----- HIT RN and its text modification
HITSTR ----- HIT RN, its text modification, its CA index name, and
its structure diagram
HITSEQ ----- HIT RN, its text modification, its CA index name, its
structure diagram, plus NTE and SEQ fields
FHITSTR ----- First HIT RN, its text modification, its CA index name, and
its structure diagram
FHITSEQ ----- First HIT RN, its text modification, its CA index name, its
structure diagram, plus NTE and SEQ fields
KWIC ----- Hit term plus 20 words on either side
OCC ----- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field codes. For a list of the display field codes, enter HELP DFIELDS at an arrow prompt (=>). Examples of formats include: TI; TI,AU; BIB,ST; TI,IND; TI,SO. You may specify the format fields in any order and the information will be displayed in the same order as the format specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR, FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC to view a specified Accession Number.
ENTER DISPLAY FORMAT (BIB):end


=> d 14 1-124 bib hitstr

10/574,087


L4 ANSWER 1 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2007:1467729 CAPLUS
TI Preparation of N-(3,4-disubstituted phenyl)salicylamide derivatives as
inhibitors of STAT6 and NF- κ B activation
IN Tokuyama, Ryukou; Wakamatsu, Toshifumi; Ichige, Tatsurou; Muto, Susumu;
Itai, Akiko
PA Institute of Medicinal Molecular Design. Inc., Japan
SO PCT Int. Appl., 135pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 2007148711	A1	20071227	WO 2007-JP62377	20070620
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA,				
	CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI,				
	GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG,				
	KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,				
	MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL,				
	PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN,				
	TR, TT, TZ, UA, UG, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,				
	IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,				
	BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,				
	GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,				
	BY, KG, KZ, MD, RU, TJ, TM				
PRAI	JP 2006-171221	A	20060621		
IT	1000049-05-7P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU				
	(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES				
	(Uses)				
	(preparation of N-phenylsalicylamide derivs. as inhibitors of STAT6 and				
	NF- κ B activation)				
RN	1000049-05-7 CAPLUS				
CN	Benzamide, 5-chloro-N-[3-fluoro-4-[4-(1-pyrrolidinyl)-1-				
	piperidinyl]phenyl]-2-hydroxy-, hydrochloride (1:1) (CA INDEX NAME)				

10/574,087



IT 943752-48-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of N-phenylsalicylamide derivs. as inhibitors of STAT6 and
NF- κ B activation)
RN 943752-48-5 CAPLUS
CN Benzenamine, 3-fluoro-4-[4-(1-pyrrolidinyl)-1-piperidinyl]- (CA INDEX
NAME)




RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/574,087


L4 ANSWER 2 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2007:1454668 CAPLUS
DN 148:79020
TI Preparation of substituted thiazolidinones as CGRP receptor antagonists
IN Gutierrez, Corey; Termin, Andreas; Hadida-Ruah, Sara; Joshi, Pramod;
Bergeron, Daniele; Yoo, Sanghee; Binch, Hayley; Come, Jon; Nanthakumar,
Suganthi; Cao, Jingrong
PA Vertex Pharmaceuticals Incorporated, USA
SO PCT Int. Appl., 153pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007146349	A2	20071221	WO 2007-US13896	20070613
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	US 2008004261	A1	20080103	US 2007-818224	20070613
PRAI	US 2006-813178P	P	20060613		
IT	960221-09-4P 960221-12-9P 960221-57-2P 960221-58-3P 960221-59-4P 960221-60-7P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of substituted thiazolidinones for treating CGRP receptor-mediated diseases)				
RN	960221-09-4 CAPLUS				
CN	INDEX NAME NOT YET ASSIGNED				




RN 960221-12-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

10/574,087




RN 960221-57-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Relative stereochemistry.



RN 960221-58-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Relative stereochemistry.



RN 960221-59-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


10/574,087

Relative stereochemistry.



RN 960221-60-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Relative stereochemistry.



10/574,087

L4 ANSWER 3 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2007:1364245 CAPLUS
DN 148:11268
TI Substituted pyrazinone derivatives as α 2c-adrenoceptor antagonists
and their preparation, pharmaceutical compositions and use as a medicine
IN Andres-Gil, Jose Ignacio; Alcazar-Vaca, Manuel Jesus; Linares de La
Morena, Maria Lourdes; Martinez Gonzalez, Sonia; Oyarzabal Santamarina,
Julen; Pastor-Fernandez, Joaquin; Vega Ramiro, Juan Antonio;
Delgado-Jimenez, Francisca; Drinkenburg, Wilhelmus Helena Ignatius Maria
PA Janssen Pharmaceutica N.V., Belg.
SO PCT Int. Appl., 81pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	WO 2007135131	A1	20071129	WO 2007-EP54891	20070521
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA,				
	CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB,				
	GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM,				
	KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK,				
	MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO,				
	RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT,				
	TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,				
	IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,				
	BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,				
	GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,				
	BY, KG, KZ, MD, RU, TJ, TM				

PRAI EP 2006-114351 A 20060522

OS MARPAT 148:11268



IT 958446-20-3 958446-21-4

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(drug candidate; preparation of substituted pyrazinone derivs. as
 α 2c-adrenoceptor antagonists useful in the treatment of diseases)


RN 958446-20-3 CAPLUS

CN 2(1H)-Pyrazinone, 3-[[1-(2-phenoxyethyl)-4-piperidinyl]amino]-1-[3-[4-(1-
pyrrolidinyl)-1-piperidinyl]phenyl]- (CA INDEX NAME)



RN 958446-21-4 CAPLUS
 CN 2(1H)-Pyrazinone, 3-[[1-(2-phenoxyethyl)-4-piperidinyl]amino]-1-[4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]- (CA INDEX NAME)


10/574,087



10/574,087

L4 ANSWER 4 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2007:1238701 CAPLUS
DN 147:502346
TI Preparation of azolecarboxamide derivatives as trkA receptor inhibitors
IN Sugasawa, Keizo; Kawaguchi, Kenichi; Matsuzawa, Takaho; Seo, Ryushi;
Harada, Hironori; Suga, Akira; Abe, Tomoaki; Azami, Hidenori; Matsumoto,
Shunichiro; Shin, Takashi; Tanahashi, Masayuki; Watanabe, Toru
PA Astellas Pharma Inc., Japan
SO PCT Int. Appl., 234pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007123269	A1	20071101	WO 2007-JP59009	20070419
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI	JP 2006-115481	A	20060419		
OS	MARPAT 147:502346				
IT	955393-87-0P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of azolecarboxamide derivs. as trkA receptor inhibitors)				
RN	955393-87-0 CAPLUS				
CN	4-Thiazolecarboxamide, N-(2-[1,4'-bipiperidin]-1'-ylphenyl)-2-phenyl- (CA INDEX NAME)				



RE.CNT 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


10/574,087

L4 ANSWER 5 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2007:1236718 CAPLUS
DN 147:502390
TI Preparation of pyrazinones as selective α 2C-adrenoceptor antagonists.
IN Andres-Gil, Jose Ignacio; Alcazar-Vaca, Manuel Jesus; Linares De La Morena, Maria Lourdes; Martinez Gonzalez, Sonia; Oyarzabal Santamarina, Julien; Pastor-Fernandez, Joaquin; Vega Ramiro, Juan Antonio; Delgado-Jimenez, Francisca; Drinkenburg, Wilhelmus Helena Ignatius Maria
PA Janssen Pharmaceutica N.V., Belg.
SO PCT Int. Appl., 144pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	WO 2007122173	A1	20071101	WO 2007-EP53821	20070419
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI	EP 2006-112814	A	20060420		
OS	MARPAT 147:502390				
IT	955922-90-4P 955922-91-5P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of pyrazinones as selective α 2C-adrenoceptor antagonists)				
RN	955922-90-4 CAPLUS				
CN	2(1H)-Pyrazinone, 3-[[1-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-4-piperidinyl]amino]-1-[3-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]- (CA INDEX NAME)				

Double bond geometry as shown.


10/574,087



RN 955922-91-5 CAPLUS

CN 2(1H)-Pyrazinone, 3-[[1-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-4-piperidinyl]amino]-1-[4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]- (CA INDEX NAME)

Double bond geometry as shown.




RE.CNT 3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/574,087

L4 ANSWER 6 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2007:1177774 CAPLUS
DN 147:486232
TI Preparation of benzamide derivatives as inhibitors of histone deacetylase
IN Moradei, Oscar; Paquin, Isabelle; Frechette, Sylvie; Mallais, Tammy; Roy,
Simon; Machaalani, Roger; Vaisburg, Arkadii; Besterman, Jeffrey M.;
Tessier, Pierre; Mancuso, John; Smil, David; Leit, Silvana; Deziel, Robert
PA Methylgene Inc., Can.
SO PCT Int. Appl., 310pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007118137	A1	20071018	WO 2007-US66045	20070405
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI	US 2006-744427P	P	20060407		
	US 2007-886019P	P	20070122		
OS	MARPAT 147:486232				
IT	953431-90-8P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of benzamide derivs. as inhibitors of histone deacetylase)				
RN	953431-90-8 CAPLUS				
CN	Benzamide, N-[2-amino-5-(2-thienyl)phenyl]-4-[4-(1-pyrrolidinyl)-1-piperidinyl]- (CA INDEX NAME)				




RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/574,087

L4 ANSWER 7 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2007:1116761 CAPLUS
DN 147:412668
TI Hair dye composition containing a thiol/disulfide fluorescent dye
comprising a heterocycle with an external cationic charge
IN Greaves, Andrew; Daubresse, Nicolas
PA L'Oreal, Fr.
SO PCT Int. Appl., 68pp.
CODEN: PIXXD2
DT Patent
LA French
FAN.CNT 13

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007110532	A2	20071004	WO 2007-FR50998	20070323
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	FR 2898903	A1	20070928	FR 2006-51035	20060324
PRAI	FR 2006-51035	A	20060324		
	US 2006-792941P	P	20060419		
	FR 2007-53075	A	20070205		
	US 2007-901322P	P	20070215		
OS	MARPAT 147:412668				
IT	951154-01-1D, salts 951154-08-8D, salts				
	RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)				
	(hair dye composition containing thiol/disulfide fluorescent dye comprising heterocycle with external cationic charge)				
RN	951154-01-1 CAPLUS				
CN	Pyridinium, 2-[(1E)-2-[4-[4-[1-(2-mercaptoethyl)pyrrolidinio]-1-piperidinyl]phenyl]ethenyl]-1-methyl- (CA INDEX NAME)				

Double bond geometry as shown.




10/574,087

RN 951154-08-8 CAPLUS


CN Pyridinium, 1-ethyl-4-[(1E)-2-[4-[4-[1-(2-mercaptoethyl)pyrrolidinio]-1-piperidinyl]phenyl]ethenyl]- (CA INDEX NAME)

Double bond geometry as shown.




10/574,087

L4 ANSWER 8 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2007:1111800 CAPLUS
DN 148:390
TI Antiproliferative activity of chalcones with basic functionalities
AU Liu, Xiaoling; Go, Mei-Lin
CS Department of Pharmacy, National University of Singapore, Singapore,
117543, Singapore
SO Bioorganic & Medicinal Chemistry (2007), 15(22), 7021-7034
CODEN: BMECEP; ISSN: 0968-0896
PB Elsevier Ltd.
DT Journal
LA English
IT 958453-64-0P 958453-66-2P
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic
preparation); THU (Therapeutic use); BIOL (Biological study); PREP
(Preparation); USES (Uses)
(antiproliferative activity of chalcones with basic functionalities)
RN 958453-64-0 CAPLUS
CN 2-Propen-1-one, 1-(5-[1,4'-bipiperidin]-1'-yl-2,4-dimethoxyphenyl)-3-(2-
chlorophenyl)- (CA INDEX NAME)




RN 958453-66-2 CAPLUS
CN 2-Propen-1-one, 1-(5-[1,4'-bipiperidin]-1'-yl-2,4-dimethoxyphenyl)-3-(2-
fluorophenyl)- (CA INDEX NAME)



IT 958453-93-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(antiproliferative activity of chalcones with basic functionalities)
RN 958453-93-5 CAPLUS
CN Ethanone, 1-(5-[1,4'-bipiperidin]-1'-yl-2,4-dimethoxyphenyl)- (CA INDEX
NAME)

10/574,087



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/574,087

L4 ANSWER 9 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2007:1028764 CAPLUS

DN 147:365521

TI Preparation of pyrazolo[1,5a]pyrimidin-7-ylamines for the treatment of Eph receptor-related neurological disorders

IN Sivasankaran, Rajeev; Zimmermann, Kaspar

PA Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.

SO PCT Int. Appl., 114pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007103432	A2	20070913	WO 2007-US5822	20070306
	WO 2007103432	A3	20071122		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
PRAI	US 2006-780951P	P	20060308		
OS	MARPAT 147:365521				
IT	861250-98-8P 861251-00-5P 948999-01-7P 948999-09-5P 948999-19-7P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of pyrazolopyrimidinylamines for the treatment of Eph receptor-related neurol. disorders)				
RN	861250-98-8 CAPLUS				
CN	Pyrazolo[1,5-a]pyrimidin-7-amine, 6-(3-chlorophenyl)-5-methyl-3-[3-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]- (CA INDEX NAME)				



RN 861251-00-5 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-(4-fluorophenyl)-5-methyl-3-[3-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]- (CA INDEX NAME)

10/574,087




RN 948999-01-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-(3-chlorophenyl)-3-[2-methoxy-5-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]-5-methyl- (CA INDEX NAME)




RN 948999-09-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(5-[1,4'-bipiperidin]-1'-yl)-2-methoxyphenyl)-6-(3-chlorophenyl)-5-methyl- (CA INDEX NAME)



RN 948999-19-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-(3-chlorophenyl)-3-[2-fluoro-5-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]-5-methyl- (CA INDEX NAME)



IT 861250-99-9P


10/574,087

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyrazolopyrimidinylamines for the treatment of Eph receptor-related neurol. disorders)

RN 861250-99-9 CAPLUS

CN 1H-Pyrazol-3-amine, 4-[3-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]- (CA INDEX NAME)




10/574,087

L4 ANSWER 10 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2007:906246 CAPLUS
DN 147:277637
TI Sulfonylated piperidine and piperazine derivatives as 11- β HSD1
inhibitors and their preparation, pharmaceutical compositions and use in
the treatment of diseases
IN Xiang, Jason Shaoyun; Saiah, Eddine; Tam, Steve Y.; Mckew, John C.; Chen,
Lihren; Ipek, Manus; Lee, Katherine; Li, Huan-Qui; Li, Jianchang; Li, Wei;
Mansour, Tarek Suhayl; Suri, Vipin; Vargas, Richard; Wu, Yuchuan; Wan,
Zhao-Kui; Lee, Jinbo; Binnun, Eva; Wilson, Douglas P.
PA Wyeth, John, and Brother Ltd., USA
SO PCT Int. Appl., 277pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 2007092435	A2	20070816	WO 2007-US3134	20070207
	WO 2007092435	A3	20071227		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
	US 2007219198	A1	20070920	US 2007-703522	20070207
PRAI	US 2006-771262P	P	20060207		
OS	MARPAT 147:277637				
IT	946397-86-0P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (drug candidate; preparation of sulfonylated piperidine and piperazine derivs. as 11- β HSD1 inhibitors useful in the treatment of diseases)				
RN	946397-86-0 CAPLUS				
CN	Piperazine, 4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methyl-1-[[3-[4-(1- pyrrolidinyl)-1-piperidinyl]phenyl]sulfonyl]-, (2R)- (CA INDEX NAME)				

Absolute stereochemistry.

10/574,087



10/574,087

L4 ANSWER 11 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2007:817917 CAPLUS

DN 147:211739

TI Diaryl piperidines as CB1 modulators and their preparation, pharmaceutical compositions and use in the treatment of diseases

IN Scott, Jack D.; Weinstein, Jay; Miller, Michael W.; Stamford, Andrew W.; Gilbert, Eric J.; Xia, Yan; Greenlee, William J.; Li, Wei

PA Schering Corp., USA

SO PCT Int. Appl., 286pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 2007084319	A2	20070726	WO 2007-US705	20070111
	WO 2007084319	A3	20070920		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
	US 2007203183	A1	20070830	US 2007-652227	20070111
PRAI	US 2006-759091P	P	20060113		
	US 2006-802990P	P	20060524		

OS MARPAT 147:211739

IT 944747-94-8P 944747-95-9P 944747-98-2P

RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)


(preparation of diaryl piperidines as CB1 modulators for treating metabolic syndrome, neuroinflammatory disorders, psychiatric disorders, and other diseases)

RN 944747-94-8 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[2-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-piperidinyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.

10/574,087




RN 944747-95-9 CAPLUS

CN [1,4'-Bipiperidine]-3-carboxamide, 2'-(4-chlorophenyl)-1'-(2,4-dichlorophenyl)- (CA INDEX NAME)



RN 944747-98-2 CAPLUS

CN 1,4'-Bipiperidine, 2'-(4-chlorophenyl)-1'-(2,4-dichlorophenyl)-4-(phenylmethyl)- (CA INDEX NAME)




IT 944751-17-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of diaryl piperidines as CB1 modulators for treating metabolic syndrome, neuroinflammatory disorders, psychiatric disorders, and other

10/574,087

diseases)
RN 944751-17-1 CAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[2-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-piperidinyl]- (CA INDEX NAME)



L4 ANSWER 12 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2007:730889 CAPLUS

DN 147:166204

TI Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo-1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihydro-3(2H)-isoquinolones as CDK inhibitors and their preparation, pharmaceutical composition and use in the treatment of cancer, infections and other diseases

IN Tsou, Hwei-Ru; Ayrar-Kaloustian, Semiramis; Birnberg, Gary Harold; Floyd, Middleton Brawner; Kaplan, Joshua; Kutterer, Kristina M. K.; Liu, Xiaoxiang; Nilakantan, Ramaswamy; Otteng, Mercy Adufa; Tang, Zhilian; Zask, Arie; Reich, Marvin; Tran, Tritan

PA Wyeth, John, and Brother Ltd., USA

SO PCT Int. Appl., 933pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007075783	A2	20070705	WO 2006-US48603	20061220
	WO 2007075783	A3	20071122		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			

PRAI US 2005-753701P P 20051222

OS MARPAT 147:166204

IT 943746-98-3P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate and intermediate; preparation of isoquinoline compds. as CDK inhibitors for treating cancer, infections, and other diseases)

RN 943746-98-3 CAPLUS

CN 1,3(2H,4H)-Isoquinolinedione, 6-bromo-4-[[[3-fluoro-4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]amino]methylene]-, (4Z)- (CA INDEX NAME)

Double bond geometry as shown.



10/574,087

IT 943746-99-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of isoquinoline compds. as CDK inhibitors for treating cancer, infections, and other diseases)

RN 943746-99-4 CAPLUS

CN 1,3(2H,4H)-Isoquinolinedione, 4-[[[3-fluoro-4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]amino]methylene]-6-(3-thienyl)-, (4Z)- (CA INDEX NAME)

Double bond geometry as shown.




IT 943752-48-5

RL: RCT (Reactant); RACT (Reactant or reagent)

(starting material; preparation of isoquinoline compds. as CDK inhibitors for treating cancer, infections, and other diseases)

RN 943752-48-5 CAPLUS

CN Benzenamine, 3-fluoro-4-[4-(1-pyrrolidinyl)-1-piperidinyl]- (CA INDEX NAME)




10/574,087

L4 ANSWER 13 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2007:703843 CAPLUS
DN 147:118265
TI Preparation of substituted pyrazinone derivatives as α 2c-
adrenoreceptor antagonists
IN Andres-Gil, Jose Ignacio; Alcazar-Vaca, Manuel Jesus; Linares de la
Morena, Maria Lourdes; Martinez Gonzalez, Sonia; Oyarzabal Santamarina,
Julen; Pastor-Fernandez, Joaquin; Vega Ramiro, Juan Antonio; Drinkenburg,
Wilhelmus Helena Ignatius Maria
PA Janssen Pharmaceutica N. V., Belg.
SO PCT Int. Appl., 142pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 2007071639	A1	20070628	WO 2006-EP69815	20061218
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI	EP 2005-112646	A	20051221		
OS	MARPAT 147:118265				
IT	943018-44-8P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of substituted pyrazinone derivs. as α 2c-adrenoreceptor antagonists)				
RN	943018-44-8 CAPLUS				
CN	2(1H)-Pyrazinone, 5-chloro-1-[(4-methoxyphenyl)methyl]-3-[[1-(2- naphthalenylmethyl)-4-piperidinyl]amino]-6-[3-[4-(1-pyrrolidinyl)-1- piperidinyl]phenyl]- (CA INDEX NAME)				

10/574,087



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/574,087

L4 ANSWER 14 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2007:702536 CAPLUS

DN 147:118155

TI Preparation of phenanthridine derivatives as inhibitors of bradykinin B1 receptor

IN Beke, Gyula; Bozo, Eva; Czira, Gabor; Eles, Janos; Farkas, Sandor; Hornok, Katalin; Schmidt, Eva; Szentirmay, Eva; Vago, Istvan; Vastag, Monika

PA Richter Gedeon Vegyeszeti Gyar Rt., Hung.

SO PCT Int. Appl., 49pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007072092	A2	20070628	WO 2006-HU120	20061219
	WO 2007072092	A3	20071101		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
	HU 2005001169	A2	20070928	HU 2005-1169	20051220

PRAI HU 2005-1169 A 20051220

OS CASREACT 147:118155; MARPAT 147:118155


IT 942613-21-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of phenanthridine derivs. as inhibitors of bradykinin B1 receptor)

RN 942613-21-0 CAPLUS

CN 6-Phenanthridineacetamide, N-(4-[1,4'-bipiperidin]-1'-ylphenyl)-5-[(3,4-dichlorophenyl)sulfonyl]-5,6-dihydro- (CA INDEX NAME)



10/574,087


IT 478055-47-9

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of phenanthridine derivs. as inhibitors of bradykinin B1
receptor)

RN 478055-47-9 CAPLUS

CN Benzenamine, 4-[1,4'-bipiperidin]-1'-yl- (CA INDEX NAME)



10/574,087

L4 ANSWER 15 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2007:675451 CAPLUS

DN 147:95473

TI Purine derivatives and related compounds as kinase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of kinase-associated diseases

IN Ding, Pingyu; Argade, Ankush; Goff, Dane; Singh, Rajinder; Masuda, Esteban; Taylor, Vanessa; Holland, Sacha

PA Rigel Pharmaceuticals, Inc., USA

SO U.S. Pat. Appl. Publ., 86pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2007142402	A1	20070621	US 2006-611568	20061215
PRAI	US 2005-751373P	P	20051215		

OS MARPAT 147:95473

IT 942138-49-0P 942138-50-3P 942138-67-2P


942138-81-0P 942138-86-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of purine derivs. and related compds. as kinase inhibitors useful in the prevention and treatment of kinase-associated diseases)

RN 942138-49-0 CAPLUS


CN Bicyclo[2.2.1]hept-5-ene-2-carboxamide, 3-[[2-[(4-[1,4'-bipiperidin]-1'-yl)-3-fluorophenyl)amino]thieno[3,2-d]pyrimidin-4-yl]amino]- (CA INDEX NAME)



RN 942138-50-3 CAPLUS


CN Bicyclo[2.2.1]hept-5-ene-2-carboxamide, 3-[[2-[[3-fluoro-4-(4-methyl[1,4'-bipiperidin]-1'-yl)phenyl]amino]thieno[3,2-d]pyrimidin-4-yl]amino]- (CA INDEX NAME)

10/574,087



RN 942138-67-2 CAPLUS

CN Bicyclo[2.2.1]hept-5-ene-2-carboxamide, 3-[[2-[[3-fluoro-4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]amino]thieno[3,2-d]pyrimidin-4-yl]amino]- (CA INDEX NAME)




RN 942138-81-0 CAPLUS

CN Bicyclo[2.2.1]hept-5-ene-2-carboxamide, 3-[[2-[[3-fluoro-4-(4-methyl[1,4'-bipiperidin]-1'-yl)phenyl]amino]-6-(trifluoromethyl)thieno[3,2-d]pyrimidin-4-yl]amino]-, (1S,2S,3R,4R)- (CA INDEX NAME)

Absolute stereochemistry.


10/574,087



RN 942138-86-5 CAPLUS

CN Bicyclo[2.2.1]hept-5-ene-2-carboxamide, 3-[[6-chloro-2-[[3-fluoro-4-(4-methyl[1,4'-bipiperidin]-1'-yl)phenyl]amino]thieno[3,2-d]pyrimidin-4-yl]amino]-, (1S,2S,3R,4R)- (CA INDEX NAME)

Absolute stereochemistry.



10/574,087

L4 ANSWER 16 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2007:671919 CAPLUS

DN 147:95689

TI Preparation of bicyclic pyrimidine compounds as kinase inhibitors

IN Ding, Pingyu; Argade, Ankush; Goff, Dane; Singh, Rajinder; Masuda, Esteban; Taylor, Vanessa; Holland, Sacha

PA Rigel Pharmaceuticals, Inc., USA

SO PCT Int. Appl., 129pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007070872	A1	20070621	WO 2006-US62162	20061215
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRAI US 2005-751393P P 20051215

OS MARPAT 147:95689

IT 942138-49-0P 942138-50-3P 942138-67-2P


942138-81-0P 942138-86-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of bicyclic pyrimidine compds. as kinase inhibitors)

RN 942138-49-0 CAPLUS


CN Bicyclo[2.2.1]hept-5-ene-2-carboxamide, 3-[[2-[(4-[1,4'-bipiperidin]-1'-yl)-3-fluorophenyl]amino]thieno[3,2-d]pyrimidin-4-yl]amino]- (CA INDEX NAME)



RN 942138-50-3 CAPLUS


CN Bicyclo[2.2.1]hept-5-ene-2-carboxamide, 3-[[2-[[3-fluoro-4-(4-methyl[1,4'-bipiperidin]-1'-yl)phenyl]amino]thieno[3,2-d]pyrimidin-4-yl]amino]- (CA INDEX NAME)

10/574,087



RN 942138-67-2 CAPLUS

CN Bicyclo[2.2.1]hept-5-ene-2-carboxamide, 3-[[2-[[3-fluoro-4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]amino]thieno[3,2-d]pyrimidin-4-yl]amino]- (CA INDEX NAME)




RN 942138-81-0 CAPLUS

CN Bicyclo[2.2.1]hept-5-ene-2-carboxamide, 3-[[2-[[3-fluoro-4-(4-methyl[1,4'-bipiperidin]-1'-yl)phenyl]amino]-6-(trifluoromethyl)thieno[3,2-d]pyrimidin-4-yl]amino]-, (1S,2S,3R,4R)- (CA INDEX NAME)

Absolute stereochemistry.


10/574,087



RN 942138-86-5 CAPLUS

CN Bicyclo[2.2.1]hept-5-ene-2-carboxamide, 3-[[6-chloro-2-[[3-fluoro-4-(4-methyl[1,4'-bipiperidin]-1'-yl)phenyl]amino]thieno[3,2-d]pyrimidin-4-yl]amino]-, (1S,2S,3R,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/574,087

L4 ANSWER 17 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2007:671779 CAPLUS

DN 147:95660

TI Substituted pyrazolo[4,3-c]pyridine derivatives as tyrosine kinase inhibitors, particularly IGF-1R inhibitors, their preparation, pharmaceutical compositions, and use in therapy

IN Bandiera, Tiziano; Lombardi Borgia, Andrea; Polucci, Paolo; Villa, Manuela; Nesi, Marcella; Angiolini, Mauro; Varasi, Mario

PA Nerviano Medical Sciences S.r.l., Italy

SO PCT Int. Appl., 238pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007068619	A1	20070621	WO 2006-EP69285	20061206
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRAI EP 2005-111959 A 20051212

OS MARPAT 147:95660


IT 942470-83-9P, N-[5-(3,5-Difluorophenylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-4-[4-(pyrrolidin-1-yl)piperidin-1-yl]-2-[(tetrahydropyran-4-yl)amino]benzamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrazolopyridine derivs. as tyrosine kinase inhibitors for treating cancer)

RN 942470-83-9 CAPLUS

CN Benzamide, N-[5-[(3,5-difluorophenyl)sulfonyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-4-[4-(1-pyrrolidinyl)-1-piperidinyl]-2-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD

10/574,087

ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/574,087

L4 ANSWER 18 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2007:507562 CAPLUS

DN 146:500897

TI Preparation of pyrrolidinylpiperidines and related compounds as antagonists of chemokine CCR2 inhibitors.

IN Ghosh, Shomir; Raman, Prakash; Sprott, Kevin; Elder, Amy M.; Griffiths, Sian; Soucy, Francois; Ye, Qing

PA Millennium Pharmaceuticals, Inc., USA

SO PCT Int. Appl., 157pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 2007053498	A1	20070510	WO 2006-US42180	20061026
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI	US 2005-732343P	P	20051101		
OS	MARPAT 146:500897				
IT	936447-05-1P				
	RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)				
	(preparation of pyrrolidinylpiperidines and related compds. as antagonists of chemokine CCR2 inhibitors)				
RN	936447-05-1 CAPLUS				
CN	Benzoic acid, 4-[4-[(3R)-3-[[2-[[3-(trifluoromethyl)benzoyl]amino]acetyl]amino]-1-pyrrolidinyl]-1-piperidinyl]-, phenylmethyl ester (CA INDEX NAME)				

Absolute stereochemistry.

10/574,087



IT 936446-73-0P 936446-76-3P 936446-77-4P
936446-78-5P 936446-80-9P 936446-81-0P
936446-82-1P 936446-84-3P 936446-85-4P
936446-86-5P 936446-87-6P 936446-88-7P
936446-89-8P 936446-91-2P 936446-92-3P
936446-93-4P 936446-96-7P 936446-97-8P
936446-98-9P 936446-99-0P 936447-00-6P
936447-03-9P 936447-04-0P 936447-06-2P
936447-07-3P 936447-08-4P 936447-09-5P
936447-10-8P 936447-12-0P 936447-14-2P
936447-15-3P 936447-16-4P 936447-17-5P
936447-19-7P 936447-23-3P 936447-24-4P
936447-26-6P 936447-27-7P 936447-28-8P
936447-29-9P 936447-30-2P 936447-31-3P
936447-32-4P 936447-34-6P 936447-35-7P
936447-36-8P 936447-37-9P 936447-38-0P
936447-40-4P 936447-41-5P 936447-43-7P
936447-45-9P 936447-46-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)


(preparation of pyrrolidinylpiperidines and related compds. as antagonists
of chemokine CCR2 inhibitors)

RN 936446-73-0 CAPLUS

CN Benzamide, N-[2-[[[(3R)-1-[1-[4-(acetylamino)phenyl]-4-piperidinyl]-3-
pyrrolidinyl]amino]-2-oxoethyl]-3-(trifluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.


10/574,087



RN 936446-76-3 CAPLUS

CN Benzamide, N-[2-[[(3R)-1-[1-(4-methoxyphenyl)-4-piperidinyl]-3-pyrrolidinyl]amino]-2-oxoethyl]-3-(trifluoromethoxy)- (CA INDEX NAME)

Absolute stereochemistry.




RN 936446-77-4 CAPLUS

CN Benzamide, N-[2-[[(3R)-1-[1-(4-fluorophenyl)-4-piperidinyl]-3-pyrrolidinyl]amino]-2-oxoethyl]-3-(trifluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.


10/574,087



RN 936446-78-5 CAPLUS

CN Acetamide, N-[(3R)-1-[1-(3-methylphenyl)-4-piperidinyl]-3-pyrrolidinyl]-2-[[6-(trifluoromethyl)-4-quinazolinyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 936446-80-9 CAPLUS

CN Benzamide, N-[2-[[[(3R)-1-[1-(3-chlorophenyl)-4-piperidinyl]-3-pyrrolidinyl]amino]-2-oxoethyl]-3-(trifluoromethyl)-5-pyridinyl]benzamide (CA INDEX NAME)

Absolute stereochemistry.


10/574,087



RN 936446-81-0 CAPLUS

CN Benzamide, 4-fluoro-N-[2-[[(3R)-1-[1-(4-methoxyphenyl)-4-piperidinyl]-3-pyrrolidinyl]amino]-2-oxoethyl]-3-(trifluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 936446-82-1 CAPLUS

CN Benzamide, N-[2-[[(3R)-1-[1-[4-(acetylmethylamino)phenyl]-4-piperidinyl]-3-pyrrolidinyl]amino]-2-oxoethyl]-3-(trifluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.


10/574,087



RN 936446-84-3 CAPLUS

CN Benzamide, N,N-dimethyl-4-[[4-[(3R)-3-[[2-[[3-(trifluoromethyl)benzoyl]amino]acetyl]amino]-1-pyrrolidinyl]-1-piperidinyl]-1-phenyl]acetamide (CA INDEX NAME)

Absolute stereochemistry.




RN 936446-85-4 CAPLUS

CN Benzamide, 3-(1,1-dimethylethyl)-N-[2-[[[(3R)-1-[1-(3-methylphenyl)-4-piperidinyl]-3-pyrrolidinyl]amino]-2-oxoethyl]-1-phenyl]acetamide (CA INDEX NAME)

Absolute stereochemistry.


10/574,087



RN 936446-86-5 CAPLUS

CN Benzamide, 3-fluoro-N-[2-[[(3R)-1-[1-(3-methylphenyl)-4-piperidinyl]-3-pyrrolidinyl]amino]-2-oxoethyl]-5-(trifluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 936446-87-6 CAPLUS

CN Benzamide, N-[2-[[(3R)-1-[1-(4-methoxy-2-methylphenyl)-4-piperidinyl]-3-pyrrolidinyl]amino]-2-oxoethyl]-3-(trifluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.


10/574,087



RN 936446-88-7 CAPLUS

CN Benzamide, N-[2-oxo-2-[[[(3R)-1-[1-[4-(trifluoromethyl)phenyl]-4-piperidinyl]-3-pyrrolidinyl]amino]ethyl]-3-(trifluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 936446-89-8 CAPLUS

CN Benzamide, N-[2-[[[(3R)-1-[1-(4-cyanophenyl)-4-piperidinyl]-3-pyrrolidinyl]amino]-2-oxoethyl]-3-(trifluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.

N#Cc1ccc(cc1)N2CCN(CC2)N3CCCC3NC(=O)CCNC(=O)c1ccc(cc1)C(F)(F)F


CN Benzamide, N-[2-[[(3R)-1-[1-(4-methoxyphenyl)-4-piperidinyl]-3-pyrrolidinyl]amino]-2-oxoethyl]-3-(trifluoromethyl)- (CA INDEX NAME)

COc1ccc(cc1)N2CCN(CC2)N3CCCC3NC(=O)CCNC(=O)c4ccc(C(F)(F)F)cc4

CN Benzamide, N-[2-[[(3R)-1-[1-(2-methoxyphenyl)-4-piperidinyl]-3-pyrrolidinyl]amino]-2-oxoethyl]-3-(trifluoromethyl)- (CA INDEX NAME)


Absolute stereochemistry.

10/574,087



RN 936446-93-4 CAPLUS
CN Benzamide, N-[2-[[(3R)-1-[1-(4-methoxyphenyl)-4-piperidinyl]-3-pyrrolidinyl]amino]-2-oxoethyl]-3,5-bis(trifluoromethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 936446-96-7 CAPLUS
CN Benzamide, N-[2-[[(3R)-1-[1-[4-(5-oxazolyl)phenyl]-4-piperidinyl]-3-pyrrolidinyl]amino]-2-oxoethyl]-3-(trifluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.


10/574,087



RN 936446-97-8 CAPLUS

CN Benzamide, N-[2-[[(3R)-1-[1-[4-[(methylamino)carbonyl]phenyl]-4-piperidinyl]-3-pyrrolidinyl]amino]-2-oxoethyl]-3-(trifluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 936446-98-9 CAPLUS

CN Benzamide, N-[2-[[(3R)-1-[1-(2-fluorophenyl)-4-piperidinyl]-3-pyrrolidinyl]amino]-2-oxoethyl]-3-(trifluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.


10/574,087



RN 936446-99-0 CAPLUS

CN Benzamide, N-[2-[[(3R)-1-[1-[3-(aminocarbonyl)phenyl]-4-piperidinyl]-3-pyrrolidinyl]amino]-2-oxoethyl]-3-(trifluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 936447-00-6 CAPLUS

CN Benzamide, N-[2-[[(3R)-1-[1-(3-methylphenyl)-4-piperidinyl]-3-pyrrolidinyl]amino]-2-oxoethyl]-3,5-bis(trifluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.


10/574,087



RN 936447-03-9 CAPLUS

CN 1H-Benzimidazole-2-acetamide, N-[(3R)-1-[1-(3-methylphenyl)-4-piperidinyl]-3-pyrrolidinyl]-7-(trifluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 936447-04-0 CAPLUS

CN 1H-Benzimidazole-2-acetamide, N-[(3R)-1-[1-(4-fluorophenyl)-4-piperidinyl]-3-pyrrolidinyl]-7-(trifluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.


10/574,087



RN 936447-06-2 CAPLUS

CN Benzamide, N-[2-[[(3R)-1-[1-(3-ethoxyphenyl)-4-piperidinyl]-3-pyrrolidinyl]amino]-2-oxoethyl]-3-(trifluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 936447-07-3 CAPLUS

CN Benzamide, N-[2-[[(3R)-1-[1-(3-chloro-4-fluorophenyl)-4-piperidinyl]-3-pyrrolidinyl]amino]-2-oxoethyl]-3-(trifluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.


10/574,087



RN 936447-08-4 CAPLUS

CN Benzamide, N-[2-[[1-[(2R,4R)-1-(4-fluorophenyl)-2-methyl-4-piperidinyl]-3-pyrrolidinyl]amino]-2-oxoethyl]-3-(trifluoromethyl)-, rel- (CA INDEX NAME)



Relative stereochemistry.



RN 936447-09-5 CAPLUS

CN Benzamide, N-[2-[[[(3S)-1-[1-[4-(4-morpholinylcarbonyl)phenyl]-4-piperidinyl]-3-pyrrolidinyl]amino]-2-oxoethyl]-3-(trifluoromethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 936447-10-8 CAPLUS

CN Benzamide, N-[2-oxo-2-[[(3R)-1-[1-[4-(1-pyrrolidinylcarbonyl)phenyl]-4-piperidinyl]-3-pyrrolidinyl]amino]ethyl]-3-(trifluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.



10/574,087


PAGE 1-B



RN 936447-12-0 CAPLUS

CN 1H-Benzimidazole-2-acetamide, N-[(3R)-1-[1-(4-methoxyphenyl)-4-piperidinyl]-3-pyrrolidinyl]-7-(trifluoromethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 936447-14-2 CAPLUS

CN Benzoic acid, 4-[4-[(3R)-3-[[2-[[3-(trifluoromethyl)benzoyl]amino]acetyl]amino]-1-pyrrolidinyl]-1-piperidinyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




10/574,087

RN 936447-15-3 CAPLUS

CN Benzamide, N-[2-[[(3R)-1-[1-[4-(1H-imidazol-1-yl)phenyl]-4-piperidinyl]-3-pyrrolidinyl]amino]-2-oxoethyl]-3-(trifluoromethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 936447-16-4 CAPLUS

CN Benzamide, N,N-diethyl-4-[4-[(3R)-3-[[2-[[3-(trifluoromethyl)benzoyl]amino]acetyl]amino]-1-pyrrolidinyl]-1-piperidinyl]- (CA INDEX NAME)



Absolute stereochemistry.



RN 936447-17-5 CAPLUS

CN Benzamide, N-[2-[[(3R)-1-[1-[4-(4-morpholinyl)phenyl]-4-piperidinyl]-3-pyrrolidinyl]amino]-2-oxoethyl]-3-(trifluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 936447-19-7 CAPLUS

CN Benzamide, 3-fluoro-N-[2-[[[(3R)-1-[1-(4-methoxyphenyl)-4-piperidinyl]-3-pyrrolidinyl]amino]-2-oxoethyl]-5-(trifluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.


10/574,087



RN 936447-23-3 CAPLUS

CN Benzamide, N-[2-[[[(3R)-1-[1-[4-(acetamido)-3-methylphenyl]-4-piperidinyl]-3-pyrrolidinyl]amino]-2-oxoethyl]-3-(trifluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 936447-24-4 CAPLUS

CN Benzamide, N-[2-[[[(3R)-1-[1-(3-methylphenyl)-4-piperidinyl]-3-pyrrolidinyl]amino]-2-oxoethyl]-3-(trifluoromethoxy)- (CA INDEX NAME)

Absolute stereochemistry.


10/574,087



RN 936447-26-6 CAPLUS

CN Benzamide, 4-fluoro-N-[2-[[[(3R)-1-[1-(3-methylphenyl)-4-piperidinyl]-3-pyrrolidinyl]amino]-2-oxoethyl]-3-(trifluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 936447-27-7 CAPLUS

CN Benzamide, N-[2-[[[(3R)-1-[1-[3-(methylthio)phenyl]-4-piperidinyl]-3-pyrrolidinyl]amino]-2-oxoethyl]-3-(trifluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.

10/574,087




RN 936447-28-8 CAPLUS

CN Benzamide, N-[2-oxo-2-[[(3R)-1-[1-[4-(1-piperidinylcarbonyl)phenyl]-4-piperidinyl]-3-pyrrolidinyl]amino]ethyl]-3-(trifluoromethyl)- (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



10/574,087


PAGE 2-A



RN 936447-29-9 CAPLUS

CN Benzoic acid, 2-[4-[(3R)-3-[[2-[[3-(trifluoromethyl)benzoyl]amino]acetyl]amino]-1-pyrrolidinyl]-1-piperidinyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 936447-30-2 CAPLUS

CN Benzamide, N-[2-[[[(3R)-1-[1-(3-methylphenyl)-4-piperidinyl]-3-pyrrolidinyl]amino]-2-oxoethyl]-3-(trifluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.


10/574,087



RN 936447-31-3 CAPLUS

CN Benzamide, N-[2-[[(3R)-1-[1-(4-methoxyphenyl)-2-oxo-4-piperidinyl]-3-pyrrolidinyl]amino]-2-oxoethyl]-3-(trifluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 936447-32-4 CAPLUS

CN Benzoic acid, 4-[4-[(3R)-3-[[[2-oxo-2-[[3-(trifluoromethyl)phenyl]amino]ethyl]amino]carbonyl]-1-pyrrolidinyl]-1-piperidinyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.


10/574,087



RN 936447-34-6 CAPLUS

CN Benzamide, N-[2-[[[(3R)-1-[1-(3,5-dimethylphenyl)-4-piperidinyl]-3-pyrrolidinyl]amino]-2-oxoethyl]-3-(trifluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 936447-35-7 CAPLUS

CN Benzamide, N-[2-[[[(3R)-1-[1-(3-chloro-4-methylphenyl)-4-piperidinyl]-3-pyrrolidinyl]amino]-2-oxoethyl]-3-(trifluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.


10/574,087



RN 936447-36-8 CAPLUS

CN Benzamide, N-[2-[[1-[(2R,4S)-1-(4-fluorophenyl)-2-methyl-4-piperidinyl]-3-pyrrolidinyl]amino]-2-oxoethyl]-3-(trifluoromethyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 936447-37-9 CAPLUS

CN Benzoic acid, 4-[4-[(3R)-3-[[2-[7-(trifluoromethyl)-1H-benzimidazol-2-yl]acetyl]amino]-1-pyrrolidinyl]-1-piperidinyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.


10/574,087



RN 936447-38-0 CAPLUS

CN 1H-Benzimidazole-2-acetamide, N-[(3R)-1-[1-[4-(4-morpholinylcarbonyl)phenyl]-4-piperidinyl]-3-pyrrolidinyl]-7-(trifluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 936447-40-4 CAPLUS

CN Benzamide, 3-chloro-N-[2-[[(3R)-1-[1-(4-methoxyphenyl)-4-piperidinyl]-3-pyrrolidinyl]amino]-2-oxoethyl]- (CA INDEX NAME)

Absolute stereochemistry.

10/574,087





RN 936447-41-5 CAPLUS

CN Benzamide, N-[2-[[[(3R)-1-[1-[4-[[(2R,6S)-2,6-dimethyl-4-morpholinyl]carbonyl]phenyl]-4-piperidinyl]-3-pyrrolidinyl]amino]-2-oxoethyl]-3-(trifluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A





RN 936447-43-7 CAPLUS
 CN Benzamide, N-[2-[[[(3R)-1-[1-[4-(4-morpholinylcarbonyl)phenyl]-4-piperidinyl]-3-pyrrolidinyl]amino]-2-oxoethyl]-3-(trifluoromethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 936447-45-9 CAPLUS
 CN Benzamide, 3,4-dichloro-N-[2-[[[(3R)-1-[1-(4-methoxyphenyl)-4-piperidinyl]-3-pyrrolidinyl]amino]-2-oxoethyl]- (CA INDEX NAME)


Absolute stereochemistry.

10/574,087



RN 936447-46-0 CAPLUS
CN Benzamide, N-[2-[[[(3R)-1-[1-(2-methylphenyl)-4-piperidinyl]-3-pyrrolidinyl]amino]-2-oxoethyl]-3-(trifluoromethyl)- (CA INDEX NAME)


Absolute stereochemistry.



IT 936448-09-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of pyrrolidinylpiperidines and related compds. as antagonists of chemokine CCR2 inhibitors)
RN 936448-09-8 CAPLUS
CN Benzoic acid, 4-[4-[(3R)-3-[[2-[[[3-(trifluoromethyl)benzoyl]amino]acetyl]amino]-1-pyrrolidinyl]-1-piperidinyl]- (CA INDEX NAME)


Absolute stereochemistry.

10/574,087



IT 936447-55-1P 936447-56-2P 936447-57-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of pyrrolidinylpiperidines and related compds. as antagonists
of chemokine CCR2 inhibitors)
RN 936447-55-1 CAPLUS
CN 3-Pyrrolidinamine, 1-[1-(4-methoxyphenyl)-4-piperidinyl]-, hydrochloride
(1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 936447-56-2 CAPLUS
CN Carbamic acid, N-[2-[[(3R)-1-[1-(4-methoxyphenyl)-4-piperidinyl]-3-pyrrolidinyl]amino]-2-oxoethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

10/574,087


Absolute stereochemistry.



RN 936447-57-3 CAPLUS

CN Acetamide, 2-amino-N-[(3R)-1-[1-(4-methoxyphenyl)-4-piperidinyl]-3-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.





RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/574,087



L4 ANSWER 19 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2006:1337416 CAPLUS
DN 146:62711
TI Preparation of tetrahydroindole and tetrahydroindazole derivatives as
anticancer agents
IN Xia, Min; Zhang, Tongxiang; Wang, Yifei; Xing, Guowen
PA Peop. Rep. China
SO PCT Int. Appl., 110pp.
CODEN: PIXXD2
DT Patent
LA Chinese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006133634	A1	20061221	WO 2006-CN1281	20060612
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	CN 1896060	A	20070117	CN 2006-10087495	20060612
PRAI	CN 2005-10075307	A	20050614		
OS	CASREACT 146:62711; MARPAT 146:62711				
IT	917001-72-0P 917001-83-3P 917002-40-5P 917002-53-0P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(drug candidate; preparation of tetrahydroindole and tetrahydroindazole derivs. as anticancer agents)				
RN	917001-72-0 CAPLUS				
CN	Benzamide, 2-[4-(1-pyrrolidinyl)-1-piperidinyl]-4-(4,5,6,7-tetrahydro-3,6,6-trimethyl-4-oxo-1H-indol-1-yl)- (CA INDEX NAME)				





RN 917001-83-3 CAPLUS
CN Benzamide, 2-[4-(1-pyrrolidinyl)-1-piperidinyl]-4-(4,5,6,7-tetrahydro-3,6,6-trimethyl-4-oxo-1H-indazol-1-yl)- (CA INDEX NAME)

10/574,087





RN 917002-40-5 CAPLUS
CN Benzamide, 2-[4-(1-pyrrolidinyl)-1-piperidinyl]-4-(4,5,6,7-tetrahydro-3,6,6-trimethyl-4-oxo-1H-indol-1-yl)-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl


RN 917002-53-0 CAPLUS
CN Benzamide, 2-[4-(1-pyrrolidinyl)-1-piperidinyl]-4-(4,5,6,7-tetrahydro-3,6,6-trimethyl-4-oxo-1H-indazol-1-yl)-, hydrochloride (1:?) (CA INDEX NAME)

10/574,087




● x HCl

IT 917003-11-3P 917003-23-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of tetrahydroindole and tetrahydroindazole derivs. as anticancer agents)
RN 917003-11-3 CAPLUS
CN Benzonitrile, 2-[4-(1-pyrrolidinyl)-1-piperidinyl]-4-(4,5,6,7-tetrahydro-3,6,6-trimethyl-4-oxo-1H-indol-1-yl)- (CA INDEX NAME)



RN 917003-23-7 CAPLUS
CN Benzonitrile, 2-[4-(1-pyrrolidinyl)-1-piperidinyl]-4-(4,5,6,7-tetrahydro-3,6,6-trimethyl-4-oxo-1H-indazol-1-yl)- (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/574,087

L4 ANSWER 20 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2006:1279462 CAPLUS

DN 146:27827

TI Preparation of pyrazolone derivatives as inhibitors of transcription factor I κ B α -ubiquitination enzymes and activity of transcription factor NF κ B

IN Fujiwara, Hideyasu; Nakajima, Hiroto; Masuda, Takanobu; Furuichi, Yasuhiro; Shimbara, Naoki

PA Genecare Research Institute Co., Ltd., Japan

SO PCT Int. Appl., 201pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006129583	A1	20061207	WO 2006-JP310632	20060529
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRAI JP 2005-158217 A 20050530

OS MARPAT 146:27827


IT 916233-86-8P 916234-01-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazolone derivs. as inhibitors of transcription factor I κ B α -ubiquitination enzymes and activity of transcription factor NF κ B)

RN 916233-86-8 CAPLUS


CN Benzoic acid, 3-[4,5-dihydro-3-methyl-5-oxo-4-[[4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]methylene]-1H-pyrazol-1-yl]- (CA INDEX NAME)



RN 916234-01-0 CAPLUS

CN Benzoic acid, 4-[4,5-dihydro-3-methyl-5-oxo-4-[[4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]methylene]-1H-pyrazol-1-yl]- (CA INDEX NAME)

10/574,087



RE.CNT 60 THERE ARE 60 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/574,087

L4 ANSWER 21 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2006:1279375 CAPLUS
DN 146:45506
TI Preparation of pyrazolone derivatives as inhibitors of
I κ B α -ubiquitination enzyme and activity of transcription
factor NF κ B
IN Nakajima, Hiroto; Fujiwara, Hideyasu; Fujita, Kumiko; Furuichi, Yasuhiro;
Shimbara, Naoki
PA Genecare Research Institute Co., Ltd., Japan
SO PCT Int. Appl., 266pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006129587	A1	20061207	WO 2006-JP310640	20060529
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRAI JP 2005-158218 A 20050530

OS MARPAT 146:45506


IT 916233-86-8P 916234-01-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazolone derivs. as inhibitors of I κ B α -ubiquitination enzyme and activity of transcription factor NF κ B)

RN 916233-86-8 CAPLUS


CN Benzoic acid, 3-[4,5-dihydro-3-methyl-5-oxo-4-[[4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]methylene]-1H-pyrazol-1-yl]- (CA INDEX NAME)



RN 916234-01-0 CAPLUS

CN Benzoic acid, 4-[4,5-dihydro-3-methyl-5-oxo-4-[[4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]methylene]-1H-pyrazol-1-yl]- (CA INDEX NAME)

10/574,087




RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/574,087

L4 ANSWER 22 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2006:1226989 CAPLUS
DN 146:7980
TI Preparation of tetraazacyclopentanaphthalenones as protein kinase inhibitors
IN Ren, Pingda; Gray, Nathanael S.; Wang, Xia; Zhang, Guobao; Sim, Taebo; Jiang, Songchun
PA Irm LLC, Bermuda
SO PCT Int. Appl., 60pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006124731	A2	20061123	WO 2006-US18644	20060512
	WO 2006124731	A3	20070329		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRAI	US 2005-680892P	P	20050512		
OS	MARPAT 146:7980				
IT	915402-58-3P 915402-72-1P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of tetraazacyclopentanaphthalenones as protein kinase inhibitors useful in treatment and prevention of diseases)				
RN	915402-58-3 CAPLUS				
CN	Benzamide, N-[4-methyl-3-(1,2,4,7-tetrahydro-1-methyl-2-oxo-3H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-3-yl)phenyl]-3-[4-(1-pyrrolidinyl)-1-piperidinyl]-5-(trifluoromethyl)- (CA INDEX NAME)				



RN 915402-72-1 CAPLUS
CN Benzamide, N-[3-(1-ethyl-1,2,4,7-tetrahydro-2-oxo-3H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-3-yl)-5-methoxyphenyl]-3-[4-(1-

10/574,087

pyrrolidinyl)-1-piperidinyl]-5-(trifluoromethyl)- (CA INDEX NAME)



L4 ANSWER 23 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2006:1097510 CAPLUS

DN 145:438420

TI Preparation of N-[[ureido]phenoxy]hetero/aryl]benzamides and related derivatives as NPY antagonists and their use for treating obesity, and abnormal food behavior and for controlling food intake

IN Botez, Iuliana; David-Basei, Christelle; Gourlaouen, Nelly; Nicolaie, Eric; Balavoine, Fabrice; Valette, Gerard; Serradeil-Le Gal, Claudine

PA Cerep, Fr.

SO PCT Int. Appl., 430pp.

CODEN: PIXXD2

DT Patent

LA French

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006108965	A2	20061019	WO 2006-FR829	20060414
	WO 2006108965	A3	20070329		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	FR 2884516	A1	20061020	FR 2005-3795	20050415
	FR 2884516	B1	20070622		
	AU 2006234413	A1	20061019	AU 2006-234413	20060414
PRAI	FR 2005-3795	A	20050415		
	WO 2006-FR829	W	20060414		

OS MARPAT 145:438420

IT 912943-79-4P, 4-([1,4']Bipiperidinyl-1'-yl)-N-[5-[4-[3-(1-ethylpropyl)ureido]-2-methoxyphenoxy]thiazol-2-yl]benzamide


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of NPY antagonists and their use for treating obesity, and abnormal food behavior and for controlling food intake)


RN 912943-79-4 CAPLUS

CN Benzamide, 4-[1,4'-bipiperidin]-1'-yl-N-[5-[4-[[(1-ethylpropyl)amino]carbonyl]amino]-2-methoxyphenoxy]-2-thiazolyl]- (CA INDEX NAME)


10/574,087



IT 179163-79-2P, 4-([1,4']Bipiperidinyl-1'-yl)benzoic acid
 912948-12-0P, Ethyl 4-([1,4']bipiperidinyl-1'-yl)benzoate
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (intermediate; preparation of NPY antagonists and their use for treating
 obesity, and abnormal food behavior and for controlling food intake)
 RN 179163-79-2 CAPLUS
 CN Benzoic acid, 4-[1,4'-bipiperidin]-1'-yl- (CA INDEX NAME)



RN 912948-12-0 CAPLUS
 CN Benzoic acid, 4-[1,4'-bipiperidin]-1'-yl-, ethyl ester (CA INDEX NAME)



10/574,087

L4 ANSWER 24 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2006:1095117 CAPLUS

DN 145:438398

TI Dinitroanilines as antiparasitic compounds, their preparation,
pharmaceutical compositions, and use to treat parasite infections

IN Best, Wayne Morris; Sims, Colette Gloria; Thompson, Richard Christopher
Andrew; Reid, Simon Andrew; Armson, Anthony; Reynoldson, James Alexander

PA Murdoch University, Australia

SO PCT Int. Appl., 74pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006108224	A1	20061019	WO 2006-AU488	20060411
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	AU 2006235206	A1	20061019	AU 2006-235206	20060411
	EP 1871743	A1	20080102	EP 2006-721370	20060411
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
PRAI	AU 2005-901779	A	20050411		
	WO 2006-AU488	W	20060411		
OS	CASREACT 145:438398; MARPAT 145:438398				
IT	912588-03-5P, 1-[4-(1-Pyrrolidinyl)-1-piperidinyl]-2,4-dinitro-6-(trifluoromethyl)benzene				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(drug candidate; preparation of dinitroanilines as antiparasitic compds.)				
RN	912588-03-5 CAPLUS				
CN	Piperidine, 1-[2,4-dinitro-6-(trifluoromethyl)phenyl]-4-(1-pyrrolidinyl)-(CA INDEX NAME)				

10/574,087



RE.CNT 33

THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/574,087

L4 ANSWER 25 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2006:1009967 CAPLUS

DN 145:377368

TI Preparation of anilinoimidazolyl substituted fused pyrimidine compounds as protein kinase inhibitors

IN Ren, Pingda; Gray, Nathanael S.; Wang, Xia; Zhang, Gubao

PA IRM LLC, Bermuda

SO PCT Int. Appl., 45pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006101783	A2	20060928	WO 2006-US8719	20060310
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	AU 2006227790	A1	20060928	AU 2006-227790	20060310
	CA 2600144	A1	20060928	CA 2006-2600144	20060310
	EP 1858521	A2	20071128	EP 2006-737854	20060310
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
	IN 2007DN07160	A	20071005	IN 2007-DN7160	20070917
	KR 2007119690	A	20071220	KR 2007-723507	20071012
PRAI	US 2005-662330P	P	20050315		
	WO 2006-US8719	W	20060310		
OS	MARPAT 145:377368				
IT	911122-15-1P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of anilinoimidazolyl substituted fused pyrimidine compds. as protein kinase inhibitors useful in treatment and prevention of diseases)				
RN	911122-15-1 CAPLUS				
CN	Benzamide, N-[4-methyl-3-[[1-(1H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-imidazol-2-yl]amino]phenyl]-3-[4-(1-pyrrolidinyl)-1-piperidinyl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)				

10/574,087



10/574,087

L4 ANSWER 26 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2006:945673 CAPLUS
DN 145:336057
TI Preparation of heterocyclic compounds as inhibitors of plasminogen activator inhibitor-1
IN Muto, Susumu; Kubo, Asako; Itai, Akiko; Sotome, Tomomi; Yamaguchi, Yoichi
PA Institute of Medicinal Molecular Design. Inc., Japan
SO PCT Int. Appl., 311pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006095713	A1	20060914	WO 2006-JP304324	20060307
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRAI JP 2005-63255 A 20050308

OS MARPAT 145:336057


IT 909790-31-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heterocyclic compds. as inhibitors of plasminogen activator inhibitor-1)

RN 909790-31-4 CAPLUS

CN Benzoic acid, 3-[4,5-dihydro-3-(1-methylethyl)-5-oxo-4-[[4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]methylene]-1H-pyrazol-1-yl]- (CA INDEX NAME)



IT 909789-08-8P, 4-[4-(Pyrrolidin-1-yl)piperidin-1-yl]benzaldehyde


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of heterocyclic compds. as inhibitors of plasminogen activator inhibitor-1)

RN 909789-08-8 CAPLUS

CN Benzaldehyde, 4-[4-(1-pyrrolidinyl)-1-piperidinyl]- (CA INDEX NAME)

10/574,087



RE.CNT 29

THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/574,087

L4 ANSWER 27 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2006:740674 CAPLUS

DN 145:167252

TI Preparation of ureido substituted benzoic acids, particularly (imidazolidin-1-yl)benzoic acids, as promoters of nonsense mutation suppression in messenger RNA (mRNA) and/or as modulators of translation termination for treatment of related diseases

IN Wilde, Richard G.; Takasugi, James J.; Hwang, Seongwoo; Welch, Ellen M.; Chen, Guangming

PA USA

SO U.S. Pat. Appl. Publ., 70 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2006167065	A1	20060727	US 2005-48656	20050121
PRAI	US 2005-48656		20050121		

OS MARPAT 145:167252


IT 651749-22-3P, 3-[3-[4-([1,4']Bipiperidinyl-1'-yl)phenyl]-2-oxoimidazolidin-1-yl]benzoic acid

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of ureido substituted benzoic acids as promoters of nonsense mutation suppression in mRNA and/or as modulators of translation termination)

RN 651749-22-3 CAPLUS

CN Benzoic acid, 3-[3-(4-[1,4'-bipiperidin]-1'-ylphenyl)-2-oxo-1-imidazolidinyl]- (CA INDEX NAME)



10/574,087

L4 ANSWER 28 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2006:630015 CAPLUS

DN 145:103688

TI Preparation of triazolone, tetrazolone and imidazolone derivatives for use as α 2C-adrenoreceptor antagonists

IN Andres-Gil, Jose Ignacio; Alcazar-Vaca, Manuel Jesus; Pastor-Fernandez, Joaquin; Drinkenburg, Wilhelmus Helena Ignatius Maria; Langlois, Xavier Jean Michel; Oyarzabal-Santamarina, Julen; Vega-Ramiro, Juan Antonio

PA Janssen Pharmaceutica N.V., Belg.

SO PCT Int. Appl., 136 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006067139	A1	20060629	WO 2005-EP56951	20051220
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	AU 2005318188	A1	20060629	AU 2005-318188	20051220
	CA 2588028	A1	20060629	CA 2005-2588028	20051220
	EP 1831185	A1	20070912	EP 2005-823472	20051220
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
	CN 101084201	A	20071205	CN 2005-80043606	20051220
	IN 2007DN04693	A	20070817	IN 2007-DN4693	20070619
	KR 2007090941	A	20070906	KR 2007-714061	20070621
PRAI	EP 2004-106817	A	20041221		
	EP 2005-104873	A	20050603		
	WO 2005-EP56951	W	20051220		

OS MARPAT 145:103688

IT 895134-85-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of triazolone, tetrazolone and imidazolone derivs. for use as α 2C-adrenoreceptor antagonists)

RN 895134-85-7 CAPLUS


CN 3H-1,2,4-Triazol-3-one, 2,4-dihydro-2-[2-[(2-phenoxyethyl)amino]ethyl]-4-[4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 895134-84-6

CMF C27 H36 N6 O2


10/574,087



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RE.CNT 16

THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 29 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2006:608560 CAPLUS
 DN 145:83228
 TI Preparation of pyrid-2-ones useful as inhibitors of Tec family protein
 kinases for the treatment of inflammatory, proliferative and
 immunologically-mediated diseases
 IN Charrier, Jean-Damien; Durrant, Steven; Ramaya, Sharn; Jimenez,
 Juan-Miguel; Rutherford, Alistair
 PA Vertex Pharmaceuticals Incorporated, USA
 SO PCT Int. Appl., 130 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006065946	A1	20060622	WO 2005-US45336	20051215
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	AU 2005316540	A1	20060622	AU 2005-316540	20051215
	CA 2591413	A1	20060622	CA 2005-2591413	20051215
	US 2006183911	A1	20060817	US 2005-304057	20051215
	EP 1831168	A1	20070912	EP 2005-854119	20051215
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
	IN 2007KN02260	A	20070817	IN 2007-KN2260	20070619
	KR 2007095952	A	20071001	KR 2007-716337	20070716
PRAI	US 2004-636754P	P	20041216		
	US 2005-673870P	P	20050422		
	WO 2005-US45336	W	20051215		
OS	MARPAT 145:83228				
IT	893435-52-4P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of pyridones as inhibitors of Tec family protein kinases useful for treating and preventing inflammatory, proliferative, hyperproliferative, autoimmune or immunol.-mediated disease)				
RN	893435-52-4 CAPLUS				
CN	Benzamide, N-(1,6-dihydro-6-oxo[3,4'-bipyridin]-5-yl)-4-[4-(1-pyrrolidinyl)-1-piperidinyl]- (CA INDEX NAME)				


10/574,087




RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/574,087

L4 ANSWER 30 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2006:548786 CAPLUS
DN 145:201958
TI 3-Benzimidazol-2-yl-1H-indazoles as potent c-ABL inhibitors
AU McBride, Christopher M.; Renhowe, Paul A.; Gesner, Thomas G.; Jansen, Johanna M.; Lin, Julie; Ma, Sylvia; Zhou, Yasheen; Shafer, Cynthia M.
CS Small Molecule Drug Discovery, Medicinal Chemistry Department, Chiron Corporation, Emeryville, CA, 94608, USA
SO Bioorganic & Medicinal Chemistry Letters (2006), 16(14), 3789-3792
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier B.V.
DT Journal
LA English
OS CASREACT 145:201958
IT 882803-25-0P 900506-32-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(3-benzimidazol-2-yl-1H-indazoles preparation as potent c-ABL inhibitors)
RN 882803-25-0 CAPLUS
CN 1,2-Benzenediamine, 4-[1,4'-bipiperidin]-1'-yl- (CA INDEX NAME)



RN 900506-32-3 CAPLUS
CN Benzenamine, 5-[1,4'-bipiperidin]-1'-yl-2-nitro- (CA INDEX NAME)



RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 31 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2006:513602 CAPLUS

DN 145:46271

TI Preparation of glycopeptide antibiotic monomer derivatives having antibacterial activity against vancomycin-resistant bacteria

IN Arimoto, Hirokazu; Lu, Jun; Yamano, Yoshinori; Yasukata, Tatsuro; Yoshida, Osamu; Iwaki, Tsutomu; Yoshida, Yutaka; Kato, Issei; Morimoto, Kenji; Yasoshima, Kayo

PA National University Corporation Nagoya University, Japan; Shionogi & Co., Ltd.

SO PCT Int. Appl., 244 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006057303	A1	20060601	WO 2005-JP21587	20051124
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	AU 2005308160	A1	20060601	AU 2005-308160	20051124
	CA 2588285	A1	20060601	CA 2005-2588285	20051124
	EP 1818340	A1	20070815	EP 2005-809139	20051124
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
	IN 2007CN02297	A	20070907	IN 2007-CN2297	20070529
	KR 2007092719	A	20070913	KR 2007-714842	20070628
PRAI	JP 2004-344231	A	20041129		
	JP 2005-212471	A	20050722		
	WO 2005-JP21587	W	20051124		

OS MARPAT 145:46271

IT 889684-04-2P



RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of glycopeptide antibiotic monomer derivs. having antibacterial activity against vancomycin-resistant bacteria)

RN 889684-04-2 CAPLUS


CN Vancomycin, N3''-[[4-[4-(1-pyrrolidinyl)-1-piperidinyl]-3-[[3-(trifluoromethoxy)benzoyl]amino]phenyl]methyl]-, hydrochloride (5:13) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



10/574,087

PAGE 2-B




PAGE 3-A

●13/5 HCl


RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/574,087

L4 ANSWER 32 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2006:499167 CAPLUS
DN 145:167154
TI Design and structure-activity relationship of 3-benzimidazol-2-yl-1H-indazoles as inhibitors of receptor tyrosine kinases
AU McBride, Christopher M.; Renhowe, Paul A.; Heise, Carla; Jansen, Johanna M.; Lapointe, Gena; Ma, Sylvia; Pineda, Ramon; Vora, Jayesh; Wiesmann, Marion; Shafer, Cynthia M.
CS Small Molecule Drug Discovery, Biopharma Division, Chiron Corporation, Emeryville, CA, 94608, USA
SO Bioorganic & Medicinal Chemistry Letters (2006), 16(13), 3595-3599
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier B.V.
DT Journal
LA English
IT 882803-25-0P, 4-(4-Piperidinopiperidino)-1,2-benzenediamine
900506-32-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(design and structure-activity relationship of 3-benzimidazol-2-yl-1H-indazoles as inhibitors of receptor tyrosine kinases)
RN 882803-25-0 CAPLUS
CN 1,2-Benzenediamine, 4-[1,4'-bipiperidin]-1'-yl- (CA INDEX NAME)



RN 900506-32-3 CAPLUS
CN Benzenamine, 5-[1,4'-bipiperidin]-1'-yl-2-nitro- (CA INDEX NAME)



RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/574,087

L4 ANSWER 33 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2006:485850 CAPLUS

DN 144:495337

TI Substituted biaryl-carboxylate derivatives as bradykinin B1 antagonists or inverse agonists useful in the treatment of pain and inflammation

IN Wood, Michael R.; Bock, Mark G.; Books, Kathy M.; Freidinger, Roger M.; Kim, June J.

PA USA

SO U.S. Pat. Appl. Publ., 18 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2006111392	A1	20060525	US 2005-284740	20051122
PRAI	US 2004-630594P	P	20041123		
OS	MARPAT 144:495337				
IT	887142-88-3 887142-89-4				

RL: RCT (Reactant); RACT (Reactant or reagent)

(substituted biaryl-carboxylate derivs. as bradykinin B1 antagonists or inverse agonists useful in the treatment of pain and inflammation)


RN 887142-88-3 CAPLUS

CN Benzeneacetic acid, 4-[1,4'-bipiperidin]-1'-yl- (CA INDEX NAME)



RN 887142-89-4 CAPLUS

CN Benzeneacetic acid, 4-[1,4'-bipiperidin]-1'-yl-, methyl ester (CA INDEX NAME)



IT 887142-90-7P 887142-91-8P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(substituted biaryl-carboxylate derivs. as bradykinin B1 antagonists or inverse agonists useful in the treatment of pain and inflammation)

RN 887142-90-7 CAPLUS

CN Benzeneacetic acid, 4-[1,4'-bipiperidin]-1'-yl- α -methyl- (CA INDEX NAME)


10/574,087



RN 887142-91-8 CAPLUS
CN Benzeneacetic acid, 4-[1,4'-bipiperidin]-1'-yl- α -methyl-,
mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 887142-90-7
CMF C19 H28 N2 O2




CM 2

CRN 76-05-1
CMF C2 H F3 O2




IT 887142-66-7P 887142-67-8P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(substituted biaryl-carboxylate derivs. as bradykinin B1 antagonists or inverse agonists useful in the treatment of pain and inflammation)
RN 887142-66-7 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[(4-[1,4'-bipiperidin]-1'-ylphenyl)acetyl]amino]methyl]-3,3'-difluoro-, methyl ester (9CI) (CA INDEX NAME)

10/574,087



RN 887142-67-8 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[2-(4-[1,4'-bipiperidin]-1'-ylphenyl)-1-oxopropyl]amino]methyl]-3,3'-difluoro-, methyl ester (CA INDEX NAME)




IT 887142-70-3 887142-71-4 887142-73-6
887142-75-8 887142-79-2 887142-80-5
887142-82-7

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(substituted biaryl-carboxylate derivs. as bradykinin B1 antagonists or
inverse agonists useful in the treatment of pain and inflammation)

RN 887142-70-3 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[(4-[1,4'-bipiperidin]-1'-ylphenyl)amino]carbonyl]amino]methyl]-3,3'-difluoro-, methyl ester (CA INDEX NAME)




10/574,087

RN 887142-71-4 CAPLUS


CN [1,1'-Biphenyl]-2-carboxylic acid, 4'--[(1R)-1-[[[(4-[1,4'-bipiperidin]-1'-ylphenyl)amino]carbonyl]amino]ethyl]-3,3'-difluoro-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 887142-73-6 CAPLUS


CN [1,1'-Biphenyl]-2-carboxylic acid, 4'--[[[(4-[1,4'-bipiperidin]-1'-ylphenyl)amino]carbonyl]amino]methyl]-, methyl ester (CA INDEX NAME)



RN 887142-75-8 CAPLUS


CN [1,1'-Biphenyl]-2-carboxylic acid, 4'--[[[(4-[1,4'-bipiperidin]-1'-ylphenyl)amino]carbonyl]amino]methyl]-3-fluoro-, methyl ester (CA INDEX NAME)

10/574,087



RN 887142-79-2 CAPLUS


CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[(4-[1,4'-bipiperidin]-1'-ylphenyl)methylamino]carbonyl]amino]methyl]-3,3'-difluoro-, methyl ester (CA INDEX NAME)



RN 887142-80-5 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1R)-1-[[[(4-[1,4'-bipiperidin]-1'-ylphenyl)methylamino]carbonyl]amino]ethyl]-3,3'-difluoro-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



10/574,087

RN 887142-82-7 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[(4-[1,4'-bipiperidin]-1'-ylphenyl)amino]carbonyl]methylamino]methyl]-3,3'-difluoro-, methyl ester
(CA INDEX NAME)



L4 ANSWER 34 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2006:471917 CAPLUS

DN 144:488675

TI Preparation of 1,4-substituted pyrazolopyrimidines as kinase inhibitors, particularly EphB4 inhibitors

IN Schmiedeberg, Niko; Furet, Pascal; Imbach, Patricia; Holzer, Philipp

PA Novartis AG, Switz.; Novartis Pharma GmbH

SO PCT Int. Appl., 88 pp.

CODEN: PIXXD2

DT Patent

LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006050946	A1	20060518	WO 2005-EP12045	20051110
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	AU 2005303965	A1	20060518	AU 2005-303965	20051110
	CA 2585660	A1	20060518	CA 2005-2585660	20051110
	EP 1812441	A1	20070801	EP 2005-819276	20051110
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
	CN 101098873	A	20080102	CN 2005-80046410	20051110
	IN 2007DN03269	A	20070831	IN 2007-DN3269	20070501
	KR 2007084191	A	20070824	KR 2007-710778	20070511
PRAI	GB 2004-25035	A	20041112		
	WO 2005-EP12045	W	20051110		
OS	MARPAT 144:488675				
IT	887327-62-0P, [1-[4-[4-(Pyrrolidin-1-yl)piperidin-1-yl]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl](2-methylphenyl)amine 887327-63-1P 887327-64-2P, (2,6-Dimethylphenyl)[1-[4-[4-(pyrrolidin-1-yl)piperidin-1-yl]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]amine 887327-65-3P 887328-12-3P, (5-Fluoro-2-methylphenyl)[1-[4-[4-(pyrrolidin-1-yl)piperidin-1-yl]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]amine 887328-13-4P 887328-28-1P, (2-Chlorophenyl)[1-[4-[4-(pyrrolidin-1-yl)piperidin-1-yl]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]amine 887328-29-2P 887328-44-1P, (4-Fluoro-2-methylphenyl)[1-[4-[4-(pyrrolidin-1-yl)piperidin-1-yl]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]amine 887328-45-2P 887328-60-1P, (4-Fluoro-2,6-dimethylphenyl)[1-[4-[4-(pyrrolidin-1-yl)piperidin-1-yl]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]amine 887328-61-2P 887328-75-8P, (2-Chloro-4-Fluorophenyl)[1-[4-[4-(pyrrolidin-1-yl)piperidin-1-yl]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]amine 887328-76-9P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(drug candidate; preparation of 1,4-substituted pyrazolopyrimidines as EphB4 inhibitors)				

10/574,087

RN 887327-62-0 CAPLUS

CN 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, N-(2-methylphenyl)-1-[4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]- (CA INDEX NAME)




RN 887327-63-1 CAPLUS

CN 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, N-(2-methylphenyl)-1-[4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]-, tris(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 887327-62-0


CMF C27 H31 N7



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 887327-64-2 CAPLUS

CN 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, N-(2,6-dimethylphenyl)-1-[4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]- (CA INDEX NAME)

10/574,087




RN 887327-65-3 CAPLUS

CN 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, N-(2,6-dimethylphenyl)-1-[4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]-, tris(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 887327-64-2


CMF C28 H33 N7



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 887328-12-3 CAPLUS

CN 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, N-(5-fluoro-2-methylphenyl)-1-[4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]- (CA INDEX NAME)

10/574,087




RN 887328-13-4 CAPLUS

CN 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, N-(5-fluoro-2-methylphenyl)-1-[4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]-, tris(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 887328-12-3


CMF C27 H30 F N7



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 887328-28-1 CAPLUS

CN 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, N-(2-chlorophenyl)-1-[4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]- (CA INDEX NAME)

10/574,087




RN 887328-29-2 CAPLUS

CN 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, N-(2-chlorophenyl)-1-[4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]-, tris(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 887328-28-1


CMF C26 H28 Cl N7



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 887328-44-1 CAPLUS

CN 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, N-(4-fluoro-2-methylphenyl)-1-[4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]- (CA INDEX NAME)

10/574,087




RN 887328-45-2 CAPLUS

CN 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, N-(4-fluoro-2-methylphenyl)-1-[4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]-, tris(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 887328-44-1


CMF C27 H30 F N7



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 887328-60-1 CAPLUS

CN 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, N-(4-fluoro-2,6-dimethylphenyl)-1-[4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]- (CA INDEX NAME)

10/574,087




RN 887328-61-2 CAPLUS

CN 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, N-(4-fluoro-2,6-dimethylphenyl)-1-[4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]-, tris(trifluoroacetate) (9CI)
(CA INDEX NAME)

CM 1

CRN 887328-60-1


CMF C28 H32 F N7



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 887328-75-8 CAPLUS

CN 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, N-(2-chloro-4-fluorophenyl)-1-[4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]- (CA INDEX NAME)

10/574,087




RN 887328-76-9 CAPLUS

CN 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, N-(2-chloro-4-fluorophenyl)-1-[4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]-, tris(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 887328-75-8


CMF C26 H27 Cl F N7



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/574,087

L4 ANSWER 35 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2006:340649 CAPLUS
DN 144:390914
TI Preparation of (indazolyl)benzimidazoles and analogs for inhibiting c-ABL
IN Jansen, Johanna M.; McBride, Christopher; Renhowe, Paul A.; Shafer, Cynthia
PA USA
SO U.S. Pat. Appl. Publ., 243 pp., Cont.-in-part of U.S. Ser. No. 187,967.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 2006079564	A1	20060413	US 2005-261995	20051027
	US 2003207883	A1	20031106	US 2002-187967	20020702
	US 7064215	B2	20060620		
PRAI	US 2001-302791P	P	20010703		
	US 2002-187967	A2	20020702		

OS MARPAT 144:390914


IT 882803-25-0

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of (indazolyl)benzimidazole kinase inhibitors by cyclizing
indazolyl aldehydes or ketones with phenylenediamines)

RN 882803-25-0 CAPLUS

CN 1,2-Benzenediamine, 4-[1,4'-bipiperidin]-1'-yl- (CA INDEX NAME)



L4 ANSWER 36 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2006:333441 CAPLUS

DN 144:350710

TI Preparation of pyrimidine compounds as FAK and/or ALK inhibitors

IN Kawahara, Eiji; Miyake, Takahiro; Roesel, Johannes

PA Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.

SO PCT Int. Appl., 83 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006021457	A2	20060302	WO 2005-EP9255	20050826
	WO 2006021457	A3	20060713		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	AU 2005276585	A1	20060302	AU 2005-276585	20050826
	CA 2575720	A1	20060302	CA 2005-2575720	20050826
	EP 1784399	A2	20070516	EP 2005-782820	20050826
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR			
	CN 101006079	A	20070725	CN 2005-80028095	20050826
	IN 2007DN00959	A	20070803	IN 2007-DN959	20070205
	KR 2007038567	A	20070410	KR 2007-704528	20070226
	NO 2007001504	A	20070525	NO 2007-1504	20070322
PRAI	GB 2004-19160	A	20040827		
	WO 2005-EP9255	W	20050826		
OS	MARPAT 144:350710				
IT	881414-49-9P				
	RL:	PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)			
		(preparation of pyrimidine compds. as FAK and/or ALK inhibitors for treatment of tumor, osteosarcomas, etc.)			
RN	881414-49-9	CAPLUS			
CN	1H-Isoindol-1-one, 7-[[2-[(4-[1,4'-bipiperidin]-1'-yl-2-methoxyphenyl)amino]-5-chloro-4-pyrimidinyl]amino]-2,3-dihydro-2-methyl-4-[4-(1-methylethyl)-1-piperazinyl]- (CA INDEX NAME)				

10/574,087



10/574,087

L4 ANSWER 37 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2006:317348 CAPLUS
DN 144:370114
TI Preparation of pyrimidone derivatives as inhibitors of tau protein kinase
1 for treatment of neurodegenerative diseases
IN Watanabe, Kazutoshi; Fukunaga, Kenji; Kohara, Toshiyuki; Uehara, Fumiaki;
Hiki, Shinsuke; Yokoshima, Satoshi
PA Mitsubishi Pharma Corporation, Japan; Sanofi-Aventis
SO PCT Int. Appl., 232 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006036015	A2	20060406	WO 2005-JP18497	20050929
	WO 2006036015	A3	20060601		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	AU 2005288045	A1	20060406	AU 2005-288045	20050929
	CA 2581179	A1	20060406	CA 2005-2581179	20050929
	EP 1805164	A2	20070711	EP 2005-790292	20050929
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR			
	CN 101048397	A	20071003	CN 2005-80033025	20050929
	KR 2007057931	A	20070607	KR 2007-708236	20070411
	NO 2007002214	A	20070612	NO 2007-2214	20070427
	IN 2007CN01835	A	20070831	IN 2007-CN1835	20070430
PRAI	JP 2004-313115	A	20040929		
	WO 2005-JP18497	W	20050929		

OS MARPAT 144:370114

IT 881916-44-5P 881916-46-7P 881916-51-4P
881916-52-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(drug candidate; preparation of pyrimidone derivs. as inhibitors of tau protein kinase 1 for treatment of neurodegenerative diseases)

RN 881916-44-5 CAPLUS

CN 4(3H)-Pyrimidinone, 6-(3-fluoro-4-pyridinyl)-3-methyl-2-[(2S)-2-[4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]-4-morpholinyl]- (CA INDEX NAME)

Absolute stereochemistry.


10/574,087



RN 881916-46-7 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[(2S)-2-(4-[1,4'-bipiperidin]-1'-ylphenyl)-4-morpholinyl]-6-(3-fluoro-4-pyridinyl)-3-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 881916-51-4 CAPLUS

CN 4(3H)-Pyrimidinone, 6-(3-fluoro-4-pyridinyl)-3-methyl-2-[(3S)-3-[4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]-1-piperazinyl]-, tetrahydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/574,087



● 4 HCl

RN 881916-52-5 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[(3S)-3-(4-[1,4'-bipiperidin]-1'-ylphenyl)-1-piperazinyl]-6-(3-fluoro-4-pyridinyl)-3-methyl-, tetrahydrochloride (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



● 4 HCl

10/574,087

L4 ANSWER 38 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2006:317255 CAPLUS

DN 144:370107

TI Preparation of phthalazinone derivatives as cytokine modulators

IN Zembower, David E.; Singh, Jasbir; Mishra, Rama K.

PA Angion Biomedica Corp., USA

SO PCT Int. Appl., 143 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 2006036981	A2	20060406	WO 2005-US34669	20050928
	WO 2006036981	A3	20060727		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	AU 2005289560	A1	20060406	AU 2005-289560	20050928
	CA 2579240	A1	20060406	CA 2005-2579240	20050928
	US 2006116365	A1	20060601	US 2005-238285	20050928
	EP 1799651	A2	20070627	EP 2005-815067	20050928
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR			
	CN 101039918	A	20070919	CN 2005-80032410	20050928
	IN 2007KN01468	A	20070720	IN 2007-KN1468	20070424
PRAI	US 2004-613740P	P	20040928		
	US 2005-675241P	P	20050427		
	WO 2005-US34669	W	20050928		
OS	CASREACT 144:370107; MARPAT 144:370107				
IT	882000-45-5P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of phthalazinone derivs. as cytokine modulators)				
RN	882000-45-5 CAPLUS				
CN	1(2H)-Phthalazinone, 4-(4-[1,4'-bipiperidin]-1'-yl-3-nitrophenyl)- (CA INDEX NAME)				

10/574,087




10/574,087

L4 ANSWER 39 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2006:240736 CAPLUS
DN 144:292779
TI 2-Morpholino-4-pyrimidinones as tau protein kinase 1 inhibitors, their
preparation, pharmaceutical compositions, and use in therapy
IN Watanabe, Kazutoshi; Uehara, Fumiaki; Hiki, Shinsuke; Kohara, Toshiyuki;
Fukunaga, Kenji; Yokoshima, Satoshi
PA Mitsubishi Pharma Corporation, Japan; Sanofi-Aventis
SO PCT Int. Appl., 144 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006028290	A1	20060316	WO 2005-JP17080	20050909
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	AU 2005280885	A1	20060316	AU 2005-280885	20050909
	CA 2578434	A1	20060316	CA 2005-2578434	20050909
	EP 1789414	A1	20070530	EP 2005-783586	20050909
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
	CN 101035781	A	20070912	CN 2005-80030353	20050909
	NO 2007001787	A	20070509	NO 2007-1787	20070404
	KR 2007058586	A	20070608	KR 2007-707681	20070404
	IN 2007CN01433	A	20070831	IN 2007-CN1433	20070409
PRAI	JP 2004-296926	A	20040909		
	WO 2005-JP17080	W	20050909		
OS	MARPAT 144:292779				
IT	879203-84-6P 879203-85-7P 879203-86-8P 879203-87-9P 879206-08-3P, 2-[2-[4-[4-(Pyrrolidin-1-yl)piperidin-1-yl]phenyl]morpholin-4-yl]-3-methyl-6-(pyrimidin-4-yl)-3H-pyrimidin-4-one 879206-09-4P, 2-[2-[4-[4-(Piperidin-1-yl)piperidin-1-yl]phenyl]morpholin-4-yl]-3-methyl-6-(pyrimidin-4-yl)-3H-pyrimidin-4-one				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (drug candidate; preparation of morpholinopyrimidinones as tau protein kinase 1 inhibitors)				
RN	879203-84-6 CAPLUS				
CN	4(3H)-Pyrimidinone, 3-methyl-6-(4-pyridinyl)-2-[(2S)-2-[4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]-4-morpholinyl]- (CA INDEX NAME)				

Absolute stereochemistry.


10/574,087



RN 879203-85-7 CAPLUS

CN [4,4'-Bipyrimidin]-6(1H)-one, 1-methyl-2-[(2S)-2-[4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]-4-morpholinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 879203-86-8 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[(2S)-2-(4-[1,4'-bipiperidin]-1'-ylphenyl)-4-morpholinyl]-3-methyl-6-(4-pyridinyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 879203-87-9 CAPLUS

CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[(2S)-2-(4-[1,4'-bipiperidin]-1'-ylphenyl)-4-morpholinyl]-1-methyl- (CA INDEX NAME)


10/574,087

Absolute stereochemistry.




RN 879206-08-3 CAPLUS

CN [4,4'-Bipyrimidin]-6(1H)-one, 1-methyl-2-[2-[4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]-4-morpholinyl]- (CA INDEX NAME)



RN 879206-09-4 CAPLUS

CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[2-(4-[1,4'-bipiperidin]-1'-yl)phenyl]-4-morpholinyl]-1-methyl- (CA INDEX NAME)




RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/574,087

L4 ANSWER 40 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2006:193590 CAPLUS
DN 144:274291
TI Preparation of bis(arylamino)pyrimidine derivatives as antitumor agents
IN Imbach, Patricia; Kawahara, Eiji; Konishi, Kazuhide; Matsuura, Naoko;
Miyake, Takahiro; Ohmori, Osamu; Roesel, Johannes; Teno, Naoki; Umemura,
Ichiro
PA Novartis AG, Switz.; Novartis Pharma GmbH
SO PCT Int. Appl., 118 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006021454	A2	20060302	WO 2005-EP9251	20050826
	WO 2006021454	A3	20060504		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	AU 2005276582	A1	20060302	AU 2005-276582	20050826
	CA 2577251	A1	20060302	CA 2005-2577251	20050826
	EP 1784392	A2	20070516	EP 2005-776772	20050826
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR			
	CN 101048386	A	20071003	CN 2005-80036888	20050826
	IN 2007DN01410	A	20070824	IN 2007-DN1410	20070221
	KR 2007054223	A	20070528	KR 2007-706800	20070326
	NO 2007001593	A	20070522	NO 2007-1593	20070327
PRAI	GB 2004-19161	A	20040827		
	WO 2005-EP9251	W	20050826		
OS	MARPAT 144:274291				
IT	878158-51-1P 878158-58-8P 878158-92-0P 878159-17-2P 878159-18-3P 878159-42-3P 878159-52-5P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of bis(arylamino)pyrimidine derivs. as kinase inhibitors and antitumor agents)				
RN	878158-51-1 CAPLUS				
CN	Benzenesulfonamide, 2-[[2-[(4-[1,4'-bipiperidin]-1'-yl-2-methoxyphenyl)amino]-5-chloro-4-pyrimidinyl]amino]-N-(2-methylpropyl)-(CA INDEX NAME)				

10/574,087




RN 878158-58-8 CAPLUS

CN Benzenesulfonamide, 2-[[2-[(5-[1,4'-bipiperidin]-1'-yl)-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-(2-methylpropyl)- (CA INDEX NAME)



RN 878158-92-0 CAPLUS


CN Benzenesulfonamide, 2-[[2-[(5-[1,4'-bipiperidin]-1'-yl)-2-methoxyphenyl]amino]-5-bromo-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 878159-17-2 CAPLUS

CN Benzamide, 5-[1,4'-bipiperidin]-1'-yl-2-[[5-chloro-2-[[2-methoxy-5-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)


10/574,087



RN 878159-18-3 CAPLUS
 CN Benzamide, 5-[1,4'-bipiperidin]-1'-yl-2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 878159-42-3 CAPLUS
 CN 1H-Isoindol-1-one, 7-[[2-[[4-[1,4'-bipiperidin]-1'-yl-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-2,3-dihydro-2-methyl- (CA INDEX NAME)



RN 878159-52-5 CAPLUS
 CN 1(2H)-Isoquinolinone, 8-[[2-[[4-[1,4'-bipiperidin]-1'-yl-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-3,4-dihydro-2-methyl- (CA INDEX NAME)

10/574,087





IT 878159-78-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of bis(arylamino)pyrimidine derivs. as kinase inhibitors and antitumor agents)

RN 878159-78-5 CAPLUS

CN Benzamide, 5-[1,4'-bipiperidin]-1'-yl-2-[(2,5-dichloro-4-pyrimidinyl)amino]-N-methyl- (CA INDEX NAME)



10/574,087

L4 ANSWER 41 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2006:192143 CAPLUS

DN 144:274287

TI Preparation of 2-amino-7,8-dihydro-6-pteridinols and related compounds as protein PLK1 inhibitors

IN Stadtmueller, Heinz; Engelhardt, Harald; Schoop, Andreas; Steegmaier, Martin; Hoffmann, Matthias; Grauert, Matthias

PA Boehringer Ingelheim International G.m.b.H., Germany

SO PCT Int. Appl., 55 pp.

CODEN: PIXXD2

DT Patent


LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006021548	A1	20060302	WO 2005-EP54099	20050819
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	CA 2578560	A1	20060302	CA 2005-2578560	20050819
	EP 1784406	A1	20070516	EP 2005-779168	20050819
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
	US 2006046990	A1	20060302	US 2005-211783	20050825
PRAI	EP 2004-20339	A	20040827		
	WO 2005-EP54099	W	20050819		
OS	MARPAT 144:274287				
IT	877675-85-9P 877675-91-7P 877676-10-3P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of aminodihydropteridinols and related compds. as protein PLK1 inhibitors)				
RN	877675-85-9 CAPLUS				
CN	6(5H)-Pteridinone, 7-ethyl-7,8-dihydro-2-[[2-methoxy-4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]amino]-5-methyl-8-(1-methylethyl)-, (7R)- (CA INDEX NAME)				

Absolute stereochemistry.


10/574,087



RN 877675-91-7 CAPLUS

CN 6(5H)-Pteridinone, 2-[(4-[1,4'-bipiperidin]-1'-yl-2-methoxyphenyl)amino]-7-ethyl-7,8-dihydro-5-methyl-8-(1-methylethyl)-, (7R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 877676-10-3 CAPLUS

CN 6(5H)-Pteridinone, 2-[[4-[4-(1-azetidiny)-1-piperidinyl]-2-methoxyphenyl]amino]-7-ethyl-7,8-dihydro-5-methyl-8-(1-methylethyl)-, (7R)- (CA INDEX NAME)

Absolute stereochemistry.



IT 761440-23-7P 761440-78-2P 761440-83-9P
877676-41-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of aminodihydropteridinols and related compds. as protein PLK1 inhibitors)

10/574,087


RN 761440-23-7 CAPLUS

CN Piperidine, 1-(3-methoxy-4-nitrophenyl)-4-(1-pyrrolidinyl)- (CA INDEX NAME)




RN 761440-78-2 CAPLUS

CN Benzenamine, 2-methoxy-4-[4-(1-pyrrolidinyl)-1-piperidinyl]- (CA INDEX NAME)



RN 761440-83-9 CAPLUS


CN Benzenamine, 4-[1,4'-bipiperidin]-1'-yl-2-methoxy- (CA INDEX NAME)



RN 877676-41-0 CAPLUS

CN Benzenamine, 4-[4-(1-azetidinyl)-1-piperidinyl]-2-methoxy- (CA INDEX NAME)

10/574,087



RE.CNT 3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 42 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2006:103531 CAPLUS

DN 144:192281

TI Preparation of 1,2,3,4-tetrahydropyrazin-2-yl acetamides as bradykinin B1 receptor antagonists for treating pain and diseases such as inflammation-mediated diseases.

IN Askew, Benny C.; Aya, Toshihiro; Biswas, Kaustav; Cai, Guolin; Chen, Jian J.; Han, Nianhe; Liu, Qingyian; Nguyen, Thomas; Nishimura, Nobuko; Nomak, Rana; Peterkin, Tanya; Qian, Wenyan; Yang, Kevin; Yuan, Chester Chenguang; Zhu, Jiawang; D' Amico, Derin C.; Human, Jason B.; Huang, Qi

PA USA

SO U.S. Pat. Appl. Publ., 83 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	US 2006025400	A1	20060202	US 2005-182216	20050715	
	AU 2005275036	A1	20060223	AU 2005-275036	20050715	
	CA 2573730	A1	20060223	CA 2005-2573730	20050715	
	WO 2006019975	A1	20060223	WO 2005-US25090	20050715	
	W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW		
	RW:			AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
	EP 1817294	A1	20070815	EP 2005-771399	20050715	
	R:			AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU		
PRAI	US 2004-588904P	P	20040715			
	WO 2005-US25090	W	20050715			

OS MARPAT 144:192281

IT 875130-21-5P, N-[4-(1,4'-Bipiperidin-1'-yl)phenyl]-2-[(2R)-1-[(4-methylphenyl)sulfonyl]-3-oxo-1,2,3,4-tetrahydro-2-pyrazinyl]acetamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(drug candidate; preparation of 1,2,3,4-tetrahydropyrazin-2-yl acetamides as bradykinin B1 receptor antagonists for treating pain and diseases such as inflammation-mediated diseases)

RN 875130-21-5 CAPLUS

CN Pyrazineacetamide, N-(4-[1,4'-bipiperidin]-1'-ylphenyl)-1,2,3,4-tetrahydro-1-[(4-methylphenyl)sulfonyl]-3-oxo-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



10/574,087



10/574,087

L4 ANSWER 43 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2006:75243 CAPLUS
DN 144:150384
TI Preparation of 1,4-disubstituted naphthalenes as inhibitors of p38 MAP
kinase
IN Ashwell, Mark Antony; Liu, Yanbin; Ali, Syed; Hill, Jason; Wrona, Woj
PA Arqule, Inc., USA
SO PCT Int. Appl., 261 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006010082	A1	20060126	WO 2005-US24441	20050708
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI	US 2004-585862P	P	20040708		
OS	MARPAT 144:150384				
IT	874135-02-1P, N-[4-[2-(Morpholino)ethoxy]naphthalen-1-yl]-3-[4-(pyrrolidin-1-yl)piperidin-1-yl]benzamide				
	RL: ARG (Analytical reagent use); BUU (Biological use, unclassified); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(drug candidate, anal. reagent for P38 protein; preparation of N-(4-substituted naphthalen-1-yl)carboxamides as inhibitors of p38 MAP kinase)				
RN	874135-02-1 CAPLUS				
CN	Benzamide, N-[4-[2-(4-morpholinyl)ethoxy]-1-naphthalenyl]-3-[4-(1-pyrrolidinyl)-1-piperidinyl]- (CA INDEX NAME)				



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/574,087

L4 ANSWER 44 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2005:1350083 CAPLUS

DN 144:88305

TI Preparation of imidazolylypyrimidinamines as protein kinase inhibitors

IN Ren, Pingda; Wang, Xia; Zhang, Guobao; Ding, Qiang; You, Shuli; Zhang, Qiong; Chopiuk, Greg; Albaugh, Pamela A.; Sim, Taebo; Gray, Nathanael Schiander

PA IRM LLC, Bermuda

SO PCT Int. Appl., 103 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005123719	A1	20051229	WO 2005-US20371	20050609
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2005254982	A1	20051229	AU 2005-254982	20050609
	CA 2567662	A1	20051229	CA 2005-2567662	20050609
	EP 1758892	A1	20070307	EP 2005-759571	20050609
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, LV				
	CN 1960988	A	20070509	CN 2005-80017534	20050609
	IN 2006DN06842	A	20070831	IN 2006-DN6842	20061116
	KR 2007020504	A	20070221	KR 2006-725907	20061208
	NO 2007000160	A	20070109	NO 2007-160	20070109
	US 2007225286	A1	20070927	US 2007-628881	20070309
PRAI	US 2004-578491P	P	20040610		
	WO 2005-US20371	W	20050609		
OS	CASREACT 144:88305; MARPAT 144:88305				
IT	872331-07-2P 872331-09-4P 872331-27-6P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of imidazolylypyrimidinamines as protein kinase inhibitors)				
RN	872331-07-2 CAPLUS				
CN	Benzamide, N-[3-[[1-(6-amino-4-pyrimidinyl)-1H-imidazol-2-yl]amino]-4-methylphenyl]-3-[4-(1-pyrrolidinyl)-1-piperidinyl]-5-(trifluoromethyl)-(CA INDEX NAME)				

10/574,087




RN 872331-09-4 CAPLUS

CN Benzamide, N-[3-[[1-[6-(cyclopropylamino)-4-pyrimidinyl]-1H-imidazol-2-yl]amino]-4-methylphenyl]-3-[4-(1-pyrrolidinyl)-1-piperidinyl]-5-(trifluoromethyl)- (CA INDEX NAME)



RN 872331-27-6 CAPLUS

CN Benzamide, N-[3-[[1-[6-(cyclopropylamino)-4-pyrimidinyl]-1H-imidazol-2-yl]amino]-5-methoxyphenyl]-3-[4-(1-pyrrolidinyl)-1-piperidinyl]-5-(trifluoromethyl)- (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 45 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2005:1290311 CAPLUS

DN 144:36339

TI Preparation of cinnamide, 3-benzylidenepiperidin-2-one, phenylpropynamide compounds as amyloid β production inhibitors

IN Kimura, Teiji; Kawano, Koki; Doi, Eriko; Kitazawa, Noritaka; Shin, Kogyoku; Miyagawa, Takehiko; Kaneko, Toshihiko; Ito, Koichi; Takaishi, Mamoru; Sasaki, Takeo; Hagiwara, Hiroaki

PA Eisai Co., Ltd., Japan

SO PCT Int. Appl., 679 pp.

CODEN: PIXXD2

DT Patent


LA Japanese

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005115990	A1	20051208	WO 2005-JP9537	20050525
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2005247746	A1	20051208	AU 2005-247746	20050525
	CA 2566094	A1	20051208	CA 2005-2566094	20050525
	US 2006004013	A1	20060105	US 2005-136355	20050525
	EP 1757591	A1	20070228	EP 2005-743758	20050525
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
	CN 1972916	A	20070530	CN 2005-80020584	20050525
	IN 2006DN06740	A	20070831	IN 2006-DN6740	20061114
	NO 2006005789	A	20070226	NO 2006-5789	20061214
PRAI	JP 2004-155790	A	20040526		
	JP 2004-310909	A	20041026		
	WO 2005-JP9537	W	20050525		
OS	MARPAT 144:36339				
IT	870846-11-0P 870846-93-8P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of cinnamide, 3-benzylidenepiperidin-2-one, phenylpropynamide compds. as amyloid β production inhibitors for treatment of neurodegenerative diseases)				
RN	870846-11-0 CAPLUS				
CN	Benzonitrile, 4-[(3E)-3-[[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]methylene]-2-oxo[1,4'-bipiperidin]-1'-yl]- (9CI) (CA INDEX NAME)				

Double bond geometry as shown.


10/574,087



RN 870846-93-8 CAPLUS

CN [1,4'-Bipiperidin]-2-one, 3-[[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]methylene]-1'-(4-methoxyphenyl)-, (3E)- (CA INDEX NAME)

Double bond geometry as shown.



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 46 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2005:1262333 CAPLUS

DN 144:22949

TI Preparation of 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles as antibacterial agents

IN Tsubochi, Hidetsugu; Sasaki, Hirofumi; Kuroda, Hideaki; Itotani, Motohiro; Hasegawa, Takeshi; Haraguchi, Yoshikazu; Kuroda, Takeshi; Matsuzaki, Takayuki; Tai, Kuninori; Komatsu, Makoto; Matsumoto, Makoto; Hashizume, Hiroyuki; Tomishige, Tatsuo; Seike, Yuji; Kawasaki, Masanori; Sumida, Takumi; Miyamura, Shin; Oguro, Kinue; Tanaka, Kazuho; Takemura, Isao

PA Ohtsuka Pharmaceutical Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 1050 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	JP 2005330266	A	20051202	JP 2005-113726	20050411
PRAI	JP 2004-114975	A	20040409		
	JP 2004-125055	A	20040421		

OS MARPAT 144:22949

IT 851686-09-4P 851686-11-8P 851686-13-0P
 851686-19-6P 851692-97-2P 851693-01-1P
 851693-15-7P 851693-17-9P 851693-19-1P
 851693-21-5P 851693-23-7P 851693-29-3P
 851693-32-8P 851693-37-3P 851697-52-4P
 851697-53-5P 851697-54-6P 851697-55-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles as antibacterial agents and antitubercular agents)

RN 851686-09-4 CAPLUS

CN Imidazo[2,1-b]oxazole, 2,3-dihydro-2-methyl-6-nitro-2-[[4-[4-[[4-(trifluoromethoxy)phenyl]methoxy][1,4'-bipiperidin]-1'-yl]phenoxy]methyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



10/574,087

PAGE 1-B




RN 851686-11-8 CAPLUS


CN Imidazo[2,1-b]oxazole, 2,3-dihydro-2-methyl-6-nitro-2-[[4-[4-[4-(trifluoromethoxy)phenoxy][1,4'-bipiperidin]-1'-yl]phenoxy]methyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 851686-13-0 CAPLUS


CN Imidazo[2,1-b]oxazole, 2-[[4-[4-[(4-chlorophenyl)methyl][1,4'-bipiperidin]-1'-yl]phenoxy]methyl]-2,3-dihydro-2-methyl-6-nitro-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 851686-19-6 CAPLUS

CN [1,4'-Bipiperidin]-4-amine, N-(4-chlorophenyl)-1'-[4-[[[(2R)-2,3-dihydro-2-methyl-6-nitroimidazo[2,1-b]oxazol-2-yl]methoxy]phenyl]]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



10/574,087


PAGE 1-B




RN 851692-97-2 CAPLUS
CN Imidazo[2,1-b]oxazole, 2,3-dihydro-2-methyl-6-nitro-2-[[4-[4-[[4-(trifluoromethoxy)phenyl]methyl][1,4'-bipiperidin]-1'-yl]phenoxy]methyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 851693-01-1 CAPLUS
CN [1,4'-Bipiperidin]-4-amine, 1'-[4-[[(2R)-2,3-dihydro-2-methyl-6-nitroimidazo[2,1-b]oxazol-2-yl]methoxy]phenyl]-N-methyl-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)


Absolute stereochemistry.

10/574,087

PAGE 1-A



PAGE 1-B




RN 851693-15-7 CAPLUS

CN [1,4'-Bipiperidin]-4-amine, 1'-[4-[[(2R)-2,3-dihydro-6-nitroimidazo[2,1-b]oxazol-2-yl]methoxy]phenyl]-N-methyl-N-[4-(trifluoromethoxy)phenyl]-
(CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



10/574,087

PAGE 1-B




RN 851693-17-9 CAPLUS


CN [1,4'-Bipiperidin]-4-amine, N-(4-chlorophenyl)-1'-[4-[[(2R)-2,3-dihydro-6-nitroimidazo[2,1-b]oxazol-2-yl]methoxy]phenyl]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 851693-19-1 CAPLUS


CN [1,4'-Bipiperidin]-4-amine, 1'-[4-[[(2R)-2,3-dihydro-6-nitroimidazo[2,1-b]oxazol-2-yl]methoxy]phenyl]-N-methyl-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 851693-21-5 CAPLUS

CN [1,4'-Bipiperidin]-4-amine, 1'-[4-[[(2R)-2,3-dihydro-6-nitroimidazo[2,1-b]oxazol-2-yl]methoxy]phenyl]-N-(4-fluorophenyl)-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



10/574,087

PAGE 1-B




RN 851693-23-7 CAPLUS


CN [1,4'-Bipiperidin]-4-amine, 1'-[4-[[(2R)-2,3-dihydro-2-methyl-6-nitroimidazo[2,1-b]oxazol-2-yl]methoxy]phenyl]-N-(4-fluorophenyl)-N-methyl-
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 851693-29-3 CAPLUS

CN Imidazo[2,1-b]oxazole, 2,3-dihydro-2-methyl-6-nitro-2-[(4-[1,4':1'',4'''-terpiperidin]-1-ylphenoxy)methyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/574,087



RN 851693-32-8 CAPLUS

CN [1,4'-Bipiperidin]-4-amine, 1'-[4-[[(2R)-2,3-dihydro-2-methyl-6-nitroimidazo[2,1-b]oxazol-2-yl]methoxy]phenyl]-N-methyl-N-(2-phenylethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 851693-37-3 CAPLUS

CN Imidazo[2,1-b]oxazole, 2-[[4-[[4-[(3,4-dichlorophenyl)methyl][1,4'-bipiperidin]-1'-yl]phenoxy]methyl]-2,3-dihydro-2-methyl-6-nitro-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.

10/574,087

PAGE 1-A




PAGE 1-B



RN 851697-52-4 CAPLUS
CN [1,4'-Bipiperidin]-4-amine, 1'-[4-[[(2R)-2,3-dihydro-2-methyl-6-nitroimidazo[2,1-b]oxazol-2-yl]methoxy]phenyl]-N-methyl-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



10/574,087


PAGE 1-B




RN 851697-53-5 CAPLUS
CN [1,4'-Bipiperidin]-4-amine, 1'-[4-[[(2R)-2,3-dihydro-2-methyl-6-nitroimidazo[2,1-b]oxazol-2-yl]methoxy]phenyl]-N-ethyl-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





PAGE 1-B



RN 851697-54-6 CAPLUS
CN [1,4'-Bipiperidin]-4-amine, N-(4-chlorophenyl)-1'-[4-[[(2R)-2,3-dihydro-2-methyl-6-nitroimidazo[2,1-b]oxazol-2-yl]methoxy]phenyl]-N-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 851697-55-7 CAPLUS

CN [1,4'-Bipiperidin]-4-amine, 1'-[4-[(2R)-2,3-dihydro-2-methyl-6-nitroimidazo[2,1-b]oxazol-2-yl]methoxy]phenyl]-N,N-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 47 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2005:1155540 CAPLUS
 DN 143:405903
 TI Preparation of benzoyldiaminothiazoles as selective Cdk4 inhibitors useful
 against cancer
 IN Ding, Qingjie; Jiang, Nan; Kim, Kyungjin
 PA Hoffmann-La Roche Inc., USA
 SO U.S. Pat. Appl. Publ., 84 pp.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005239843	A1	20051027	US 2005-98563	20050404
	US 7211576	B2	20070501		
	AU 2005235679	A1	20051103	AU 2005-235679	20050408
	CA 2562377	A1	20051103	CA 2005-2562377	20050408
	WO 2005103034	A1	20051103	WO 2005-EP3734	20050408
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1740576	A1	20070110	EP 2005-730856	20050408
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
	CN 1942464	A	20070404	CN 2005-80011762	20050408
	BR 2005010001	A	20070918	BR 2005-10001	20050408
	JP 2007533674	T	20071122	JP 2007-508763	20050408
	IN 2006CN03862	A	20070615	IN 2006-CN3862	20061019
PRAI	US 2004-563712P	P	20040420		
	WO 2005-EP3734	W	20050408		
OS	CASREACT 143:405903; MARPAT 143:405903				
IT	867291-51-8P, [4-Amino-2-[[4-[4-(pyrrolidin-1-yl)piperidin-1-yl]phenyl]amino]thiazol-5-yl](3-fluoro-4-methoxyphenyl)methanone				
	867291-52-9P, [4-Amino-2-[[4-[4-(pyrrolidin-1-yl)piperidin-1-yl]phenyl]amino]thiazol-5-yl](3-fluorophenyl)methanone				
	867291-53-0P, [4-Amino-2-[[4-[4-(pyrrolidin-1-yl)piperidin-1-yl]phenyl]amino]thiazol-5-yl]benzodioxol-5-ylmethanone				
	867291-54-1P, [4-Amino-2-[[4-[4-(pyrrolidin-1-yl)piperidin-1-yl]phenyl]amino]thiazol-5-yl](2,3-dihydrobenzo[1,4]dioxin-6-yl)methanone				
	867291-55-2P, [4-Amino-2-[[4-[4-(pyrrolidin-1-yl)piperidin-1-yl]phenyl]amino]thiazol-5-yl](3-methoxyphenyl)methanone				
	867291-56-3P, [4-Amino-2-[[4-[4-(pyrrolidin-1-yl)piperidin-1-yl]phenyl]amino]thiazol-5-yl](4-hydroxyphenyl)methanone				
	867291-57-4P, [4-Amino-2-[[4-([1,4']bipiperidinyl-1'-yl)phenyl]amino]thiazol-5-yl](4-hydroxyphenyl)methanone				
	867291-58-5P, [4-Amino-2-[[4-([1,4']bipiperidinyl-1'-yl)phenyl]amino]thiazol-5-yl](3-fluorophenyl)methanone				
	867291-59-6P, [4-Amino-2-[[4-([1,4']bipiperidinyl-1'-yl)phenyl]amino]thiazol-5-yl](3-fluoro-4-methoxyphenyl)methanone				
	867291-60-9P, [4-Amino-2-[[4-([1,4']bipiperidinyl-1'-yl)phenyl]amino]thiazol-5-yl](3-fluoro-4-methoxyphenyl)methanone				

yl)phenyl]amino]thiazol-5-yl]benzodioxol-5-ylmethanone
867291-61-0P, [4-Amino-2-[[4-([1,4']bipiperidinyl-1'-yl)phenyl]amino]thiazol-5-yl](2,3-dihydrobenzo[1,4]dioxin-6-yl)methanone
867291-62-1P, [4-Amino-2-[[4-([1,4']bipiperidinyl-1'-yl)phenyl]amino]thiazol-5-yl](3-methoxyphenyl)methanone
867291-63-2P, [4-Amino-2-[[4-(3-hydroxy-[1,4']bipiperidinyl-1'-yl)phenyl]amino]thiazol-5-yl](3-fluorophenyl)methanone
867291-64-3P, [4-Amino-2-[[4-(3-hydroxy-[1,4']bipiperidinyl-1'-yl)phenyl]amino]thiazol-5-yl](3-fluoro-4-methoxyphenyl)methanone
867291-65-4P, [4-Amino-2-[[4-(3-hydroxy-[1,4']bipiperidinyl-1'-yl)phenyl]amino]thiazol-5-yl]benzodioxol-5-ylmethanone
867291-66-5P, [4-Amino-2-[[4-(3-hydroxy-[1,4']bipiperidinyl-1'-yl)phenyl]amino]thiazol-5-yl](2,3-dihydrobenzo[1,4]dioxin-6-yl)methanone
867291-67-6P, [4-Amino-2-[[4-(3-hydroxy-[1,4']bipiperidinyl-1'-yl)phenyl]amino]thiazol-5-yl](3-methoxyphenyl)methanone
867291-68-7P, [4-Amino-2-[[4-(3-hydroxy-[1,4']bipiperidinyl-1'-yl)phenyl]amino]thiazol-5-yl](4-hydroxyphenyl)methanone
867291-79-0P, 4-[[4-Amino-2-[[4-(3-hydroxy-[1,4']bipiperidinyl-1'-yl)phenyl]amino]thiazol-5-yl]carbonyl]benzonitrile 867291-80-3P, [4-Amino-2-[[4-(3-hydroxy-[1,4']bipiperidinyl-1'-yl)phenyl]amino]thiazol-5-yl](4-nitrophenyl)methanone 867291-81-4P, [4-Amino-2-[[4-[(pyrrolidin-1-yl)piperidin-1-yl]phenyl]amino]thiazol-5-yl](4-nitrophenyl)methanone 867291-82-5P, 4-[[4-Amino-2-[[4-[(pyrrolidin-1-yl)piperidin-1-yl]phenyl]amino]thiazol-5-yl]carbonyl]benzonitrile 867291-83-6P, 4-[[4-Amino-2-[[4-([1,4']bipiperidinyl-1'-yl)phenyl]amino]thiazol-5-yl]carbonyl]benzonitrile 867291-84-7P, [4-Amino-2-[[4-([1,4']bipiperidinyl-1'-yl)phenyl]amino]thiazol-5-yl](4-nitrophenyl)methanone 867291-85-8P, [4-Amino-2-[[4-([1,4']bipiperidinyl-1'-yl)phenyl]amino]thiazol-5-yl](3,5-difluorophenyl)methanone 867291-86-9P, [4-Amino-2-[[4-([1,4']bipiperidinyl-1'-yl)phenyl]amino]thiazol-5-yl](4-chlorophenyl)methanone 867291-87-0P, [4-Amino-2-[[4-([1,4']bipiperidinyl-1'-yl)phenyl]amino]thiazol-5-yl](3,4-difluorophenyl)methanone 867291-88-1P, [4-Amino-2-[[4-([1,4']bipiperidinyl-1'-yl)phenyl]amino]thiazol-5-yl](3,4-dichlorophenyl)methanone 867291-89-2P, [4-Amino-2-[[4-([1,4']bipiperidinyl-1'-yl)phenyl]amino]thiazol-5-yl](4-fluorophenyl)methanone 867291-90-5P, [4-Amino-2-[[4-([1,4']bipiperidinyl-1'-yl)phenyl]amino]thiazol-5-yl](4-chloro-3-nitrophenyl)methanone 867291-91-6P, 4-[[4-Amino-2-[[4-([1,4']bipiperidinyl-1'-yl)phenyl]amino]thiazol-5-yl]carbonyl]benzoic acid 867291-92-7P, 3-[[4-Amino-2-[[4-([1,4']bipiperidinyl-1'-yl)phenyl]amino]thiazol-5-yl]carbonyl]benzonitrile 867291-93-8P, [4-Amino-2-[[4-([1,4']bipiperidinyl-1'-yl)phenyl]amino]thiazol-5-yl](3-hydroxyphenyl)methanone 867291-94-9P, [4-Amino-2-[[4-[(pyrrolidin-1-yl)piperidin-1-yl]phenyl]amino]thiazol-5-yl](3,5-difluorophenyl)methanone 867291-95-0P, [4-Amino-2-[[4-[(pyrrolidin-1-yl)piperidin-1-yl]phenyl]amino]thiazol-5-yl](4-chlorophenyl)methanone 867291-96-1P, [4-Amino-2-[[4-[(pyrrolidin-1-yl)piperidin-1-yl]phenyl]amino]thiazol-5-yl](3,4-difluorophenyl)methanone 867291-97-2P, [4-Amino-2-[[4-[(pyrrolidin-1-yl)piperidin-1-yl]phenyl]amino]thiazol-5-yl](3,4-dichlorophenyl)methanone 867291-98-3P, [4-Amino-2-[[4-[(pyrrolidin-1-yl)piperidin-1-yl]phenyl]amino]thiazol-5-yl](4-fluorophenyl)methanone 867291-99-4P, [4-Amino-2-[[4-[(pyrrolidin-1-yl)piperidin-1-yl]phenyl]amino]thiazol-5-yl](4-chloro-3-nitrophenyl)methanone 867292-00-0P, 3-[[4-Amino-2-[[4-[(pyrrolidin-1-yl)piperidin-1-yl]phenyl]amino]thiazol-5-yl]carbonyl]benzonitrile 867292-01-1P, [4-Amino-2-[[4-(3-hydroxy-[1,4']bipiperidinyl-1'-yl)phenyl]amino]thiazol-5-yl](3,5-


difluorophenyl)methanone 867292-02-2P, [4-Amino-2-[[4-(3-hydroxy-[1,4']bipiperidinyl-1'-yl)phenyl]amino]thiazol-5-yl](4-chlorophenyl)methanone 867292-03-3P, [4-Amino-2-[[4-(3-hydroxy-[1,4']bipiperidinyl-1'-yl)phenyl]amino]thiazol-5-yl](3,4-difluorophenyl)methanone 867292-04-4P, [4-Amino-2-[[4-(3-hydroxy-[1,4']bipiperidinyl-1'-yl)phenyl]amino]thiazol-5-yl](3,4-dichlorophenyl)methanone 867292-05-5P, [4-Amino-2-[[4-(3-hydroxy-[1,4']bipiperidinyl-1'-yl)phenyl]amino]thiazol-5-yl](4-fluorophenyl)methanone 867292-06-6P, [4-Amino-2-[[4-(3-hydroxy-[1,4']bipiperidinyl-1'-yl)phenyl]amino]thiazol-5-yl](4-chloro-3-nitrophenyl)methanone 867292-07-7P, 4-[[4-Amino-2-[[4-(3-hydroxy-[1,4']bipiperidinyl-1'-yl)phenyl]amino]thiazol-5-yl]carbonyl]benzoic acid 867292-08-8P, 3-[[4-Amino-2-[[4-(3-hydroxy-[1,4']bipiperidinyl-1'-yl)phenyl]amino]thiazol-5-yl]carbonyl]benzonitrile 867292-09-9P, [4-Amino-2-[[4-(3-hydroxy-[1,4']bipiperidinyl-1'-yl)phenyl]amino]thiazol-5-yl](3-hydroxyphenyl)methanone 867292-17-9P, [4-Amino-2-[[4-([1,4']bipiperidinyl-1'-yl)phenyl]amino]thiazol-5-yl](3-nitrophenyl)methanone 867292-18-0P, [4-Amino-2-[[4-[4-(pyrrolidin-1-yl)piperidin-1-yl]phenyl]amino]thiazol-5-yl](3-nitrophenyl)methanone 867292-19-1P, [4-Amino-2-[[4-(3-hydroxy-[1,4']bipiperidinyl-1'-yl)phenyl]amino]thiazol-5-yl](3-nitrophenyl)methanone 867292-22-6P, 5-[[4-Amino-2-[[4-[4-(pyrrolidin-1-yl)piperidin-1-yl]phenyl]amino]thiazol-5-yl]carbonyl]-2-hydroxybenzamide 867292-23-7P, [4-Amino-2-[[4-[4-(pyrrolidin-1-yl)piperidin-1-yl]phenyl]amino]thiazol-5-yl](3-hydroxyphenyl)methanone 867292-24-8P, [4-Amino-2-[[4-([1,4']bipiperidinyl-1'-yl)phenyl]amino]thiazol-5-yl](3-aminophenyl)methanone 867292-34-0P, [4-Amino-2-[[4-[4-(pyrrolidin-1-yl)piperidin-1-yl]phenyl]amino]thiazol-5-yl](4-methoxy-3-nitrophenyl)methanone 867292-35-1P, [4-Amino-2-[[4-([1,4']bipiperidinyl-1'-yl)phenyl]amino]thiazol-5-yl](4-methoxy-3-nitrophenyl)methanone 867292-36-2P, [4-Amino-2-[[4-[4-(pyrrolidin-1-yl)piperidin-1-yl]phenyl]amino]thiazol-5-yl](3-tolyl)methanone 867292-38-4P, [4-Amino-2-[[4-([1,4']bipiperidinyl-1'-yl)phenyl]amino]thiazol-5-yl](3-tolyl)methanone 867292-41-9P, [4-Amino-2-[[4-[4-(pyrrolidin-1-yl)piperidin-1-yl]phenyl]amino]thiazol-5-yl](3-ethylphenyl)methanone 867292-44-2P, [4-Amino-2-[[4-([1,4']bipiperidinyl-1'-yl)phenyl]amino]thiazol-5-yl](3-ethylphenyl)methanone 867292-45-3P, [4-Amino-2-[[4-[4-(pyrrolidin-1-yl)piperidin-1-yl]phenyl]amino]thiazol-5-yl](3-ethoxyphenyl)methanone 867292-46-4P, [4-Amino-2-[[4-[4-(pyrrolidin-1-yl)piperidin-1-yl]phenyl]amino]thiazol-5-yl](3-cyclopropylphenyl)methanone 867292-48-6P, [4-Amino-2-[[4-[4-(pyrrolidin-1-yl)piperidin-1-yl]phenyl]amino]thiazol-5-yl](3-fluoro-4-methylphenyl)methanone 867292-49-7P, [4-Amino-2-[[4-[4-(pyrrolidin-1-yl)piperidin-1-yl]phenyl]amino]thiazol-5-yl](3-ethyl-4-fluorophenyl)methanone 867292-50-0P, [4-Amino-2-[[4-[4-(pyrrolidin-1-yl)piperidin-1-yl]phenyl]amino]thiazol-5-yl](4-hydroxy-3-propylphenyl)methanone 867292-51-1P, 6-[[4-Amino-2-[[4-[4-(pyrrolidin-1-yl)piperidin-1-yl]phenyl]amino]thiazol-5-yl]carbonyl]-1H-indole-2-carboxylic acid ethyl ester
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of benzoyldiaminothiazoles as selective Cdk4 inhibitors useful against cancer)

RN 867291-51-8 CAPLUS


CN Methanone, [4-amino-2-[[4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]amino]-5-thiazolyl](3-fluoro-4-methoxyphenyl)- (CA INDEX NAME)

10/574,087




RN 867291-52-9 CAPLUS

CN Methanone, [4-amino-2-[[4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]amino]-5-thiazolyl](3-fluorophenyl)- (CA INDEX NAME)




RN 867291-53-0 CAPLUS

CN Methanone, [4-amino-2-[[4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]amino]-5-thiazolyl]-1,3-benzodioxol-5-yl- (CA INDEX NAME)



RN 867291-54-1 CAPLUS


CN Methanone, [4-amino-2-[[4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]amino]-5-thiazolyl](2,3-dihydro-1,4-benzodioxin-6-yl)- (CA INDEX NAME)



RN 867291-55-2 CAPLUS


CN Methanone, [4-amino-2-[[4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]amino]-5-thiazolyl](3-methoxyphenyl)- (CA INDEX NAME)

10/574,087




RN 867291-56-3 CAPLUS

CN Methanone, [4-amino-2-[[4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]amino]-5-thiazolyl](4-hydroxyphenyl)- (CA INDEX NAME)



RN 867291-57-4 CAPLUS


CN Methanone, [4-amino-2-[(4-[1,4'-bipiperidin]-1'-ylphenyl)amino]-5-thiazolyl](4-hydroxyphenyl)- (CA INDEX NAME)



RN 867291-58-5 CAPLUS


CN Methanone, [4-amino-2-[(4-[1,4'-bipiperidin]-1'-ylphenyl)amino]-5-thiazolyl](3-fluorophenyl)- (CA INDEX NAME)

10/574,087




RN 867291-59-6 CAPLUS

CN Methanone, [4-amino-2-[(4-[1,4'-bipiperidin]-1'-yl)phenyl]amino]-5-thiazolyl[(3-fluoro-4-methoxyphenyl)- (CA INDEX NAME)]



RN 867291-60-9 CAPLUS


CN Methanone, [4-amino-2-[(4-[1,4'-bipiperidin]-1'-yl)phenyl]amino]-5-thiazolyl[(2,3-dihydro-1,4-benzodioxin-6-yl)- (CA INDEX NAME)]



RN 867291-61-0 CAPLUS


CN Methanone, [4-amino-2-[(4-[1,4'-bipiperidin]-1'-yl)phenyl]amino]-5-thiazolyl[(2,3-dihydro-1,4-benzodioxin-6-yl)- (CA INDEX NAME)]

10/574,087




RN 867291-62-1 CAPLUS

CN Methanone, [4-amino-2-[(4-[1,4'-bipiperidin]-1'-yl)phenyl]amino]-5-thiazolyl](3-methoxyphenyl)- (CA INDEX NAME)



RN 867291-63-2 CAPLUS


CN Methanone, [4-amino-2-[[4-(3-hydroxy[1,4'-bipiperidin]-1'-yl)phenyl]amino]-5-thiazolyl](3-fluorophenyl)- (CA INDEX NAME)



RN 867291-64-3 CAPLUS


CN Methanone, [4-amino-2-[[4-(3-hydroxy[1,4'-bipiperidin]-1'-yl)phenyl]amino]-5-thiazolyl](3-fluoro-4-methoxyphenyl)- (CA INDEX NAME)

10/574,087




RN 867291-65-4 CAPLUS

CN Methanone, [4-amino-2-[[4-(3-hydroxy[1,4'-bipiperidin]-1'-yl)phenyl]amino]-5-thiazolyl]-1,3-benzodioxol-5-yl- (CA INDEX NAME)



RN 867291-66-5 CAPLUS


CN Methanone, [4-amino-2-[[4-(3-hydroxy[1,4'-bipiperidin]-1'-yl)phenyl]amino]-5-thiazolyl]-(2,3-dihydro-1,4-benzodioxin-6-yl)- (CA INDEX NAME)



RN 867291-67-6 CAPLUS


CN Methanone, [4-amino-2-[[4-(3-hydroxy[1,4'-bipiperidin]-1'-yl)phenyl]amino]-5-thiazolyl]-(3-methoxyphenyl)- (CA INDEX NAME)

10/574,087



RN 867291-68-7 CAPLUS


CN Methanone, [4-amino-2-[[4-(3-hydroxy[1,4'-bipiperidin]-1'-yl)phenyl]amino]-5-thiazolyl](4-hydroxyphenyl)- (CA INDEX NAME)



RN 867291-79-0 CAPLUS


CN Benzonitrile, 4-[[4-amino-2-[[4-(3-hydroxy[1,4'-bipiperidin]-1'-yl)phenyl]amino]-5-thiazolyl]carbonyl]- (CA INDEX NAME)

10/574,087




RN 867291-80-3 CAPLUS

CN Methanone, [4-amino-2-[[4-(3-hydroxy[1,4'-bipiperidin]-1'-yl)phenyl]amino]-5-thiazolyl](4-nitrophenyl)- (CA INDEX NAME)



RN 867291-81-4 CAPLUS


CN Methanone, [4-amino-2-[[4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]amino]-5-thiazolyl](4-nitrophenyl)- (CA INDEX NAME)



10/574,087


RN 867291-82-5 CAPLUS

CN Benzonitrile, 4-[[4-amino-2-[[4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]amino]-5-thiazolyl]carbonyl]- (CA INDEX NAME)



RN 867291-83-6 CAPLUS


CN Benzonitrile, 4-[[4-amino-2-[(4-[1,4'-bipiperidin]-1'-yl)phenyl]amino]-5-thiazolyl]carbonyl]- (CA INDEX NAME)



RN 867291-84-7 CAPLUS


CN Methanone, [4-amino-2-[(4-[1,4'-bipiperidin]-1'-yl)phenyl]amino]-5-thiazolyl](4-nitrophenyl)- (CA INDEX NAME)

10/574,087




RN 867291-85-8 CAPLUS

CN Methanone, [4-amino-2-[(4-[1,4'-bipiperidin]-1'-yl)phenyl]amino]-5-thiazolyl](3,5-difluorophenyl)- (CA INDEX NAME)



RN 867291-86-9 CAPLUS


CN Methanone, [4-amino-2-[(4-[1,4'-bipiperidin]-1'-yl)phenyl]amino]-5-thiazolyl](4-chlorophenyl)- (CA INDEX NAME)



10/574,087


RN 867291-87-0 CAPLUS

CN Methanone, [4-amino-2-[(4-[1,4'-bipiperidin]-1'-ylphenyl)amino]-5-thiazolyl](3,4-difluorophenyl)- (CA INDEX NAME)



RN 867291-88-1 CAPLUS


CN Methanone, [4-amino-2-[(4-[1,4'-bipiperidin]-1'-ylphenyl)amino]-5-thiazolyl](3,4-dichlorophenyl)- (CA INDEX NAME)



RN 867291-89-2 CAPLUS


CN Methanone, [4-amino-2-[(4-[1,4'-bipiperidin]-1'-ylphenyl)amino]-5-thiazolyl](4-fluorophenyl)- (CA INDEX NAME)

10/574,087



RN 867291-90-5 CAPLUS


CN Methanone, [4-amino-2-[(4-[1,4'-bipiperidin]-1'-yl)phenyl]amino]-5-thiazolyl](4-chloro-3-nitrophenyl)- (CA INDEX NAME)



RN 867291-91-6 CAPLUS


CN Benzoic acid, 4-[[4-amino-2-[(4-[1,4'-bipiperidin]-1'-yl)phenyl]amino]-5-thiazolyl]carbonyl]- (CA INDEX NAME)

10/574,087




RN 867291-92-7 CAPLUS

CN Benzonitrile, 3-[[4-amino-2-[(4-[1,4'-bipiperidin]-1'-yl)phenyl]amino]-5-thiazolyl]carbonyl]- (CA INDEX NAME)



RN 867291-93-8 CAPLUS

CN Methanone, [4-amino-2-[(4-[1,4'-bipiperidin]-1'-yl)phenyl]amino]-5-thiazolyl] (3-hydroxyphenyl)- (CA INDEX NAME)




RN 867291-94-9 CAPLUS

CN Methanone, [4-amino-2-[[4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]amino]-


10/574,087

5-thiazolyl] (3,5-difluorophenyl)- (CA INDEX NAME)




RN 867291-95-0 CAPLUS

CN Methanone, [4-amino-2-[[4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]amino]-5-thiazolyl] (4-chlorophenyl)- (CA INDEX NAME)



RN 867291-96-1 CAPLUS


CN Methanone, [4-amino-2-[[4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]amino]-5-thiazolyl] (3,4-difluorophenyl)- (CA INDEX NAME)



RN 867291-97-2 CAPLUS


CN Methanone, [4-amino-2-[[4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]amino]-5-thiazolyl] (3,4-dichlorophenyl)- (CA INDEX NAME)

10/574,087




RN 867291-98-3 CAPLUS

CN Methanone, [4-amino-2-[[4-[[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]amino]-5-thiazolyl](4-fluorophenyl)- (CA INDEX NAME)



RN 867291-99-4 CAPLUS

CN Methanone, [4-amino-2-[[4-[[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]amino]-5-thiazolyl](4-chloro-3-nitrophenyl)- (CA INDEX NAME)




RN 867292-00-0 CAPLUS

CN Benzonitrile, 3-[[4-amino-2-[[4-[[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]amino]-5-thiazolyl]carbonyl]- (CA INDEX NAME)




10/574,087



RN 867292-04-4 CAPLUS


CN Methanone, [4-amino-2-[[4-(3-hydroxy[1,4'-bipiperidin]-1'-yl)phenyl]amino]-5-thiazolyl](3,4-dichlorophenyl)- (CA INDEX NAME)



RN 867292-05-5 CAPLUS


CN Methanone, [4-amino-2-[[4-(3-hydroxy[1,4'-bipiperidin]-1'-yl)phenyl]amino]-5-thiazolyl](4-fluorophenyl)- (CA INDEX NAME)

10/574,087



RN 867292-06-6 CAPLUS


CN Methanone, [4-amino-2-[[4-(3-hydroxy[1,4'-bipiperidin]-1'-yl)phenyl]amino]-5-thiazolyl](4-chloro-3-nitrophenyl)- (CA INDEX NAME)



RN 867292-07-7 CAPLUS


CN Benzoic acid, 4-[[4-amino-2-[[4-(3-hydroxy[1,4'-bipiperidin]-1'-yl)phenyl]amino]-5-thiazolyl]carbonyl]- (CA INDEX NAME)

10/574,087




RN 867292-08-8 CAPLUS

CN Benzonitrile, 3-[[4-amino-2-[[4-(3-hydroxy[1,4'-bipiperidin]-1'-yl)phenyl]amino]-5-thiazolyl]carbonyl]- (CA INDEX NAME)



RN 867292-09-9 CAPLUS


CN Methanone, [4-amino-2-[[4-(3-hydroxy[1,4'-bipiperidin]-1'-yl)phenyl]amino]-5-thiazolyl](3-hydroxyphenyl)- (CA INDEX NAME)



10/574,087


RN 867292-17-9 CAPLUS

CN Methanone, [4-amino-2-[(4-[1,4'-bipiperidin]-1'-yl)phenyl]amino]-5-thiazolyl](3-nitrophenyl)- (CA INDEX NAME)




RN 867292-18-0 CAPLUS

CN Methanone, [4-amino-2-[[4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]amino]-5-thiazolyl](3-nitrophenyl)- (CA INDEX NAME)



RN 867292-19-1 CAPLUS


CN Methanone, [4-amino-2-[[4-(3-hydroxy[1,4'-bipiperidin]-1'-yl)phenyl]amino]-5-thiazolyl](3-nitrophenyl)- (CA INDEX NAME)



10/574,087


RN 867292-22-6 CAPLUS

CN Benzamide, 5-[[4-amino-2-[[4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]amino]-5-thiazolyl]carbonyl]-2-hydroxy- (CA INDEX NAME)




RN 867292-23-7 CAPLUS

CN Methanone, [4-amino-2-[[4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]amino]-5-thiazolyl](3-hydroxyphenyl)- (CA INDEX NAME)



RN 867292-24-8 CAPLUS


CN Methanone, [4-amino-2-[(4-[1,4'-bipiperidin]-1'-ylphenyl)amino]-5-thiazolyl](3-aminophenyl)- (CA INDEX NAME)



RN 867292-34-0 CAPLUS


CN Methanone, [4-amino-2-[[4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]amino]-5-thiazolyl](4-methoxy-3-nitrophenyl)- (CA INDEX NAME)

10/574,087




RN 867292-35-1 CAPLUS

CN Methanone, [4-amino-2-[(4-[1,4'-bipiperidin]-1'-yl)phenyl]amino]-5-thiazolyl]-4-methoxy-3-nitrophenyl- (CA INDEX NAME)



RN 867292-36-2 CAPLUS


CN Methanone, [4-amino-2-[[4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]amino]-5-thiazolyl]-3-methylphenyl- (CA INDEX NAME)



RN 867292-38-4 CAPLUS


CN Methanone, [4-amino-2-[(4-[1,4'-bipiperidin]-1'-yl)phenyl]amino]-5-thiazolyl]-3-methylphenyl- (CA INDEX NAME)

10/574,087




RN 867292-41-9 CAPLUS

CN Methanone, [4-amino-2-[[4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]amino]-5-thiazolyl](3-ethylphenyl)- (CA INDEX NAME)



RN 867292-44-2 CAPLUS


CN Methanone, [4-amino-2-[[4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]amino]-5-thiazolyl](3-ethylphenyl)- (CA INDEX NAME)



RN 867292-45-3 CAPLUS


CN Methanone, [4-amino-2-[[4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]amino]-5-thiazolyl](3-ethoxyphenyl)- (CA INDEX NAME)

10/574,087




RN 867292-46-4 CAPLUS

CN Methanone, [4-amino-2-[[4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]amino]-5-thiazolyl](3-cyclopropylphenyl)- (CA INDEX NAME)



RN 867292-48-6 CAPLUS


CN Methanone, [4-amino-2-[[4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]amino]-5-thiazolyl](3-fluoro-4-methylphenyl)- (CA INDEX NAME)



RN 867292-49-7 CAPLUS


CN Methanone, [4-amino-2-[[4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]amino]-5-thiazolyl](3-ethyl-4-fluorophenyl)- (CA INDEX NAME)

10/574,087




RN 867292-50-0 CAPLUS

CN Methanone, [4-amino-2-[[4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]amino]-5-thiazolyl](4-hydroxy-3-propylphenyl)- (CA INDEX NAME)



RN 867292-51-1 CAPLUS

CN 1H-Indole-2-carboxylic acid, 6-[[4-amino-2-[[4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]amino]-5-thiazolyl]carbonyl]-, ethyl ester (CA INDEX NAME)




IT 211247-61-9P, 1'-(4-Nitrophenyl)[1,4']bipiperidinyl
478055-47-9P, [4-([1,4']Bipiperidinyl-1'-yl)phenyl]amine
867291-44-9P, 1'-(4-Isothiocyanatophenyl)[1,4']bipiperidinyl
867291-45-0P, 1-(4-Nitrophenyl)-4-(pyrrolidin-1-yl)piperidine
867291-46-1P, [4-[4-(Pyrrolidin-1-yl)piperidin-1-yl]phenyl]amine
867291-47-2P, 1-(4-Isothiocyanatophenyl)-4-(pyrrolidin-1-yl)piperidine
867291-48-3P, 1'-(4-Nitrophenyl)[1,4']bipiperidinyl
1-3-ol 867291-49-4P, 1'-(4-Aminophenyl)[1,4']bipiperidinyl-3-ol
867291-50-7P, 1'-(4-Isothiocyanatophenyl)[1,4']bipiperidinyl-3-ol
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

10/574,087

(preparation of benzoyldiaminothiazoles as selective Cdk4 inhibitors useful against cancer)


RN 211247-61-9 CAPLUS

CN 1,4'-Bipiperidine, 1'-(4-nitrophenyl)- (CA INDEX NAME)




RN 478055-47-9 CAPLUS

CN Benzenamine, 4-[1,4'-bipiperidin]-1'-yl- (CA INDEX NAME)




RN 867291-44-9 CAPLUS

CN 1,4'-Bipiperidine, 1'-(4-isothiocyanatophenyl)- (CA INDEX NAME)



RN 867291-45-0 CAPLUS


CN Piperidine, 1-(4-nitrophenyl)-4-(1-pyrrolidinyl)- (CA INDEX NAME)



10/574,087


RN 867291-46-1 CAPLUS

CN Benzenamine, 4-[4-(1-pyrrolidinyl)-1-piperidinyl]- (CA INDEX NAME)




RN 867291-47-2 CAPLUS

CN Piperidine, 1-(4-isothiocyanatophenyl)-4-(1-pyrrolidinyl)- (CA INDEX NAME)



RN 867291-48-3 CAPLUS


CN [1,4'-Bipiperidin]-3-ol, 1'-(4-nitrophenyl)- (CA INDEX NAME)



RN 867291-49-4 CAPLUS


CN [1,4'-Bipiperidin]-3-ol, 1'-(4-aminophenyl)- (CA INDEX NAME)

10/574,087



RN 867291-50-7 CAPLUS

CN [1,4'-Bipiperidin]-3-ol, 1'-(4-isothiocyanatophenyl)- (CA INDEX NAME)



RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/574,087

L4 ANSWER 48 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2005:1078249 CAPLUS

DN 143:367318

TI A preparation of 7-aminopyrazolo[1,5-a]pyrimidine derivatives, useful for the treatment of protein kinase dependent diseases

IN Bold, Guido; Floersheimer, Andreas; Furet, Pascal; Imbach, Patricia; Masuya, Keiichi; Schoepfer, Joseph G.

PA Switz.

SO U.S. Pat. Appl. Publ., 60 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005222171	A1	20051006	US 2005-39445	20050120
PRAI	US 2004-538194P	P	20040122		
OS	MARPAT 143:367318				
IT	861250-98-8P 861251-00-5P				

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 7-aminopyrazolopyrimidine derivs. as protein kinase inhibitors)


RN 861250-98-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-(3-chlorophenyl)-5-methyl-3-[3-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]- (CA INDEX NAME)



RN 861251-00-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-(4-fluorophenyl)-5-methyl-3-[3-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]- (CA INDEX NAME)



IT 861250-99-9P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 7-aminopyrazolopyrimidine derivs. as protein kinase inhibitors)

RN 861250-99-9 CAPLUS

CN 1H-Pyrazol-3-amine, 4-[3-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]- (CA INDEX NAME)

10/574,087




10/574,087

L4 ANSWER 49 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:696749 CAPLUS
DN 143:172890
TI A preparation of 7-aminopyrazolo[1,5-a]pyrimidine derivatives, useful for
the treatment of protein kinase dependent diseases
IN Bold, Guido; Floersheimer, Andreas; Furet, Pascal; Imbach, Patricia;
Masuya, Keiichi; Schoepfer, Joseph; Martiny-Baron, Georg
PA Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.
SO PCT Int. Appl., 128 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005070431	A1	20050804	WO 2005-EP602	20050121
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2005205915	A1	20050804	AU 2005-205915	20050121
	CA 2552885	A1	20050804	CA 2005-2552885	20050121
	EP 1708710	A1	20061011	EP 2005-706961	20050121
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR, IS				
	CN 1909908	A	20070207	CN 2005-80003037	20050121
	BR 2005007071	A	20070619	BR 2005-7071	20050121
	JP 2007519662	T	20070719	JP 2006-550056	20050121
	MX 2006PA08303	A	20060929	MX 2006-PA8303	20060721
	KR 2007009546	A	20070118	KR 2006-714683	20060721
	IN 2006CN02681	A	20070608	IN 2006-CN2681	20060721
	NO 2006003758	A	20061023	NO 2006-3758	20060822
PRAI	US 2004-538220P	P	20040122		
	WO 2005-EP602	W	20050121		
OS	CASREACT 143:172890; MARPAT 143:172890				
IT	861250-98-8P 861251-00-5P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of 7-aminopyrazolopyrimidine derivs. useful as antitumor agents)				
RN	861250-98-8 CAPLUS				
CN	Pyrazolo[1,5-a]pyrimidin-7-amine, 6-(3-chlorophenyl)-5-methyl-3-[3-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]- (CA INDEX NAME)				

10/574,087



RN 861251-00-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-(4-fluorophenyl)-5-methyl-3-[3-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]- (CA INDEX NAME)




IT 861250-99-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 7-aminopyrazolopyrimidine derivs. useful as antitumor agents)

RN 861250-99-9 CAPLUS

CN 1H-Pyrazol-3-amine, 4-[3-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]- (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 50 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2005:493496 CAPLUS

DN 143:43694

TI Diaryl urea derivatives, particularly N-[4-(pyrimidin-4-yloxy)phenyl]-N'-phenylureas, useful in the treatment of protein kinase dependent diseases, especially neoplasm, and their preparation

IN Bold, Guido; Caravatti, Giorgio; Floersheimer, Andreas; Guagnano, Vito; Imbach, Patricia; Masuya, Keiichi; Roesel, Johannes; Vaupel, Andrea; Garcia-Echeverria, Carlos

PA Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.

SO PCT Int. Appl., 140 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005051366	A2	20050609	WO 2004-EP13459	20041126
	WO 2005051366	A3	20071221		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, AP, EA, EP, OA			
	AU 2004292773	A1	20050609	AU 2004-292773	20041126
	CA 2546673	A1	20050609	CA 2004-2546673	20041126
	EP 1689376	A2	20060816	EP 2004-798101	20041126
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR, IS, YU			
	BR 2004016935	A	20070116	BR 2004-16935	20041126
	JP 2007515400	T	20070614	JP 2006-540401	20041126
	MX 2006PA06036	A	20060725	MX 2006-PA6036	20060526
	IN 2006CN01867	A	20070608	IN 2006-CN1867	20060526
PRAI	GB 2003-27734	A	20031128		
	GB 2004-17805	A	20040810		
	WO 2004-EP13459	W	20041126		

OS MARPAT 143:43694

IT 853297-56-0P, 1-[4-([1,4']Bipiperidinyl-1'-yl)-3-trifluoromethylphenyl]-3-[4-[(6-chloropyrimidin-4-yl)oxy]phenyl]urea
853298-23-4P 853298-24-5P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of di-Ph ureas as protein kinase inhibitors for treating neoplasm)

RN 853297-56-0 CAPLUS


CN Urea, N-[4-[1,4'-bipiperidin]-1'-yl-3-(trifluoromethyl)phenyl]-N'-[4-[(6-chloro-4-pyrimidinyl)oxy]phenyl]- (CA INDEX NAME)

10/574,087




RN 853298-23-4 CAPLUS

CN Urea, N-[4-[(6-azido-4-pyrimidinyl)oxy]phenyl]-N'-[4-[1,4'-bipiperidin]-1'-yl]-3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 853298-24-5 CAPLUS

CN Urea, N-[4-[(6-amino-4-pyrimidinyl)oxy]phenyl]-N'-[4-[1,4'-bipiperidin]-1'-yl]-3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




IT 853297-57-1P, [4-([1,4']Bipiperidinyl-1'-yl)-3-trifluoromethylphenyl]amine 853297-58-2P, 1'-(4-Nitro-2-trifluoromethylphenyl)[1,4']bipiperidinyl
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of di-Ph ureas as protein kinase inhibitors for treating neoplasm)

RN 853297-57-1 CAPLUS


CN Benzenamine, 4-[1,4'-bipiperidin]-1'-yl-3-(trifluoromethyl)- (CA INDEX NAME)

10/574,087



RN 853297-58-2 CAPLUS

CN 1,4'-Bipiperidine, 1'-[4-nitro-2-(trifluoromethyl)phenyl]- (CA INDEX
NAME)



L4 ANSWER 51 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2005:409528 CAPLUS

DN 142:463728

TI Preparation of 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles for the treatment of tuberculosis

IN Tsubouchi, Hidetsugu; Sasaki, Hirofumi; Itotani, Motohiro; Haraguchi, Yoshikazu; Miyamura, Shin; Matsumoto, Makoto; Hashizume, Hiroyuki; Tomishige, Tatsuo; Kawasaki, Masanori; Ohguro, Kinue; Sumida, Takumi; Hasegawa, Takeshi; Tanaka, Kazuho; Takemura, Isao

PA Otsuka Pharmaceutical Co., Ltd., Japan

SO PCT Int. Appl., 941 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005042542	A1	20050512	WO 2004-JP16492	20041029
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004285811	A1	20050512	AU 2004-285811	20041029
	CA 2539335	A1	20050512	CA 2004-2539335	20041029
	EP 1678185	A1	20060712	EP 2004-793412	20041029
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	BR 2004014909	A	20061107	BR 2004-14909	20041029
	CN 1878777	A	20061213	CN 2004-80032244	20041029
	JP 2005320316	A	20051117	JP 2004-318005	20041101
	IN 2006KN00824	A	20070413	IN 2006-KN824	20060404
	MX 2006PA04064	A	20060720	MX 2006-PA4064	20060410
PRAI	JP 2003-373206	A	20031031		
	JP 2004-111720	A	20040406		
	WO 2004-JP16492	W	20041029		

OS MARPAT 142:463728

IT 851686-09-4P 851686-11-8P 851686-13-0P

851686-19-6P 851692-97-2P 851693-01-1P

851693-15-7P 851693-17-9P 851693-19-1P

851693-21-5P 851693-23-7P 851693-29-3P

851693-32-8P 851693-37-3P 851697-52-4P

851697-53-5P 851697-54-6P 851697-55-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles for the treatment of tuberculosis)


RN 851686-09-4 CAPLUS

CN Imidazo[2,1-b]oxazole, 2,3-dihydro-2-methyl-6-nitro-2-[[4-[4-[[4-(trifluoromethoxy)phenyl]methoxy][1,4'-bipiperidin]-1'-yl]phenoxy]methyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.

10/574,087

PAGE 1-A



PAGE 1-B




RN 851686-11-8 CAPLUS


CN Imidazo[2,1-b]oxazole, 2,3-dihydro-2-methyl-6-nitro-2-[[4-[4-[4-(trifluoromethoxy)phenoxy]phenoxy][1,4'-bipiperidin]-1'-yl]phenoxy]methyl]-, (2R)-
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




10/574,087


RN 851686-13-0 CAPLUS
CN Imidazo[2,1-b]oxazole, 2-[[4-[4-[(4-chlorophenyl)methyl][1,4'-bipiperidin]-1'-yl]phenoxy]methyl]-2,3-dihydro-2-methyl-6-nitro-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 851686-19-6 CAPLUS
CN [1,4'-Bipiperidin]-4-amine, N-(4-chlorophenyl)-1'-[4-[[(2R)-2,3-dihydro-2-methyl-6-nitroimidazo[2,1-b]oxazol-2-yl]methoxy]phenyl]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



10/574,087


PAGE 1-B




RN 851692-97-2 CAPLUS
CN Imidazo[2,1-b]oxazole, 2,3-dihydro-2-methyl-6-nitro-2-[[4-[4-[[4-(trifluoromethoxy)phenyl]methyl][1,4'-bipiperidin]-1'-yl]phenoxy]methyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 851693-01-1 CAPLUS
CN [1,4'-Bipiperidin]-4-amine, 1'-[4-[[(2R)-2,3-dihydro-2-methyl-6-nitroimidazo[2,1-b]oxazol-2-yl]methoxy]phenyl]-N-methyl-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)


Absolute stereochemistry.

10/574,087

PAGE 1-A



PAGE 1-B




RN 851693-15-7 CAPLUS

CN [1,4'-Bipiperidin]-4-amine, 1'-[4-[[(2R)-2,3-dihydro-6-nitroimidazo[2,1-b]oxazol-2-yl]methoxy]phenyl]-N-methyl-N-[4-(trifluoromethoxy)phenyl]-
(CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



10/574,087

PAGE 1-B




RN 851693-17-9 CAPLUS


CN [1,4'-Bipiperidin]-4-amine, N-(4-chlorophenyl)-1'-[4-[[(2R)-2,3-dihydro-6-nitroimidazo[2,1-b]oxazol-2-yl]methoxy]phenyl]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 851693-19-1 CAPLUS


CN [1,4'-Bipiperidin]-4-amine, 1'-[4-[[(2R)-2,3-dihydro-6-nitroimidazo[2,1-b]oxazol-2-yl]methoxy]phenyl]-N-methyl-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 851693-21-5 CAPLUS

CN [1,4'-Bipiperidin]-4-amine, 1'-[4-[[(2R)-2,3-dihydro-6-nitroimidazo[2,1-b]oxazol-2-yl]methoxy]phenyl]-N-(4-fluorophenyl)-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



10/574,087

PAGE 1-B




RN 851693-23-7 CAPLUS


CN [1,4'-Bipiperidin]-4-amine, 1'-[4-[[(2R)-2,3-dihydro-2-methyl-6-nitroimidazo[2,1-b]oxazol-2-yl]methoxy]phenyl]-N-(4-fluorophenyl)-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 851693-29-3 CAPLUS

CN Imidazo[2,1-b]oxazole, 2,3-dihydro-2-methyl-6-nitro-2-[(4-[1,4':1',4''-terpiperidin]-1-ylphenoxy)methyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/574,087



RN 851693-32-8 CAPLUS

CN [1,4'-Bipiperidin]-4-amine, 1'-[4-[[(2R)-2,3-dihydro-2-methyl-6-nitroimidazo[2,1-b]oxazol-2-yl]methoxy]phenyl]-N-methyl-N-(2-phenylethyl)-
(CA INDEX NAME)

Absolute stereochemistry.




RN 851693-37-3 CAPLUS

CN Imidazo[2,1-b]oxazole, 2-[[4-[4-[(3,4-dichlorophenyl)methyl][1,4'-bipiperidin]-1'-yl]phenoxy]methyl]-2,3-dihydro-2-methyl-6-nitro-, (2R)-
(CA INDEX NAME)


Absolute stereochemistry.

10/574,087

PAGE 1-A



PAGE 1-B




RN 851697-52-4 CAPLUS

CN [1,4'-Bipiperidin]-4-amine, 1'-[4-[[(2R)-2,3-dihydro-2-methyl-6-nitroimidazo[2,1-b]oxazol-2-yl]methoxy]phenyl]-N-methyl-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



10/574,087


PAGE 1-B




RN 851697-53-5 CAPLUS
CN [1,4'-Bipiperidin]-4-amine, 1'-[4-[[(2R)-2,3-dihydro-2-methyl-6-nitroimidazo[2,1-b]oxazol-2-yl]methoxy]phenyl]-N-ethyl-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 851697-54-6 CAPLUS
CN [1,4'-Bipiperidin]-4-amine, N-(4-chlorophenyl)-1'-[4-[[(2R)-2,3-dihydro-2-methyl-6-nitroimidazo[2,1-b]oxazol-2-yl]methoxy]phenyl]-N-ethyl- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 851697-55-7 CAPLUS

CN [1,4'-Bipiperidin]-4-amine, 1'-[4-[[(2R)-2,3-dihydro-2-methyl-6-nitroimidazo[2,1-b]oxazol-2-yl]methoxy]phenyl]-N,N-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 52 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2005:313150 CAPLUS
 DN 142:373566
 TI Preparation of 2- or 4-(phenylthio)cinnamides as cell adhesion-inhibiting
 antiinflammatory and immune-suppressive compounds
 IN Link, James; Liu, Gang; Pei, Zhonghua; Von Geldern, Tom; Winn, Martin;
 Xin, Zhili; Boyd, Steven A.; Zhu, Gui-Dong; Freeman, Jennifer C.;
 Gunawardana, Indrani W.; Staeger, Michael A.; Jae, Hwan-Soo; Lynch, John
 K.; Wang, Sheldon
 PA Abbott Laboratories, USA
 SO U.S., 123 pp., Cont.-in-part of U.S. Ser. No. 474,517.
 CODEN: USXXAM
 DT Patent
 LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6878700	B1	20050412	US 2000-541795	20000331
	CA 2369238	A1	20001012	CA 2000-2369238	20000403
	WO 2000059880	A1	20001012	WO 2000-US8895	20000403
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR,				
	CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,				
	ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,				
	LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE,				
	SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,				
	DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,				
	CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 200041944	A	20001023	AU 2000-41944	20000403
	AU 774564	B2	20040701		
	BR 2000009426	A	20020409	BR 2000-9426	20000403
	EE 200100513	A	20021216	EE 2001-513	20000403
	JP 2004513063	T	20040430	JP 2000-609392	20000403
	AT 275543	T	20040915	AT 2000-921654	20000403
	NZ 515237	A	20041126	NZ 2000-515237	20000403
	EP 1481968	A2	20041201	EP 2004-20808	20000403
	EP 1481968	A3	20050119		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
	IE, SI, LT, LV, FI, RO, MK, CY, AL				
	CZ 296856	B6	20060712	CZ 2001-3522	20000403
	MX 2001PA09766	A	20020621	MX 2001-PA9766	20010927
	BG 106029	A	20020531	BG 2001-106029	20011018
	HR 2001000776	A1	20021231	HR 2001-776	20011023
	HR 2001000776	B1	20060228		
	HK 1040985	A1	20050218	HK 2002-102655	20020409
	US 2004116518	A1	20040617	US 2003-725212	20031201
	US 6867203	B2	20050315		
	US 2005250768	A1	20051110	US 2004-921965	20040820
	AU 2004205260	A1	20040923	AU 2004-205260	20040825
PRAI	US 1998-114097P	P	19981229		
	US 1999-474517	A2	19991229		
	US 1999-286645	A	19990402		
	US 2000-541795	A	20000331		
	EP 2000-921654	A3	20000403		
	WO 2000-US8895	W	20000403		
	US 2000-695040	A1	20001024		
OS	MARPAT 142:373566				
IT	301179-03-3P				

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

10/574,087

(Uses)


(preparation of (phenylthio)cinnamides as cell adhesion inhibitors by coupling of thiophenols with halobenzaldehydes, conversion to cinnamic acids, amidation, and optional derivatization)

RN 301179-03-3 CAPLUS


CN 2-Propenamide, 3-[2,3-dichloro-4-[[3-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]thio]phenyl]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]-, (2E)-
(CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RE.CNT 126 THERE ARE 126 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/574,087

L4 ANSWER 53 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2005:283466 CAPLUS

DN 142:355171

TI Preparation of piperidine compounds as histamine H3 antagonists or inverse agonists

IN Ohtake, Norikazu; Mizutani, Sayaka; Yoshimoto, Ryo; Tokita, Shigeru; Kanatani, Akio

PA Banyu Pharmaceutical Co., Ltd., Japan

SO PCT Int. Appl., 117 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005028438	A1	20050331	WO 2004-JP13768	20040921
	WO 2005028438	A9	20050526		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2004274309	A1	20050331	AU 2004-274309	20040921
	CA 2551037	A1	20050331	CA 2004-2551037	20040921
	EP 1669350	A1	20060614	EP 2004-787951	20040921
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK			
	CN 1902177	A	20070124	CN 2004-80027372	20040921
	US 2007105901	A1	20070510	US 2006-574087	20060321
	IN 2006DN01894	A	20070713	IN 2006-DN1894	20060407
PRAI	JP 2003-330758	A	20030922		
	WO 2004-JP13768	W	20040921		

OS MARPAT 142:355171

IT 848822-48-0P 848822-49-1P 848822-50-4P
848822-51-5P 848822-52-6P 848822-53-7P
848822-54-8P 848822-55-9P 848822-56-0P
848822-57-1P 848822-59-3P 848822-60-6P
848822-61-7P 848822-62-8P 848822-63-9P
848822-64-0P 848822-66-2P 848822-68-4P
848822-70-8P 848822-71-9P 848822-72-0P
848822-74-2P 848822-81-1P 848822-82-2P
848822-83-3P 848822-84-4P 848822-85-5P
848822-86-6P 848822-87-7P 848822-88-8P
848822-89-9P 848822-90-2P 848822-91-3P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of piperidine compds. as histamine H3 antagonists or inverse agonists for treatment of obesity, diabetes, etc.)

RN 848822-48-0 CAPLUS


CN Benzamide, 4-[1,4'-bipiperidin]-1'-yl-N-methyl-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)

10/574,087




RN 848822-49-1 CAPLUS

CN Benzamide, 4-[1,4'-bipiperidin]-1'-yl-N-(1-methyl-4-piperidiny)- (CA INDEX NAME)




RN 848822-50-4 CAPLUS

CN Benzamide, 4-[1,4'-bipiperidin]-1'-yl-N-(1-cyclobutyl-4-piperidiny)-N-methyl- (CA INDEX NAME)



RN 848822-51-5 CAPLUS


CN Benzamide, 4-[1,4'-bipiperidin]-1'-yl-N-(1-cyclopentyl-4-piperidiny)-N-methyl- (CA INDEX NAME)



RN 848822-52-6 CAPLUS


CN Benzamide, 4-[1,4'-bipiperidin]-1'-yl-N-(1-cyclohexyl-4-piperidiny)-N-methyl- (CA INDEX NAME)

10/574,087



RN 848822-53-7 CAPLUS


CN Benzamide, 4-[1,4'-bipiperidin]-1'-yl-N-[1-(cyclohexylmethyl)-4-piperidinyl]-N-methyl- (CA INDEX NAME)



RN 848822-54-8 CAPLUS

CN Benzamide, 4-[1,4'-bipiperidin]-1'-yl-N-[(3R)-1-cyclopentyl-3-pyrrolidinyl]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 848822-55-9 CAPLUS

CN Benzamide, 4-[1,4'-bipiperidin]-1'-yl-N-[(3S)-1-cyclopentyl-3-pyrrolidinyl]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.


10/574,087



RN 848822-56-0 CAPLUS

CN Benzamide, 4-[1,4'-bipiperidin]-1'-yl-N-methyl-N-[(3R)-1-(phenylmethyl)-3-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 848822-57-1 CAPLUS

CN Benzamide, 4-[1,4'-bipiperidin]-1'-yl-N-methyl-N-[(3S)-1-(phenylmethyl)-3-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 848822-59-3 CAPLUS

CN Benzamide, 4-[1,4'-bipiperidin]-1'-yl-N-4-pyridinyl-,


10/574,087

mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 848822-58-2


CMF C22 H28 N4 O



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 848822-60-6 CAPLUS


CN Isoquinoline, 2-(4-[1,4'-bipiperidin]-1'-ylbenzoyl)-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)




RN 848822-61-7 CAPLUS

CN Quinoline, 1-(4-[1,4'-bipiperidin]-1'-ylbenzoyl)-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)


10/574,087



RN 848822-62-8 CAPLUS
CN Piperazine, 1-(4-[1,4'-bipiperidin]-1'-ylbenzoyl)-4-phenyl- (9CI) (CA INDEX NAME)




RN 848822-63-9 CAPLUS
CN Benzamide, 4-[1,4'-bipiperidin]-1'-yl-N-methyl-N-[1-(2-pyrimidinyl)-4-piperidinyl]- (CA INDEX NAME)




RN 848822-64-0 CAPLUS
CN Benzamide, 4-[1,4'-bipiperidin]-1'-yl-N-methyl-N-(2-thienylmethyl)- (CA INDEX NAME)

10/574,087



RN 848822-66-2 CAPLUS


CN Benzamide, 4-[1,4'-bipiperidin]-1'-yl-N-methyl-N-(2-phenylethyl)- (CA INDEX NAME)



RN 848822-68-4 CAPLUS


CN Pyrrolidine, 1-(4-[1,4'-bipiperidin]-1'-ylbenzoyl)-3-(3,4-difluorophenyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




10/574,087

PAGE 2-A




RN 848822-70-8 CAPLUS
CN Piperidine, 1-(4-[1,4'-bipiperidin]-1'-ylbenzoyl)- (9CI) (CA INDEX NAME)




RN 848822-71-9 CAPLUS
CN Benzamide, N-methyl-N-(1-methyl-4-piperidinyl)-4-[4-(1-pyrrolidinyl)-1-piperidinyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



10/574,087


RN 848822-72-0 CAPLUS

CN Benzamide, 4-[4-(1-azetidiny1)-1-piperidinyl]-N-methyl-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)




RN 848822-74-2 CAPLUS

CN Benzamide, 4-(4,4-difluoro[1,4'-bipiperidin]-1'-yl)-N-methyl-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)




RN 848822-81-1 CAPLUS

CN Pyridine, 3-(4-[1,4'-bipiperidin]-1'-ylphenyl)- (CA INDEX NAME)



RN 848822-82-2 CAPLUS

CN 1,4'-Bipiperidine, 1'-[4-(1-piperidinylmethyl)phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 848822-83-3 CAPLUS

CN Benzamide, 4-[1,4'-bipiperidin]-1'-yl-N-methyl-N-[2-(2-pyridinyl)ethyl]- (CA INDEX NAME)


10/574,087




RN 848822-84-4 CAPLUS

CN Benzamide, 4-[1,4'-bipiperidin]-1'-yl-N-methyl-N-[(1,2,3,4-tetrahydro-1-naphthalenyl)methyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 848822-85-5 CAPLUS

CN Benzamide, 4-[1,4'-bipiperidin]-1'-yl-N-(2,3-dihydro-1H-inden-1-yl)-N-methyl- (CA INDEX NAME)


10/574,087




RN 848822-86-6 CAPLUS
CN Pyrrolidine, 1-(4-[1,4'-bipiperidin]-1'-ylbenzoyl)-3-phenyl- (9CI) (CA INDEX NAME)



RN 848822-87-7 CAPLUS
CN Benzamide, 4-[1,4'-bipiperidin]-1'-yl-N-methyl-N-(phenylmethyl)- (CA INDEX NAME)




RN 848822-88-8 CAPLUS
CN Isoquinoline, 2-(4-[1,4'-bipiperidin]-1'-ylbenzoyl)decahydro- (9CI) (CA INDEX NAME)




RN 848822-89-9 CAPLUS
CN Piperidine, 1-(4-[1,4'-bipiperidin]-1'-ylbenzoyl)-4-(phenylmethyl)- (9CI) (CA INDEX NAME)

10/574,087




RN 848822-90-2 CAPLUS

CN Piperidine, 1-(4-[1,4'-bipiperidin]-1'-ylbenzoyl)-4-(2,3-dihydro-1H-benzimidazol-2-yl)- (9CI) (CA INDEX NAME)



RN 848822-91-3 CAPLUS

CN Benzamide, 4-[1,4'-bipiperidin]-1'-yl-N-methyl-N-(1-phenyl-4-piperidinyl)- (CA INDEX NAME)



IT 848822-99-1 848823-00-7 848823-02-9
848823-04-1


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of piperidine compds. as histamine H3 antagonists or inverse agonists for treatment of obesity, diabetes, etc.)

RN 848822-99-1 CAPLUS


CN Benzoic acid, 4-[4-(1-pyrrolidinyl)-1-piperidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

10/574,087




● HCl

RN 848823-00-7 CAPLUS
CN Benzoic acid, 4-[4-(1-azetidiny1)-1-piperidinyl]-, monohydrochloride (9CI)
(CA INDEX NAME)



● HCl


RN 848823-02-9 CAPLUS
CN Benzoic acid, 4-[(4,4-difluorobipiperidin-1-yl)methyl]piperidin-1-yl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 848823-04-1 CAPLUS
CN 1,4'-Bipiperidine, 1'-(4-bromophenyl)- (CA INDEX NAME)


10/574,087



IT 179163-14-5P 848822-92-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of piperidine compds. as histamine H3 antagonists or inverse
agonists for treatment of obesity, diabetes, etc.)
RN 179163-14-5 CAPLUS
CN Benzonitrile, 4-[1,4'-bipiperidin]-1'-yl- (CA INDEX NAME)



RN 848822-92-4 CAPLUS
CN Benzoic acid, 4-[1,4'-bipiperidin]-1'-yl-, monohydrochloride (9CI) (CA
INDEX NAME)




● HCl

RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/574,087

L4 ANSWER 54 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:216811 CAPLUS
DN 142:298107
TI Preparation of N-substituted benzimidazolyl c-KIT kinase inhibitors
IN Bolger, Joshua; Castelhana, Arlindo L.; Crew, Andrew Philip; Dong, Han-Qing; Honda, Ayako; Laufer, Radoslaw; Li, An-Hu; Mulvihill, Kristen; Qui, Li; Sambrook Smith, Colin Peter; Sun, Yingchuan; Wynne, Graham Michael; Zhang, Tao
PA Osi Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 101 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005021531	A1	20050310	WO 2004-US26482	20040816
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004268949	A1	20050310	AU 2004-268949	20040816
	CA 2535896	A1	20050310	CA 2004-2535896	20040816
	EP 1664021	A1	20060607	EP 2004-781204	20040816
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	US 2006189629	A1	20060824	US 2004-921414	20040816
	BR 2004013746	A	20061024	BR 2004-13746	20040816
	CN 1852905	A	20061025	CN 2004-80024046	20040816
	JP 2007502821	T	20070215	JP 2006-523955	20040816
	NO 2006000664	A	20060516	NO 2006-664	20060210
	MX 2006PA02018	A	20060531	MX 2006-PA2018	20060220
	IN 2006CN00606	A	20071221	IN 2006-CN606	20060220
PRAI	US 2003-496806P	P	20030821		
	WO 2004-US26482	W	20040816		
OS	MARPAT 142:298107				
IT	847690-77-1P, 1-(3-[1,4']Bipiperidinyl-1'-ylphenyl)-N-[(pyridin-3-yl)methyl]-1H-benzimidazole-5-carboxamide				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of N-substituted benzimidazolyl c-KIT kinase inhibitors)				
RN	847690-77-1 CAPLUS				
CN	1H-Benzimidazole-5-carboxamide, 1-(3-[1,4'-bipiperidin]-1'-ylphenyl)-N-(3-pyridinylmethyl)- (CA INDEX NAME)				



10/574,087

RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 55 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2005:158647 CAPLUS

DN 142:261547

TI Preparation of 2,4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders

IN Garcia-echeverria, Carlos; Kanazawa, Takanori; Kawahara, Eiji; Masuya, Keiichi; Matsuura, Naoko; Miyake, Takahiro; Ohmori, Osamu; Umemura, Ichiro; Steensma, Ruo; Chopiuk, Greg; Jiang, Jiqing; Wan, Yongqin; Ding, Qiang; Zhang, Qiong; Gray, Nathanael Schiander; Karanewsky, Donald

PA Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.; IRM LLC

SO PCT Int. Appl., 285 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005016894	A1	20050224	WO 2004-EP9099	20040813
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004264382	A1	20050224	AU 2004-264382	20040813
	CA 2533320	A1	20060224	CA 2004-2533320	20040813
	EP 1660458	A1	20060531	EP 2004-764093	20040813
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	CN 1832929	A	20060913	CN 2004-80022725	20040813
	BR 2004013616	A	20061017	BR 2004-13616	20040813
	JP 2007502260	T	20070208	JP 2006-522998	20040813
	MX 2006PA01759	A	20060512	MX 2006-PA1759	20060214
	IN 2006CN00553	A	20070706	IN 2006-CN553	20060214
	NO 2006001214	A	20060515	NO 2006-1214	20060315
PRAI	GB 2003-19227	A	20030815		
	GB 2003-22370	A	20030924		
	WO 2004-EP9099	W	20040813		
OS	MARPAT 142:261547				
IT	761437-11-0P	761437-29-0P	761437-53-0P		
	761437-54-1P	761437-66-5P	761437-67-6P		
	761437-69-8P	761437-71-2P	761437-74-5P		
	761437-81-4P	761437-97-2P	761438-15-7P		
	761438-27-1P	761438-40-8P	761438-64-6P		
	761438-91-9P	761439-18-3P	761439-25-2P		
	761439-30-9P	761439-45-6P	761439-46-7P		
	845811-18-9P	845811-19-0P	845811-20-3P		
	845811-21-4P	845811-22-5P	845811-48-5P		
	845811-49-6P	845811-50-9P	845811-51-0P		
	845811-52-1P	845811-53-2P	845811-54-3P		
	845811-55-4P	845811-72-5P	845811-78-1P		
	845811-79-2P	845811-80-5P	845812-77-3P		
	845812-78-4P	845812-79-5P	845812-80-8P		
	845812-81-9P	845813-05-0P	845813-06-1P		
	845813-07-2P	845813-30-1P	845813-66-3P		

10/574,087


845813-70-9P 845815-01-2P 845815-03-4P
845815-04-5P 845815-11-4P 845815-12-5P
845815-18-1P 845815-31-8P 845815-34-1P
845815-60-3P 845815-63-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(preparation of 2,4-pyrimidinediamines useful in the treatment of neoplastic
diseases, inflammatory and immune system disorders)


RN 761437-11-0 CAPLUS

CN Benzenesulfonamide, 2-[[2-[(5-[1,4'-bipiperidin]-1'-yl)-2-
methoxyphenyl)amino]-5-bromo-4-pyrimidinyl]amino]-N-methyl- (CA INDEX
NAME)




RN 761437-29-0 CAPLUS

CN Benzamide, 2-[[2-[(4-[1,4'-bipiperidin]-1'-yl)-2-methoxyphenyl)amino]-5-
chloro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 761437-53-0 CAPLUS

CN Benzamide, 2-[[2-[(5-[1,4'-bipiperidin]-1'-yl)-2-methoxyphenyl)amino]-5-
chloro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-54-1 CAPLUS


10/574,087

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A





RN 761437-66-5 CAPLUS

CN Benzamide, 2-[[2-[[4-[1,4'-bipiperidin]-1'-yl]-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 761437-67-6 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)



RN 761437-69-8 CAPLUS


CN Benzamide, 2-[[2-[(5-[1,4'-bipiperidin]-1'-yl)-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)



RN 761437-71-2 CAPLUS


CN Benzamide, 2-[[2-[(4-{N,N'-bis(4-methylpiperidin-1-yl)-1,4'-bipiperidin-1'-yl}-2-methoxyphenyl)amino]-5-chloro-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)

10/574,087




RN 761437-74-5 CAPLUS

CN Benzamide, 2-[[2-[(4-[1,4'-bipiperidin]-1'-yl)-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-5-fluoro-N-methyl- (CA INDEX NAME)



RN 761437-81-4 CAPLUS


CN 1H-Isoindol-1-one, 7-[[2-[(5-[1,4'-bipiperidin]-1'-yl)-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-2,3-dihydro-2-methyl- (CA INDEX NAME)



RN 761437-97-2 CAPLUS


CN Benzamide, 5-[1,4'-bipiperidin]-1'-yl-2-[[5-chloro-2-[(4-fluoro-2-methoxyphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)

10/574,087




RN 761438-15-7 CAPLUS
CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 761438-27-1 CAPLUS
CN Benzenesulfonamide, 2-[[2-[[4-[1,4'-bipiperidin]-1'-yl]-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)

10/574,087




RN 761438-40-8 CAPLUS

CN Benzenesulfonamide, 2-[[2-[(4-[1,4'-bipiperidin]-1'-yl)-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 761438-64-6 CAPLUS


CN Benzenesulfonamide, 2-[[2-[(5-[1,4'-bipiperidin]-1'-yl)-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 761438-91-9 CAPLUS


CN 2,4-Pyrimidinediamine, N2-(4-[1,4'-bipiperidin]-1'-yl)-2-methoxyphenyl)-5-chloro-N4-[2-(propylsulfonyl)phenyl]- (CA INDEX NAME)

10/574,087




RN 761439-18-3 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-methoxy-4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]-N4-[2-(propylsulfonyl)phenyl]- (CA INDEX NAME)



RN 761439-25-2 CAPLUS


CN 2,4-Pyrimidinediamine, N2-(5-[1,4'-bipiperidin]-1'-yl-2-methoxyphenyl)-5-chloro-N4-[2-(propylsulfonyl)phenyl]- (CA INDEX NAME)



RN 761439-30-9 CAPLUS


10/574,087

CN 2,4-Pyrimidinediamine, N2-(4-[1,4'-bipiperidin]-1'-yl-2-methoxyphenyl)-5-chloro-N4-[2-(ethylsulfonyl)phenyl]- (CA INDEX NAME)



RN 761439-45-6 CAPLUS


CN 2,4-Pyrimidinediamine, N2-(4-[1,4'-bipiperidin]-1'-yl-2-methoxyphenyl)-5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)



RN 761439-46-7 CAPLUS


CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-methoxy-4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)

10/574,087



RN 845811-18-9 CAPLUS


CN Benzenesulfonamide, 2-[[2-[(4-[1,4'-bipiperidin]-1'-yl]-2-methoxyphenyl)amino]-5-bromo-4-pyrimidinyl]amino]-N-(2-methylpropyl)- (CA INDEX NAME)



RN 845811-19-0 CAPLUS


CN Benzenesulfonamide, 2-[[2-[(4-[1,4'-bipiperidin]-1'-yl]-2-methoxyphenyl)amino]-5-chloro-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)

10/574,087




RN 845811-20-3 CAPLUS

CN Benzenesulfonamide, 2-[[2-[(4-[1,4'-bipiperidin]-1'-yl-2-methoxyphenyl)amino]-5-chloro-4-pyrimidinyl]amino]-N-(1-ethylpropyl)- (CA INDEX NAME)



RN 845811-21-4 CAPLUS


CN Benzenesulfonamide, 2-[[2-[(4-[1,4'-bipiperidin]-1'-yl-2-methoxyphenyl)amino]-5-chloro-4-pyrimidinyl]amino]-N-cyclopentyl- (CA INDEX NAME)



RN 845811-22-5 CAPLUS


CN Benzenesulfonamide, 2-[[2-[(4-[1,4'-bipiperidin]-1'-yl-2-methoxyphenyl)amino]-5-bromo-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)

10/574,087




RN 845811-48-5 CAPLUS

CN Benzenesulfonamide, 2-[[2-[(4-[1,4'-bipiperidin]-1'-yl)-2-ethoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)



RN 845811-49-6 CAPLUS


CN Benzenesulfonamide, 2-[[2-[(4-[1,4'-bipiperidin]-1'-yl)-2-ethoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-(cyclopropylmethyl)- (CA INDEX NAME)




RN 845811-50-9 CAPLUS

CN Benzenesulfonamide, 2-[[2-[(4-[1,4'-bipiperidin]-1'-yl)-2-ethoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-cyclobutyl- (CA INDEX NAME)


10/574,087



RN 845811-51-0 CAPLUS
CN Benzenesulfonamide, 2-[[2-[(4-[1,4'-bipiperidin]-1'-yl]-2-ethoxyphenyl)amino]-5-chloro-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 845811-52-1 CAPLUS
CN Benzenesulfonamide, 2-[[2-[(4-[1,4'-bipiperidin]-1'-yl]-2-ethoxyphenyl)amino]-5-chloro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845811-53-2 CAPLUS
CN Benzenesulfonamide, 2-[[2-[(4-[1,4'-bipiperidin]-1'-yl]-2-ethoxyphenyl)amino]-5-bromo-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)

10/574,087




RN 845811-54-3 CAPLUS

CN 2,4-Pyrimidinediamine, N2-(4-[1,4'-bipiperidin]-1'-yl-2-ethoxyphenyl)-5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)



RN 845811-55-4 CAPLUS


CN Benzamide, 2-[[2-[(4-[1,4'-bipiperidin]-1'-yl-2-ethoxyphenyl)amino]-5-chloro-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)



RN 845811-72-5 CAPLUS


CN 2,4-Pyrimidinediamine, N2-(4-[1,4'-bipiperidin]-1'-yl-2-ethoxyphenyl)-5-chloro-N4-[2-(propylsulfonyl)phenyl]- (CA INDEX NAME)

10/574,087




RN 845811-78-1 CAPLUS

CN Benzamide, 5-[1,4'-bipiperidin]-1'-yl-2-[[5-chloro-4-[[2-[(1-methylethyl)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 845811-79-2 CAPLUS


CN Benzamide, 5-[1,4'-bipiperidin]-1'-yl-2-[[5-chloro-4-[[2-[(dimethylamino)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 845811-80-5 CAPLUS


CN Benzamide, 5-[1,4'-bipiperidin]-1'-yl-2-[[5-chloro-4-[[2-[(ethylamino)carbonyl]phenyl]amino]-2-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)

10/574,087




RN 845812-77-3 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[4-[1,4'-bipiperidin]-1'-yl]-2-(1-methylethoxy)phenyl]-5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)



RN 845812-78-4 CAPLUS


CN Benzenesulfonamide, 2-[[2-[[4-[1,4'-bipiperidin]-1'-yl]-2-(1-methylethoxy)phenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)



RN 845812-79-5 CAPLUS


CN Benzenesulfonamide, 2-[[2-[[4-[1,4'-bipiperidin]-1'-yl]-2-(1-methylethoxy)phenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-cyclobutyl- (CA INDEX NAME)

10/574,087




RN 845812-80-8 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[4-[1,4'-bipiperidin]-1'-yl]-2-(1-methylethoxy)phenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-(cyclopropylmethyl)- (CA INDEX NAME)



RN 845812-81-9 CAPLUS


CN Benzamide, 2-[[2-[[4-[1,4'-bipiperidin]-1'-yl]-2-(1-methylethoxy)phenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)



RN 845813-05-0 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-ethoxy-4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)


10/574,087



RN 845813-06-1 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)

PAGE 1-A




10/574,087

PAGE 2-A




RN 845813-07-2 CAPLUS
CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-cyclobutyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 845813-30-1 CAPLUS
CN Benzenesulfonamide, 2-[[2-[[4-[1,4'-bipiperidin]-1'-yl]-2-(cyclopropylmethoxy)phenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)

10/574,087



RN 845813-66-3 CAPLUS


CN 2,4-Pyrimidinediamine, N2-[4-[1,4'-bipiperidin]-1'-yl]-2-(cyclopropylmethoxy)phenyl]-5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)



RN 845813-70-9 CAPLUS


CN Benzenesulfonamide, 2-[[2-[[4-[1,4'-bipiperidin]-1'-yl]-2-(cyclopropylmethoxy)phenyl]amino]-5-bromo-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)

10/574,087



RN 845815-01-2 CAPLUS


CN 2,4-Pyrimidinediamine, N2-[4-[1,4'-bipiperidin]-1'-yl-2-(trifluoromethyl)phenyl]-5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-(CA INDEX NAME)



RN 845815-03-4 CAPLUS


CN Benzenesulfonamide, 2-[[2-[[4-[1,4'-bipiperidin]-1'-yl-2-(trifluoromethyl)phenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N,N-dimethyl-(CA INDEX NAME)

10/574,087




RN 845815-04-5 CAPLUS

CN Benzamide, 2-[[2-[[4-[1,4'-bipiperidin]-1'-yl]-2-(trifluoromethyl)phenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)



RN 845815-11-4 CAPLUS


CN 2,4-Pyrimidinediamine, N2-[4-[1,4'-bipiperidin]-1'-yl]-2-(2,2,2-trifluoroethoxy)phenyl]-5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)



RN 845815-12-5 CAPLUS


CN Benzamide, 2-[[2-[[4-[1,4'-bipiperidin]-1'-yl]-2-(2,2,2-trifluoroethoxy)phenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)

10/574,087



RN 845815-18-1 CAPLUS

CN 2-Pyrrolidinone, 1-[1-[4-[[5-chloro-4-[[2-[(1-methylethyl)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-(1-methylethoxy)phenyl]-4-piperidinyl]-N-ethyl- (CA INDEX NAME)




RN 845815-31-8 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[[2-(1-methylethoxy)-4-[4-(2-oxo-1-pyrrolidinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)

10/574,087



PAGE 1-A




PAGE 2-A



RN 845815-34-1 CAPLUS
CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-(1-methylethoxy)-4-[4-(2-oxo-1-pyrrolidinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 845815-60-3 CAPLUS
 CN 2,4-Pyrimidinediamine, N2-(5-[1,4'-bipiperidin]-1'-yl-2-methoxyphenyl)-5-chloro-N4-[2-[(1-ethylpropyl)sulfonyl]phenyl]- (CA INDEX NAME)



RN 845815-63-6 CAPLUS
 CN 2,4-Pyrimidinediamine, N2-(5-[1,4'-bipiperidin]-1'-yl-2-methoxyphenyl)-5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)

10/574,087



IT 761440-23-7P 761440-29-3P 761440-78-2P


761440-83-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 2,4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders)


RN 761440-23-7 CAPLUS

CN Piperidine, 1-(3-methoxy-4-nitrophenyl)-4-(1-pyrrolidinyl)- (CA INDEX NAME)



RN 761440-29-3 CAPLUS


CN 1,4'-Bipiperidine, 1'-(3-methoxy-4-nitrophenyl)- (CA INDEX NAME)



RN 761440-78-2 CAPLUS


CN Benzenamine, 2-methoxy-4-[4-(1-pyrrolidinyl)-1-piperidinyl]- (CA INDEX NAME)

10/574,087



RN 761440-83-9 CAPLUS

CN Benzenamine, 4-[1,4'-bipiperidin]-1'-yl-2-methoxy- (CA INDEX NAME)



RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/574,087

L4 ANSWER 56 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2004:996144 CAPLUS
DN 141:410935
TI Preparation of substituted diphenyl isoxazoles, pyrazoles and oxadiazoles
for treating HCV infection
IN Singh, Rajinder; Goff, Dane; Partridge, John
PA Rigel Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 188 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004099164	A1	20041118	WO 2004-US13492	20040503
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 2004266840	A1	20041230	US 2004-838133	20040503
	US 7115642	B2	20061003		
PRAI	US 2003-467811P	P	20030502		
OS	MARPAT 141:410935				
IT	524685-40-3P				

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted di-Ph isoxazoles, pyrazoles and oxadiazoles for treating HCV infection)

RN 524685-40-3 CAPLUS

CN Acetamide, N-[3-[3-(2-[1,4'-bipiperidin]-1'-yl-6-chlorophenyl)-5-isoxazolyl]phenyl]-2,2-dichloro- (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD

10/574,087

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 57 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2004:996136 CAPLUS

DN 141:424185

TI Preparation of pyrazole-3-carboxylic acid amide derivatives as bradykinin B1 receptor antagonists for the treatment of inflammatory diseases

IN Garofalo, Albert W.; Tung, Jay S.; Pleiss, Michael A.; Wu, Jing; Wone, David W. G.; Guinn, Ashley C.; Dressen, Darren B.; Marugg, Jennifer; Neitzel, Martin

PA Elan Pharmaceuticals, Inc., USA

SO PCT Int. Appl., 121 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004099155	A2	20041118	WO 2004-US13655	20040430
	WO 2004099155	A3	20051110		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2524318	A1	20041118	CA 2004-2524318	20040430
	US 2005032868	A1	20050210	US 2004-836903	20040430
	EP 1635821	A2	20060322	EP 2004-751178	20040430
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR			
	JP 2006525361	T	20061109	JP 2006-514230	20040430
	US 2007123531	A1	20070531	US 2006-555508	20060825
PRAI	US 2003-467695P	P	20030502		
	US 2003-503652P	P	20030917		
	WO 2004-US13655	W	20040430		

OS MARPAT 141:424185

IT 796042-13-2P 796042-19-8P 796042-23-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazole-3-carboxylic acid amides as bradykinin B1 receptor antagonists for the treatment of inflammatory diseases)

RN 796042-13-2 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-(4-[1,4'-bipiperidin]-1'-ylphenyl)-4-bromo-5-[(2-chlorobenzoyl)amino]- (CA INDEX NAME)

10/574,087




RN 796042-19-8 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(4-[1,4'-bipiperidin]-1'-ylphenyl)-4-bromo-5-[(2-fluorobenzoyl)amino]- (CA INDEX NAME)



RN 796042-23-4 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(4-[1,4'-bipiperidin]-1'-ylphenyl)-4-bromo-5-[(2-chlorobenzoyl)amino]-1-methyl- (CA INDEX NAME)



IT 478055-47-9


10/574,087

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of pyrazole-3-carboxylic acid amides as bradykinin B1 receptor antagonists for the treatment of inflammatory diseases)

RN 478055-47-9 CAPLUS

CN Benzenamine, 4-[1,4'-bipiperidin]-1'-yl- (CA INDEX NAME)



10/574,087

L4 ANSWER 58 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2004:817871 CAPLUS
DN 141:332207
TI Preparation of 2,3,6-trisubstituted-4-pyrimidones as tau protein kinase 1 inhibitors
IN Watanabe, Kazutoshi; Uehara, Fumiaki; Hiki, Shinsuke; Yokoshima, Satoshi; Usui, Yoshihiro; Okuyama, Masahiro; Shoda, Aya; Aritomo, Keiichi; Kohara, Toshiyuki; Fukunaga, Kenji
PA Mitsubishi Pharma Corporation, Japan; Sanofi-Synthelabo
SO PCT Int. Appl., 433 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	WO 2004085408	A1	20041007	WO 2004-JP4320	20040326
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004223987	A1	20041007	AU 2004-223987	20040326
	CA 2520027	A1	20041007	CA 2004-2520027	20040326
	EP 1608630	A1	20051228	EP 2004-723777	20040326
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
	BR 2004009042	A	20060328	BR 2004-9042	20040326
	CN 1764650	A	20060426	CN 2004-80008065	20040326
	JP 2006521370	T	20060921	JP 2006-507692	20040326
	MX 2005PA10323	A	20061207	MX 2005-PA10323	20050923
	NO 2005004952	A	20051025	NO 2005-4952	20051025
	IN 2005CN02772	A	20070608	IN 2005-CN2772	20051026
	US 2006252768	A1	20061109	US 2006-550299	20060531
PRAI	JP 2003-126021	A	20030326		
	JP 2003-126022	A	20030326		
	WO 2004-JP4320	W	20040326		

OS MARPAT 141:332207

IT 769941-75-5P 769943-57-9P 769943-59-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of 2,3,6-trisubstituted-4-pyrimidones as tau protein kinase 1 inhibitors for treatment and/or prevention of neurodegenerative diseases)

RN 769941-75-5 CAPLUS

CN 4(3H)-Pyrimidinone, 3-methyl-6-(4-pyridinyl)-2-[(3S)-3-[4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]-1-piperazinyl]-, tetrahydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/574,087




● 4 HCl

RN 769943-57-9 CAPLUS

CN [4,4'-Bipyrimidin]-6(1H)-one, 2-[(3S)-3-(4-[1,4'-bipiperidin]-1'-yl)phenyl]-1-piperazinyl]-1-methyl-, tetrahydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 4 HCl

RN 769943-59-1 CAPLUS

CN [4,4'-Bipyrimidin]-6(1H)-one, 1-methyl-2-[(3S)-3-[4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]-1-piperazinyl]-, tetrahydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/574,087



● 4 HCl

RE.CNT 3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/574,087

L4 ANSWER 59 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2004:817853 CAPLUS

DN 141:331920

TI Preparation of benzamide compounds as phosphorus transport inhibitors

IN Eto, Nobuaki; Nagao, Rika; Miyazaki, Tetsuko

PA Kirin Beer Kabushiki Kaisha, Japan

SO PCT Int. Appl., 787 pp.

CODEN: PIXXD2


DT Patent

LA Japanese

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 2004085382	A1	20041007	WO 2004-JP4427	20040329
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1614676	A1	20060111	EP 2004-724132	20040329
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
	US 2006217426	A1	20060928	US 2006-550857	20060410
PRAI	JP 2003-89173	A	20030327		
	WO 2004-JP4427	W	20040329		
OS	MARPAT 141:331920				
IT	773070-92-1P 773070-93-2P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of benzamide compds. as phosphorus transport inhibitors)				
RN	773070-92-1 CAPLUS				
CN	Benzoic acid, 5-[1,4'-bipiperidin]-1'-yl-2-[[3-[(2-hydroxyethyl)thio)methyl]benzoyl]amino]-, [[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (9CI) (CA INDEX NAME)				

10/574,087



RN 773070-93-2 CAPLUS

CN Benzoic acid, 5-[1,4'-bipiperidin]-1'-yl-2-[[3-[(2-hydroxyethyl)thio)methyl]benzoyl]amino]-, [(4-methoxyphenyl)methylene]hydrazide (9CI) (CA INDEX NAME)




IT 773072-07-4

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of benzamide compds. as phosphorus transport inhibitors)

RN 773072-07-4 CAPLUS

CN Benzoic acid, 2-amino-5-[1,4'-bipiperidin]-1'-yl-, methyl ester (CA INDEX NAME)

10/574,087



RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/574,087

L4 ANSWER 60 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2004:802719 CAPLUS

DN 141:289097

TI Methods of using compounds with combined 5-HT1a and SSRI activities
as-needed to treat sexual dysfunction

IN Thor, Karl Bruce

PA Dynogen Pharmaceuticals, Inc., USA

SO PCT Int. Appl., 112 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004082686	A2	20040930	WO 2004-US7601	20040312
	WO 2004082686	A3	20050127		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 2004192730	A1	20040930	US 2004-799490	20040312
PRAI	US 2003-454220P	P	20030313		
	US 2003-480596P	P	20030620		
	US 2004-545269P	P	20040217		
IT	286468-41-5, BMS 296859				
	RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(methods of using compds. with combined 5-HT1a and SSRI activities as-needed to treat sexual dysfunction)				
RN	286468-41-5 CAPLUS				
CN	1,4'-Bipiperidine, 4-[(2-bromophenyl)methyl]-1'-(2,6-dimethoxyphenyl)- (CA INDEX NAME)				




10/574,087

L4 ANSWER 61 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2004:799557 CAPLUS
DN 141:296049
TI Preparation of piperazinone derivatives as Bradykinin antagonists
IN Bock, Mark; Dorsey, Bruce; Su, Dai-shi; Han, Wei; Wood, Michael
PA Merck & Co., Inc., USA
SO PCT Int. Appl., 50 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 2004083173	A2	20040930	WO 2004-US7942	20040315
	WO 2004083173	A3	20050303		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 2006178370	A1	20060810	US 2005-548155	20050906
PRAI	US 2003-455681P	P	20030318		
	WO 2004-US7942	W	20040315		
OS	MARPAT 141:296049				
IT	764697-41-8P 764697-95-2P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of piperazinone derivs. as bradykinin B1 antagonists)				
RN	764697-41-8 CAPLUS				
CN	2-Piperazineacetamide, N-(4-[1,4'-bipiperidin]-1'-ylphenyl)-1-(2-naphthalenylsulfonyl)-3-oxo- (CA INDEX NAME)				



10/574,087



L4 ANSWER 62 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2004:780679 CAPLUS

DN 141:296041

TI Preparation of novel 2,4-di(phenylamino)pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders

IN Garcia-Echeverria, Carlos; Kanazawa, Takanori; Kawahara, Eiji; Masuya, Keiichi; Matsuura, Naoko; Miyake, Takahiro; Ohmori, Osamu; Umemura, Ichiro

PA Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.

SO PCT Int. Appl., 185 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004080980	A1	20040923	WO 2004-EP2616	20040312
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004220338	A1	20040923	AU 2004-220338	20040312
	CA 2518932	A1	20040923	CA 2004-2518932	20040312
	EP 1606265	A1	20051221	EP 2004-719989	20040312
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	BR 2004008347	A	20060321	BR 2004-8347	20040312
	CN 1788001	A	20060614	CN 2004-80013041	20040312
	JP 2006520354	T	20060907	JP 2006-504673	20040312
	IN 2005CN02241	A	20070831	IN 2005-CN2241	20050913
	NO 2005004726	A	20051208	NO 2005-4726	20051013
	US 2006247241	A1	20061102	US 2006-549250	20060518
PRAI	GB 2003-5929	A	20030314		
	GB 2003-19227	A	20030815		
	GB 2003-22370	A	20030924		
	WO 2004-EP2616	A	20040312		
OS	MARPAT 141:296041				
IT	761437-11-0P 761437-29-0P 761437-53-0P				
	761437-54-1P 761437-66-5P 761437-67-6P				
	761437-69-8P 761437-71-2P 761437-74-5P				
	761437-81-4P 761437-97-2P 761438-15-7P				
	761438-27-1P 761438-40-8P 761438-64-6P				
	761438-91-9P 761439-18-3P 761439-25-2P				
	761439-30-9P 761439-45-6P 761439-46-7P				
	761439-70-7P 761441-30-9P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of 2,4-di(phenylamino)pyrimidines as FAK or/and IGF-1 receptor inhibitors useful in the treatment of neoplastic diseases, inflammatory and immune system disorders)				
RN	761437-11-0 CAPLUS				
CN	Benzenesulfonamide, 2-[[2-[(5-[1,4'-bipiperidin]-1'-yl)-2-methoxyphenyl]amino]-5-bromo-4-pyrimidinyl]amino]-N-methyl-			(CA INDEX	


10/574,087

NAME)




RN 761437-29-0 CAPLUS

CN Benzamide, 2-[[2-[[4-[1,4'-bipiperidin]-1'-yl]-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)





RN 761437-53-0 CAPLUS

CN Benzamide, 2-[[2-[[5-[1,4'-bipiperidin]-1'-yl]-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-54-1 CAPLUS



CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 761437-66-5 CAPLUS
 CN Benzamide, 2-[[2-[[4-[[1,4'-bipiperidin]-1'-yl]-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 761437-67-6 CAPLUS
 CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)



RN 761437-69-8 CAPLUS


CN Benzamide, 2-[[2-[(5-[1,4'-bipiperidin]-1'-yl)-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)



RN 761437-71-2 CAPLUS


CN Benzamide, 2-[[2-[(4-[1,4'-bipiperidin]-1'-yl)-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N,6-dimethyl- (CA INDEX NAME)

10/574,087




RN 761437-74-5 CAPLUS

CN Benzamide, 2-[[2-[(4-[1,4'-bipiperidin]-1'-yl)-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-5-fluoro-N-methyl- (CA INDEX NAME)



RN 761437-81-4 CAPLUS


CN 1H-Isoindol-1-one, 7-[[2-[(5-[1,4'-bipiperidin]-1'-yl)-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-2,3-dihydro-2-methyl- (CA INDEX NAME)



RN 761437-97-2 CAPLUS


CN Benzamide, 5-[1,4'-bipiperidin]-1'-yl-2-[[5-chloro-2-[(4-fluoro-2-methoxyphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)

10/574,087




RN 761438-15-7 CAPLUS
CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 761438-27-1 CAPLUS
CN Benzenesulfonamide, 2-[[2-[[4-[1,4'-bipiperidin]-1'-yl]-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)


10/574,087



RN 761438-40-8 CAPLUS
CN Benzenesulfonamide, 2-[[2-[(4-[1,4'-bipiperidin]-1'-yl]-2-methoxyphenyl)amino]-5-chloro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-64-6 CAPLUS
CN Benzenesulfonamide, 2-[[2-[(5-[1,4'-bipiperidin]-1'-yl]-2-methoxyphenyl)amino]-5-chloro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-91-9 CAPLUS
CN 2,4-Pyrimidinediamine, N2-(4-[1,4'-bipiperidin]-1'-yl]-2-methoxyphenyl)-5-chloro-N4-[2-(propylsulfonyl)phenyl]- (CA INDEX NAME)

10/574,087




RN 761439-18-3 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-methoxy-4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]-N4-[2-(propylsulfonyl)phenyl]- (CA INDEX NAME)



RN 761439-25-2 CAPLUS


CN 2,4-Pyrimidinediamine, N2-(5-[1,4'-bipiperidin]-1'-yl-2-methoxyphenyl)-5-chloro-N4-[2-(propylsulfonyl)phenyl]- (CA INDEX NAME)



RN 761439-30-9 CAPLUS


10/574,087

CN 2,4-Pyrimidinediamine, N2-(4-[1,4'-bipiperidin]-1'-yl-2-methoxyphenyl)-5-chloro-N4-[2-(ethylsulfonyl)phenyl]- (CA INDEX NAME)



RN 761439-45-6 CAPLUS


CN 2,4-Pyrimidinediamine, N2-(4-[1,4'-bipiperidin]-1'-yl-2-methoxyphenyl)-5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)



RN 761439-46-7 CAPLUS


CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-methoxy-4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- (CA INDEX NAME)

10/574,087




RN 761439-70-7 CAPLUS

CN 2,4-Pyrimidinediamine, N2-(4-[1,4'-bipiperidin]-1'-yl-2-methoxyphenyl)-5-chloro-N4-[2-[(1-ethylpropyl)sulfonyl]phenyl]- (CA INDEX NAME)



RN 761441-30-9 CAPLUS

CN 1-Butanone, 1-[2-[[2-[(4-[1,4'-bipiperidin]-1'-yl-2-methoxyphenyl)amino]-5-chloro-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



10/574,087


IT 761440-23-7P 761440-29-3P 761440-78-2P
761440-83-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(preparation of 2,4-di(phenylamino)pyrimidines as FAK or/and IGF-1 receptor
inhibitors useful in the treatment of neoplastic diseases, inflammatory
and immune system disorders)


RN 761440-23-7 CAPLUS

CN Piperidine, 1-(3-methoxy-4-nitrophenyl)-4-(1-pyrrolidinyl)- (CA INDEX
NAME)



RN 761440-29-3 CAPLUS


CN 1,4'-Bipiperidine, 1'-(3-methoxy-4-nitrophenyl)- (CA INDEX NAME)



RN 761440-78-2 CAPLUS


CN Benzenamine, 2-methoxy-4-[4-(1-pyrrolidinyl)-1-piperidinyl]- (CA INDEX
NAME)

10/574,087



RN 761440-83-9 CAPLUS

CN Benzenamine, 4-[1,4'-bipiperidin]-1'-yl-2-methoxy- (CA INDEX NAME)



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/574,087

L4 ANSWER 63 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2004:675717 CAPLUS

DN 141:207067

TI Quinoline-derived amide modulators of vanilloid VR1 receptor, and their preparation, pharmaceutical compositions, and methods of use in the treatment of pain, inflammatory, and pulmonary conditions

PA Janssen Pharmaceutica N.V., Belg.

SO PCT Int. Appl., 245 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004069792	A2	20040819	WO 2004-IB785	20040202
	WO 2004069792	A3	20050120		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI			
	RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2004209456	A1	20040819	AU 2004-209456	20040202
	CA 2514940	A1	20040819	CA 2004-2514940	20040202
	US 2004192728	A1	20040930	US 2004-770204	20040202
	EP 1603883	A2	20051214	EP 2004-707270	20040202
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	JP 2007527363	T	20070927	JP 2006-502488	20040202
PRAI	US 2003-444442P	P	20030203		
	US 2004-770204	A	20040202		
	WO 2004-IB785	W	20040202		
OS	MARPAT 141:207067				
IT	742696-66-8P, 4-[1,4']Bipiperidinyl-1'-yl-N-quinolin-3-ylbenzamide				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(drug candidate; preparation of quinoline amide modulators of vanilloid VR1 receptor as analgesics and antiinflammatories)				
RN	742696-66-8 CAPLUS				
CN	Benzamide, 4-[1,4'-bipiperidin]-1'-yl-N-3-quinolinyl-			(CA INDEX NAME)	



10/574,087

L4 ANSWER 64 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2004:493573 CAPLUS
DN 141:54069
TI Preparation of 2- or 4-(phenylthio)cinnamides as cell adhesion-inhibiting
antiinflammatory and immune-suppressive compounds
IN Gunawardana, Indrani W.
PA Abbott Laboratories, USA
SO U.S. Pat. Appl. Publ., 133 pp., Cont. of U.S. Ser. No. 695,040.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004116518	A1	20040617	US 2003-725212	20031201
	US 6867203	B2	20050315		
	US 6878700	B1	20050412	US 2000-541795	20000331
PRAI	US 1998-114097P	P	19981229		
	US 1999-474517	B2	19991229		
	US 2000-541795	A2	20000331		
	US 2000-695040	A1	20001024		

OS MARPAT 141:54069

IT 301179-03-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)


(preparation of (phenylthio)cinnamides as cell adhesion inhibitors by
coupling of thiophenols with halobenzaldehydes, conversion to cinnamic
acids, amidation, and optional derivatization)

RN 301179-03-3 CAPLUS

CN 2-Propenamide, 3-[2,3-dichloro-4-[[3-[4-(1-pyrrolidinyl)-1-
piperidinyl]phenyl]thio]phenyl]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]-, (2E)-
(CA INDEX NAME)


Double bond geometry as shown.

PAGE 1-A



10/574,087

PAGE 1-B



RE.CNT 254 THERE ARE 254 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/574,087

L4 ANSWER 65 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2004:372868 CAPLUS

DN 140:375080

TI Preparation of phenylpiperidines and phenylpyrrolidines as histamine H3 receptor inhibitors

IN Apodaca, Richard L.; Dvorak, Curt A.; Shah, Chandravadan R.; Xiao, Wei

PA Janssen Pharmaceutica N.V., Belg.

SO U.S. Pat. Appl. Publ., 47 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004087573	A1	20040506	US 2003-692080	20031023
	US 7279491	B2	20071009		
	US 2008004314	A1	20080103	US 2007-835880	20070808
PRAI	US 2002-420494P	P	20021023		
	US 2003-692080	A3	20031023		

OS MARPAT 140:375080


IT 683772-52-3P 683772-53-4P 683772-54-5P
683772-55-6P

RL: DGN (Diagnostic use); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of phenylpiperidines and phenylpyrrolidines as histamine H3 receptor inhibitors)

RN 683772-52-3 CAPLUS


CN Morpholine, 4-[[4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]methyl]- (CA INDEX NAME)



RN 683772-53-4 CAPLUS


CN Morpholine, 4-[(4-[1,4'-bipiperidin]-1'-yl)phenyl]methyl]- (CA INDEX NAME)

10/574,087




RN 683772-54-5 CAPLUS

CN 1,4'-Bipiperidine, 1'-[4-(1-piperidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 683772-55-6 CAPLUS

CN 2-Pyridinamine, N-[(4-[1,4'-bipiperidin]-1'-yl)phenyl)methyl]- (CA INDEX NAME)




IT 683772-12-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of phenylpiperidines and phenylpyrrolidines as histamine H3 receptor inhibitors)

RN 683772-12-5 CAPLUS

CN Benzaldehyde, 4-[1,4'-bipiperidin]-1'-yl- (CA INDEX NAME)




10/574,087


L4 ANSWER 66 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2004:368927 CAPLUS
DN 140:391199
TI Preparation of phenylpiperidines and phenylpyrrolidines as histamine H3
receptor modulators
IN Apodaca, Richard L.; Dvorak, Curt A.; Shah, Chandravadan R.; Xiao, Wei
PA Janssen Pharmaceutica, N.V., Belg.
SO PCT Int. Appl., 115 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004037257	A1	20040506	WO 2003-US33809	20031023
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2504272	A1	20040506	CA 2003-2504272	20031023
	AU 2003287206	A1	20040513	AU 2003-287206	20031023
	EP 1556046	A1	20050727	EP 2003-781386	20031023
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2006505590	T	20060216	JP 2004-547134	20031023
PRAI	US 2002-420494P	P	20021023		
	WO 2003-US33809	W	20031023		
OS	MARPAT 140:391199				
IT	683772-52-3P 683772-53-4P 683772-54-5P 683772-55-6P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of phenylpiperidines and phenylpyrrolidines as histamine H3 receptor modulators)				
RN	683772-52-3 CAPLUS				
CN	Morpholine, 4-[[4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]methyl]- (CA INDEX NAME)				


10/574,087




RN 683772-53-4 CAPLUS
CN Morpholine, 4-[(4-[1,4'-bipiperidin]-1'-ylphenyl)methyl]- (CA INDEX NAME)



RN 683772-54-5 CAPLUS
CN 1,4'-Bipiperidine, 1'-[4-(1-piperidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 683772-55-6 CAPLUS
CN 2-Pyridinamine, N-[(4-[1,4'-bipiperidin]-1'-ylphenyl)methyl]- (CA INDEX NAME)



IT 683772-12-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of phenylpiperidines and phenylpyrrolidines as histamine H3 receptor modulators)
RN 683772-12-5 CAPLUS
CN Benzaldehyde, 4-[1,4'-bipiperidin]-1'--yl- (CA INDEX NAME)

10/574,087



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/574,087

L4 ANSWER 67 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2004:80660 CAPLUS

DN 140:146137

TI Preparation of (phenylureido)benzoic acid compounds for use in suppression of nonsense mRNA mutations and the treatment of genetic disease

IN Wilde, Richard G.; Takasugi, James J.; Hwang, Seongwoo; Welch, Ellen M.; Chen, Guangming

PA PTC Therapeutics, Inc., USA

SO PCT Int. Appl., 134 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004009558	A2	20040129	WO 2003-US23182	20030723
	WO 2004009558	A3	20040415		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2493458	A1	20040129	CA 2003-2493458	20030723
	AU 2003256755	A1	20040209	AU 2003-256755	20030723
	EP 1542667	A2	20050622	EP 2003-766012	20030723
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
PRAI	US 2002-398333P	P	20020724		
	WO 2003-US23182	W	20030723		

OS MARPAT 140:146137

IT 651749-22-3P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of (phenylureido)benzoic acid compds. for use in suppression of nonsense mRNA mutations and the treatment of genetic disease)

RN 651749-22-3 CAPLUS

CN Benzoic acid, 3-[3-(4-[1,4'-bipiperidin]-1'-ylphenyl)-2-oxo-1-imidazolidinyl]- (CA INDEX NAME)


10/574,087



10/574,087


L4 ANSWER 68 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2004:48180 CAPLUS
DN 140:263788
TI Conditional Probability: A New Fusion Method for Merging Disparate Virtual
Screening Results
AU Raymond, John W.; Jalaie, Mehran; Bradley, Mary P.
CS Discovery Technologies, Ann Arbor Laboratories, Pfizer Global Research and
Development, Ann Arbor, MI, 48105, USA
SO Journal of Chemical Information and Computer Sciences (2004), 44(2),
601-609
CODEN: JCISD8; ISSN: 0095-2338
PB American Chemical Society
DT Journal
LA English
IT 478055-75-3
RL: PAC (Pharmacological activity); BIOL (Biological study)
(conditional probability as new fusion method for merging disparate
virtual screening results)
RN 478055-75-3 CAPLUS
CN 1H-1,4-Benzodiazepine-1-butanamide, N-(4-[1,4'-bipiperidin]-1'-ylphenyl)-5-
cyclohexyl-2,3-dihydro-2-oxo- (CA INDEX NAME)

PAGE 1-A



10/574,087

PAGE 2-A



RE.CNT 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 69 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2004:20665 CAPLUS

DN 140:94057

TI Preparation of 2,4-diaminopyrimidine-5-carboxamide derivatives as inhibitors of signal transducer and activator of transcription (STAT6)

IN Nagashima, Shinya; Nagata, Hiroshi; Iwata, Masahiro; Yokota, Masaki; Moritomo, Hiroyuki; Nakai, Eiichi; Kuromitsu, Sadao; Ohga, Keiko; Takeuchi, Makoto

PA Yamanouchi Pharmaceutical Co., Ltd., Japan

SO PCT Int. Appl., 102 pp.

CODEN: PIXXD2


DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004002964	A1	20040108	WO 2003-JP8129	20030626
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2490888	A1	20040108	CA 2003-2490888	20030626
	AU 2003244098	A1	20040119	AU 2003-244098	20030626
	EP 1518855	A1	20050330	EP 2003-761820	20030626
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	CN 1665789	A	20050907	CN 2003-815071	20030626
	MX 2004PA12855	A	20050419	MX 2004-PA12855	20041216
	US 2005272753	A1	20051208	US 2004-518043	20041216
	IN 2004DN04092	A	20070105	IN 2004-DN4092	20041222
PRAI	JP 2002-190959	A	20020628		
	WO 2003-JP8129	W	20030626		
OS	MARPAT 140:94057				
IT	643085-92-1P 643085-95-4P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of diaminopyrimidinecarboxamide derivs. as inhibitors of signal transducer and activator of transcription (STAT6), Th2 cell differentiation inhibitors, and preventives and/therapeutics for respiratory diseases)				
RN	643085-92-1 CAPLUS				
CN	5-Pyrimidinecarboxamide, 2-[(4-[1,4'-bipiperidin]-1'-ylphenyl)amino]-4-[[[(2,3,6-trifluorophenyl)methyl]amino]-, trihydrochloride (9CI) (CA INDEX NAME)				


10/574,087



●3 HCl

RN 643085-95-4 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-[3-(hydroxymethyl)[1,4'-bipiperidin]-1'-yl]phenyl]amino]-4-[[2,3,6-trifluorophenyl)methyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl


IT 478055-47-9P 643087-87-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of diaminopyrimidinecarboxamide derivs. as inhibitors of signal transducer and activator of transcription (STAT6), Th2 cell differentiation inhibitors, and preventives and/therapeutics for respiratory diseases)

RN 478055-47-9 CAPLUS


CN Benzenamine, 4-[1,4'-bipiperidin]-1'-yl- (CA INDEX NAME)



RN 643087-87-0 CAPLUS

10/574,087

CN [1,4'-Bipiperidine]-3-methanol, 1'-(4-aminophenyl)- (CA INDEX NAME)




RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/574,087


L4 ANSWER 70 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2003:931310 CAPLUS
DN 140:4852
TI Preparation of diamino-functional chalcones for pharmaceutically active
agents against bacterial and parasitic infections
IN Nielsen, Simon Feldbaek; Schonning, Kristian; Kromann, Hasse; Boesen,
Thomas; Larsen, Mogens
PA Lica Pharmaceuticals A/s, Den.
SO PCT Int. Appl., 118 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003097576	A2	20031127	WO 2003-DK333	20030519
	WO 2003097576	A3	20040318		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2003229539	A1	20031202	AU 2003-229539	20030519
	EP 1506158	A2	20050216	EP 2003-722318	20030519
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	US 2006235073	A1	20061019	US 2005-514821	20050815
PRAI	DK 2002-762	A	20020517		
	DK 2002-763	A	20020517		
	DK 2002-1114	A	20020718		
	WO 2003-DK333	W	20030519		
OS	MARPAT 140:4852				
IT	628327-85-5P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(drug candidate; preparation of amino-functional chalcone derivs. as antibacterial, parasitocidal, fungicidal agents)				
RN	628327-85-5 CAPLUS				
CN	2-Propen-1-one, 1-[2-[(dimethylamino)methyl]phenyl]-3-[2'-methyl-4-[4-(1-pyrrolidinyl)-1-piperidinyl][1,1'-biphenyl]-3-yl]- (CA INDEX NAME)				

10/574,087




IT 628325-93-9P, 2'-Methyl-4-(4-pyrrolidin-1-ylpiperidin-1-yl)biphenyl-3-carboxaldehyde
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate preparation; preparation of amino-functional chalcone derivs.
as antibacterial, parasitocidal, fungicidal agents)
RN 628325-93-9 CAPLUS
CN [1,1'-Biphenyl]-3-carboxaldehyde, 2'-methyl-4-[4-(1-pyrrolidinyl)-1-piperidinyl]- (CA INDEX NAME)



IT 628324-53-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of diamino-functional chalcone derivs. as antibacterial, parasitocidal, fungicidal agents)
RN 628324-53-8 CAPLUS
CN 2-Propen-1-one, 1-[2-[(dimethylamino)methyl]phenyl]-3-[2'-methyl-4-[4-(1-pyrrolidinyl)-1-piperidinyl][1,1'-biphenyl]-3-yl]-, (2E)- (CA INDEX NAME)


10/574,087

Double bond geometry as shown.



10/574,087

L4 ANSWER 71 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2003:901807 CAPLUS
DN 140:198944
TI Decay pathways of charge-separated states in strongly fluorescent electron
donor-acceptor compounds
AU Willemse, Robert J.; Theodori, Demy; Verhoeven, Jan W.; Brouwer, Albert M.
CS Institute of Molecular Chemistry, University of Amsterdam, Amsterdam,
NL-1018 WS, Neth.
SO Photochemical & Photobiological Sciences (2003), 2(11), 1134-1139
CODEN: PPSHCB; ISSN: 1474-905X
PB Royal Society of Chemistry
DT Journal
LA English
OS CASREACT 140:198944
IT 147328-61-8
RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP
(Physical process); PROC (Process)
(decay pathways of charge-separated states in strongly fluorescent electron
donor-acceptor compds.)
RN 147328-61-8 CAPLUS
CN 1-Naphthalenecarbonitrile, 4-[(1'-phenyl[1,4'-bipiperidin]-4-
ylidene)methyl]- (CA INDEX NAME)




RE.CNT 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/574,087

L4 ANSWER 72 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2003:875291 CAPLUS
DN 139:350751
TI Preparation of pyrazolo[1,5-a]pyrimidine derivatives as NAD(P)H oxidase inhibitors
IN Seno, Kaoru; Nishi, Koichi; Matsuo, Yoshiyuki; Fujishita, Toshio
PA Shionogi & Co., Ltd., Japan
SO PCT Int. Appl., 240 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003091256	A1	20031106	WO 2003-JP5024	20030418
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2483306	A1	20031106	CA 2003-2483306	20030418
	AU 2003227437	A1	20031110	AU 2003-227437	20030418
	EP 1505068	A1	20050209	EP 2003-717663	20030418
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003009475	A	20050301	BR 2003-9475	20030418
	CN 1662537	A	20050831	CN 2003-814483	20030418
	MX 2004PA10441	A	20050214	MX 2004-PA10441	20041022
	US 2006089362	A1	20060427	US 2005-511840	20050923
PRAI	JP 2002-121519	A	20020423		
	WO 2003-JP5024	W	20030418		
OS	MARPAT 139:350751				
IT	619306-51-3				
	RL: PAC (Pharmacological activity); BIOL (Biological study) (preparation of pyrazolo[1,5-a]pyrimidine derivs. as NAD(P)H oxidase inhibitors)				
RN	619306-51-3 CAPLUS				
CN	Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[2-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]- (CA INDEX NAME)				



RE.CNT 109 THERE ARE 109 CITED REFERENCES AVAILABLE FOR THIS RECORD

10/574,087


ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/574,087

L4 ANSWER 73 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2003:454328 CAPLUS
DN 139:36539
TI Preparation of triazolopyrimidinamines as adenosine A2a receptor
antagonists
IN Matasi, Julius J.; Caldwell, John P.; Tulshian, Deen; Silverman, Lisa S.;
Neustadt, Bernard R.
PA Schering Corporation, USA
SO PCT Int. Appl., 97 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003048164	A2	20030612	WO 2002-US38134	20021126
	WO 2003048164	A3	20031016		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SC, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2468681	A1	20030612	CA 2002-2468681	20021126
	AU 2002346572	A1	20030617	AU 2002-346572	20021126
	US 2003212080	A1	20031113	US 2002-304504	20021126
	US 7041666	B2	20060509		
	EP 1453835	A2	20040908	EP 2002-784641	20021126
	EP 1453835	B1	20060215		
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			
	HU 2004002270	A2	20050228	HU 2004-2270	20021126
	CN 1596258	A	20050316	CN 2002-823922	20021126
	JP 2005511698	T	20050428	JP 2003-549354	20021126
	AT 317844	T	20060315	AT 2002-784641	20021126
	ES 2258164	T3	20060816	ES 2002-2784641	20021126
	ZA 2004004160	A	20050408	ZA 2004-4160	20040527
	MX 2004PA05156	A	20040811	MX 2004-PA5156	20040528
	HK 1064100	A1	20060714	HK 2004-106913	20040911
PRAI	US 2001-334293P	P	20011130		
	WO 2002-US38134	W	20021126		
OS	MARPAT 139:36539				
IT	540751-96-0P				
	RL:	PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)			
		(preparation of triazolopyrimidinamines as adenosine A2a receptor antagonists)			
RN	540751-96-0 CAPLUS				
CN	[1,2,4]Triazolo[1,5-c]pyrimidin-5-amine, 2-(2-furanyl)-7-[3-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]- (CA INDEX NAME)				

10/574,087



L4 ANSWER 74 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2003:376833 CAPLUS

DN 138:368880

TI Preparation of substituted diphenyl heterocycles for treating HCV infection

IN Singh, Rajinder; Goff, Dane; Lu, Henry; Issankani, Sarkiz D.; Sun, Thomas

PA Rigel Pharmaceuticals, Inc., USA

SO PCT Int. Appl., 103 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003040112	A1	20030515	WO 2002-US35131	20021101
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2465189	A1	20030515	CA 2002-2465189	20021101
	AU 2002348157	A1	20030519	AU 2002-348157	20021101
	US 2003165561	A1	20030904	US 2002-286017	20021101
	US 6759538	B2	20040706		
	BR 2002006266	A	20031230	BR 2002-6266	20021101
	EP 1451162	A1	20040901	EP 2002-784378	20021101
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	CN 1585756	A	20050223	CN 2002-822590	20021101
	JP 2005511604	T	20050428	JP 2003-542158	20021101
	NZ 532317	A	20051028	NZ 2002-532317	20021101
	MX 2004PA04098	A	20041029	MX 2004-PA4098	20040429
	IN 2004KN00586	A	20060421	IN 2004-KN586	20040505
	US 2004236112	A1	20041125	US 2004-873914	20040622
	US 7153880	B2	20061226		
PRAI	US 2001-350107P	P	20011102		
	US 2002-405472P	P	20020823		
	US 2002-286017	A3	20021101		
	WO 2002-US35131	W	20021101		
OS	MARPAT 138:368880				
IT	524685-40-3P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of substituted di-Ph heterocycles for treating HCV infection)				
RN	524685-40-3 CAPLUS				
CN	Acetamide, N-[3-[3-(2-[1,4'-bipiperidin]-1'-yl-6-chlorophenyl)-5-isoxazolyl]phenyl]-2,2-dichloro- (CA INDEX NAME)				


10/574,087




RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 75 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2003:254708 CAPLUS
DN 138:395428
TI Benzodiazepines as Potent and Selective Bradykinin B1 Antagonists
AU Wood, Michael R.; Kim, June J.; Han, Wei; Dorsey, Bruce D.; Homnick, Carl F.; DiPardo, Robert M.; Kuduk, Scott D.; MacNeil, Tanya; Murphy, Kathy L.; Lis, Edward V.; Ransom, Richard W.; Stump, Gary L.; Lynch, Joseph J.; O'Malley, Stacey S.; Miller, Patricia J.; Chen, Tsing-Bau; Harrell, Charles M.; Chang, Raymond S. L.; Sandhu, Punam; Ellis, Joan D.; Bondiskey, Peter J.; Pettibone, Douglas J.; Freidinger, Roger M.; Bock, Mark G.
CS Departments of Medicinal Chemistry and Neuroscience, Merck Research Laboratories, West Point, PA, 19486, USA
SO Journal of Medicinal Chemistry (2003), 46(10), 1803-1806
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
OS CASREACT 138:395428
IT 478055-75-3P 528815-64-7P 528815-65-8P
528815-66-9P 528815-67-0P
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(benzodiazepines as potent and selective bradykinin B1 antagonists)
RN 478055-75-3 CAPLUS
CN 1H-1,4-Benzodiazepine-1-butanamide, N-(4-[1,4'-bipiperidin]-1'-ylphenyl)-5-cyclohexyl-2,3-dihydro-2-oxo- (CA INDEX NAME)

PAGE 1-A






RN 528815-64-7 CAPLUS

CN Urea, N-(4-[1,4'-bipiperidin]-1'-ylphenyl)-N'-[(3R)-5-cyclohexyl-2,3-dihydro-2-oxo-1-propyl-1H-1,4-benzodiazepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 528815-65-8 CAPLUS

CN Urea, N-(4-[1,4'-bipiperidin]-1'-ylphenyl)-N'-[(3S)-5-cyclohexyl-2,3-dihydro-2-oxo-1-propyl-1H-1,4-benzodiazepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.


10/574,087



RN 528815-66-9 CAPLUS

CN Urea, N-(4-[1,4'-bipiperidin]-1'-ylphenyl)-N'-[(3R)-2,3-dihydro-2-oxo-5-(2-phenylethyl)-1-propyl-1H-1,4-benzodiazepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 528815-67-0 CAPLUS

CN Urea, N-(4-[1,4'-bipiperidin]-1'-ylphenyl)-N'-[(3R)-2,3-dihydro-5-(4-methylphenyl)-2-oxo-1-propyl-1H-1,4-benzodiazepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.

10/574,087



RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/574,087

L4 ANSWER 76 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2003:174468 CAPLUS
DN 138:215278
TI Method of treating hyperresorptive bone disorders by inhibition of Src
protein tyrosine kinase
IN Safar, Pavel; Walser, Armin
PA USA
SO U.S. Pat. Appl. Publ., 33 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003045480	A1	20030306	US 2002-191446	20020709
PRAI	US 2001-303851P	P	20010709		
OS	MARPAT 138:215278				
IT	500697-75-6				

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(method of treating hyperresorptive bone disorders)

RN 500697-75-6 CAPLUS


CN 2-Benzofurancarboxamide, N-[5-[[[[4-(aminocarbonyl)cyclohexyl]methyl]amin
o]carbonyl]amino]-2-[1,4'-bipiperidin]-1'-ylphenyl]- (CA INDEX NAME)

PAGE 1-A



10/574,087

PAGE 2-A



L4 ANSWER 77 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2003:58070 CAPLUS

DN 138:122861

TI Preparation of substituted amides, sulfonamides and ureas useful for inhibiting kinase activity

IN Safar, Pavel; Walser, Armin; Shimshock, Stephen J.

PA Aventis Pharmaceuticals Inc., USA

SO PCT Int. Appl., 85 pp.

CODEN: PIXXD2

DT Patent

LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003006444	A2	20030123	WO 2002-US21525	20020709
	WO 2003006444	A3	20040311		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2453169	A1	20030123	CA 2002-2453169	20020709
	AU 2002320330	A1	20030129	AU 2002-320330	20020709
	AU 2002320330	B2	20070614		
	US 2003087832	A1	20030508	US 2002-191718	20020709
	US 6777577	B2	20040817		
	EP 1423373	A2	20040602	EP 2002-749842	20020709
	EP 1423373	B1	20051019		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	JP 2005504023	T	20050210	JP 2003-512216	20020709
	AT 307125	T	20051115	AT 2002-749842	20020709
	ES 2247357	T3	20060301	ES 2002-2749842	20020709
	MX 2004PA00040	A	20040521	MX 2004-PA40	20040107
	US 2004204582	A1	20041014	US 2004-835630	20040430
	US 7223763	B2	20070529		
	US 2007191347	A1	20070816	US 2007-738725	20070423
	US 2007208008	A1	20070906	US 2007-738733	20070423
	AU 2007216625	A1	20070927	AU 2007-216625	20070905
PRAI	US 2001-304020P	P	20010709		
	GB 2001-27615	A	20011119		
	AU 2002-320330	A3	20020709		
	US 2002-191718	A3	20020709		
	WO 2002-US21525	W	20020709		
	US 2004-835630	A3	20040430		
OS	MARPAT 138:122861				
IT	488839-58-3P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of substituted amides, sulfonamides and ureas useful for inhibiting kinase activity)				
RN	488839-58-3 CAPLUS				
CN	2-Benzofurancarboxamide, N-[5-[[[[[trans-4-(aminocarbonyl)cyclohexyl]methyl]amino]carbonyl]amino]-2-[1,4'-bipiperidin]-1'-ylphenyl]]- (CA INDEX				

10/574,087

NAME)


Relative stereochemistry.



10/574,087


L4 ANSWER 78 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2002:946561 CAPLUS
DN 138:24739
TI Benzodiazepine bradykinin antagonists
IN Wood, Michael R.; Bock, Mark G.; Su, Dai-Shi; Kuduk, Scott D.; Han, Wei;
Dorsey, Bruce D.
PA Merck & Co., Inc., USA
SO PCT Int. Appl., 71 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002099388	A2	20021212	WO 2002-US21065	20020603
	WO 2002099388	A3	20030501		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2002346048	A1	20021216	AU 2002-346048	20020603
PRAI	US 2001-296644P	P	20010607		
	WO 2002-US21065	W	20020603		
OS	MARPAT 138:24739				
IT	478055-47-9				
	RL: RCT (Reactant); RACT (Reactant or reagent)				
	(benzodiazepine bradykinin antagonists)				
RN	478055-47-9 CAPLUS				
CN	Benzenamine, 4-[1,4'-bipiperidin]-1'-yl- (CA INDEX NAME)				



IT 478055-46-8P
RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent);
USES (Uses)
(benzodiazepine bradykinin antagonists)
RN 478055-46-8 CAPLUS
CN Urea, N-(4-[1,4'-bipiperidin]-1'-ylphenyl)-N'-(5-cyclohexyl-2,3-dihydro-2-oxo-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)

10/574,087




IT 478054-99-8P 478055-01-5P 478055-20-8P
478055-33-3P 478055-34-4P 478055-35-5P
478055-37-7P 478055-51-5P 478055-52-6P
478055-53-7P 478055-54-8P 478055-55-9P
478055-56-0P 478055-57-1P 478055-58-2P
478055-59-3P 478055-60-6P 478055-61-7P
478055-62-8P 478055-63-9P 478055-64-0P
478055-65-1P 478055-66-2P 478055-67-3P
478055-68-4P 478055-72-0P 478055-75-3P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(benzodiazepine bradykinin antagonists)


RN 478054-99-8 CAPLUS

CN Benzeneacetamide, 4-[1,4'-bipiperidin]-1'-yl-N-(5-cyclohexyl-2,3-dihydro-2-oxo-1-propyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)



RN 478055-01-5 CAPLUS


CN Benzamide, 3-[1,4'-bipiperidin]-1'-yl-N-(5-cyclohexyl-2,3-dihydro-2-oxo-1-propyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)



10/574,087


RN 478055-20-8 CAPLUS

CN Urea, N-[(4-[1,4'-bipiperidin]-1'-ylphenyl)methyl]-N'-(5-cyclohexyl-2,3-dihydro-2-oxo-1-propyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)




RN 478055-33-3 CAPLUS

CN Carbamic acid, (4-[1,4'-bipiperidin]-1'-ylphenyl)-, 5-cyclohexyl-2,3-dihydro-2-oxo-1-propyl-1H-1,4-benzodiazepin-3-yl ester (9CI) (CA INDEX NAME)



RN 478055-34-4 CAPLUS


CN Urea, N-(4-[1,4'-bipiperidin]-1'-ylphenyl)-N'-[2,3-dihydro-2-oxo-5-(1-piperidinyl)-1-propyl-1H-1,4-benzodiazepin-3-yl]- (CA INDEX NAME)



RN 478055-35-5 CAPLUS


CN Urea, N-(4-[1,4'-bipiperidin]-1'-ylphenyl)-N'-[5-cyclohexyl-2,3-dihydro-2-oxo-1-(2-propenyl)-1H-1,4-benzodiazepin-3-yl]-N-2-propenyl- (9CI) (CA INDEX NAME)

10/574,087




RN 478055-37-7 CAPLUS

CN 1H-1,4-Benzodiazepine-3-acetamide, N-(4-[1,4'-bipiperidin]-1'-ylphenyl)-5-cyclohexyl-2,3-dihydro-2-oxo-1-propyl- (CA INDEX NAME)



RN 478055-51-5 CAPLUS


CN Urea, N-(4-[1,4'-bipiperidin]-1'-ylphenyl)-N'-[2,3-dihydro-1-(1-methylethyl)-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]- (CA INDEX NAME)



RN 478055-52-6 CAPLUS


CN Urea, N-(4-[1,4'-bipiperidin]-1'-ylphenyl)-N'-[5-cyclohexyl-1-(cyclopropylmethyl)-2,3-dihydro-2-oxo-1H-1,4-benzodiazepin-3-yl]- (CA INDEX NAME)

10/574,087




RN 478055-53-7 CAPLUS

CN Urea, N-(4-[1,4'-bipiperidin]-1'-ylphenyl)-N'-(2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)



RN 478055-54-8 CAPLUS


CN Urea, N-(4-[1,4'-bipiperidin]-1'-ylphenyl)-N'-(5-cyclohexyl-2,3-dihydro-2-oxo-1-propyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)



RN 478055-55-9 CAPLUS


CN Urea, N-(4-[1,4'-bipiperidin]-1'-ylphenyl)-N'-[2,3-dihydro-5-(1-methylethyl)-2-oxo-1-propyl-1H-1,4-benzodiazepin-3-yl]- (CA INDEX NAME)

10/574,087




RN 478055-56-0 CAPLUS

CN Urea, N-(4-[1,4'-bipiperidin]-1'-ylphenyl)-N'-[5-(1,1-dimethylethyl)-2,3-dihydro-2-oxo-1-propyl-1H-1,4-benzodiazepin-3-yl]- (CA INDEX NAME)




RN 478055-57-1 CAPLUS

CN Urea, N-(4-[1,4'-bipiperidin]-1'-ylphenyl)-N'-(2,3-dihydro-5-methyl-2-oxo-1-propyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)



RN 478055-58-2 CAPLUS


CN Urea, N-(4-[1,4'-bipiperidin]-1'-ylphenyl)-N'-[2,3-dihydro-2-oxo-5-(2-phenylethyl)-1-propyl-1H-1,4-benzodiazepin-3-yl]- (CA INDEX NAME)



RN 478055-59-3 CAPLUS


CN Urea, N-(4-[1,4'-bipiperidin]-1'-ylphenyl)-N'-(1-butyl-5-cyclohexyl-2,3-dihydro-2-oxo-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)

10/574,087




RN 478055-60-6 CAPLUS

CN Urea, N-(4-[1,4'-bipiperidin]-1'-ylphenyl)-N'-[5-cyclohexyl-2,3-dihydro-1-(2-methylpropyl)-2-oxo-1H-1,4-benzodiazepin-3-yl]- (CA INDEX NAME)



RN 478055-61-7 CAPLUS


CN Urea, N-(4-[1,4'-bipiperidin]-1'-ylphenyl)-N'-[5-[4-(1,1-dimethylethyl)cyclohexyl]-2,3-dihydro-2-oxo-1-propyl-1H-1,4-benzodiazepin-3-yl]- (CA INDEX NAME)



RN 478055-62-8 CAPLUS


CN Urea, N-(4-[1,4'-bipiperidin]-1'-ylphenyl)-N'-[5-(3,5-dimethylcyclohexyl)-2,3-dihydro-2-oxo-1-propyl-1H-1,4-benzodiazepin-3-yl]- (CA INDEX NAME)

10/574,087




RN 478055-63-9 CAPLUS

CN Urea, N-(4-[1,4'-bipiperidin]-1'-ylphenyl)-N'-[5-cyclohexyl-2,3-dihydro-2-oxo-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]- (CA INDEX NAME)



RN 478055-64-0 CAPLUS


CN Urea, N-(4-[1,4'-bipiperidin]-1'-ylphenyl)-N'-[2,3-dihydro-5-(4-methylphenyl)-2-oxo-1-propyl-1H-1,4-benzodiazepin-3-yl]- (CA INDEX NAME)



RN 478055-65-1 CAPLUS


CN Urea, N-(4-[1,4'-bipiperidin]-1'-ylphenyl)-N'-[5-(3-butenyl)-2,3-dihydro-2-oxo-1-propyl-1H-1,4-benzodiazepin-3-yl]- (9CI) (CA INDEX NAME)

10/574,087




RN 478055-66-2 CAPLUS

CN Urea, N-(4-[1,4'-bipiperidin]-1'-ylphenyl)-N'-(5-butyl-2,3-dihydro-2-oxo-1-propyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)




RN 478055-67-3 CAPLUS

CN Urea, N-[2,3-dihydro-5-(1-methylethyl)-2-oxo-1-propyl-1H-1,4-benzodiazepin-3-yl]-N'-[4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]- (CA INDEX NAME)



RN 478055-68-4 CAPLUS


CN Urea, N-(5-cyclohexyl-2,3-dihydro-2-oxo-1-propyl-1H-1,4-benzodiazepin-3-yl)-N'-[4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]- (CA INDEX NAME)



RN 478055-72-0 CAPLUS

10/574,087


CN Urea, N-(5-cyclohexyl-2,3-dihydro-2-oxo-1-propyl-1H-1,4-benzodiazepin-3-yl)-N'-[4-[4-(2-oxo-1-pyrrolidinyl)-1-piperidinyl]phenyl]- (CA INDEX NAME)



RN 478055-75-3 CAPLUS


CN 1H-1,4-Benzodiazepine-1-butanamide, N-(4-[1,4'-bipiperidin]-1'-ylphenyl)-5-cyclohexyl-2,3-dihydro-2-oxo- (CA INDEX NAME)

PAGE 1-A



10/574,087

PAGE 2-A



10/574,087

L4 ANSWER 79 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2002:695723 CAPLUS
DN 137:232908
TI Preparation of N-cyanomethyl amides as cathepsin cysteine protease inhibitors
IN Prasit, Petpiboon; Bayly, Christopher Ian; Robichaud, Joel Stephane; Black, W. Cameron; Setti, Eduardo L.; Rydzewski, Robert M.; Palmer, James T.
PA Merck Frosst Canada & Co., Can.; PE Corporation (NY); AXYS Pharm. Inc.
SO PCT Int. Appl., 173 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 2002069901	A2	20020912	WO 2002-US6533	20020301
	WO 2002069901	A3	20031030		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2439415	A1	20020912	CA 2002-2439415	20020301
	AU 2002254099	A1	20020919	AU 2002-254099	20020301
	EP 1372655	A2	20040102	EP 2002-723314	20020301
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	JP 2004531486	T	20041014	JP 2002-569079	20020301
	US 2004198982	A1	20041007	US 2003-469430	20030828
	US 7012075	B2	20060314		
PRAI	US 2001-272799P	P	20010302		
	WO 2002-US6533	W	20020301		

OS MARPAT 137:232908


IT 459163-42-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-cyanomethyl amides as cathepsin cysteine protease inhibitors)

RN 459163-42-9 CAPLUS

CN 2-Piperidinecarboxamide, 1-(3'-[1,4'-bipiperidin]-1'-yl[1,1'-biphenyl]-3-yl)-N-(cyanomethyl)- (CA INDEX NAME)




10/574,087

10/574,087

L4 ANSWER 80 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2002:449673 CAPLUS
DN 137:20389
TI Preparation of indenopyrazolone semicarbazides as cyclin dependent kinase inhibitors.
IN Carini, David J.
PA Bristol-Myers Squibb Company, USA
SO PCT Int. Appl., 107 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002046182	A1	20020613	WO 2001-US46904	20011207
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2430376	A1	20020613	CA 2001-2430376	20011207
	AU 200228849	A	20020618	AU 2002-28849	20011207
	US 2002091127	A1	20020711	US 2001-10979	20011207
	US 6849631	B2	20050201		
	EP 1351956	A1	20031015	EP 2001-989969	20011207
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004538247	T	20041224	JP 2002-547920	20011207
PRAI	US 2000-254116P	P	20001208		
	WO 2001-US46904	W	20011207		
OS	MARPAT 137:20389				
IT	435337-64-7P 435337-66-9P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of indenopyrazolone semicarbazides as cyclin dependent kinase inhibitors)				
RN	435337-64-7 CAPLUS				
CN	Hydrazinecarboxamide, N-[2,4-dihydro-4-oxo-3-[4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]indeno[1,2-c]pyrazol-5-yl]-2-methyl-2-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)				

10/574,087



RN 435337-66-9 CAPLUS

CN Hydrazinecarboxamide, N-[3-(4-[1,4'-bipiperidin]-1'-ylphenyl)-2,4-dihydro-4-oxoindeno[1,2-c]pyrazol-5-yl]-2-methyl-2-(tetrahydro-2H-pyran-4-yl)-
(CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/574,087

L4 ANSWER 81 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2002:293978 CAPLUS

DN 136:337341

TI Materials and methods to modulate ligand binding/enzymic activity of α/β proteins containing an allosteric regulatory site

IN Stauton, Donald E.

PA Icos Corporation, USA

SO PCT Int. Appl., 163 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002031511	A2	20020418	WO 2001-US32047	20011012
	WO 2002031511	A3	20030313		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2425581	A1	20020418	CA 2001-2425581	20011012
	AU 200213196	A	20020422	AU 2002-13196	20011012
	US 2003088061	A1	20030508	US 2001-976935	20011012
	EP 1325341	A2	20030709	EP 2001-981560	20011012
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	JP 2004511496	T	20040415	JP 2002-534845	20011012
	MX 2003PA03207	A	20040326	MX 2003-PA3207	20030411
PRAI	US 2000-239750P	P	20001012		
	WO 2001-US32047	W	20011012		
IT	415717-88-3				
	RL:	BSU (Biological study, unclassified); BIOL (Biological study) (materials and methods to modulate ligand binding/enzymic activity of α/β proteins containing allosteric regulatory site)			
RN	415717-88-3	CAPLUS			
CN	2-Propenamide, 3-[2,3-dichloro-4-[[3-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]thio]phenyl]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (CA INDEX NAME)				



L4 ANSWER 82 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2002:171600 CAPLUS

DN 136:228356

TI Preparation of disubstituted benzenes as insecticides

IN Theodoridis, George; Qi, Hongyan; Rowley, Elizabeth; Ali, Syed F.;
Crawford, Ellen M.; Cullen, Thomas G.; Yeager, Walter H.; Duggan,
Christina B.; Barron, Edward; Cohen, Daniel H.

PA FMC Corporation, USA

SO PCT Int. Appl., 118 pp.



CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002017712	A2	20020307	WO 2001-US26962	20010829
	WO 2002017712	A3	20030612		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				
	GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				
	LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL,				
	PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,				
	UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG,				
	KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR,				
	IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN,				
	GQ, GW, ML, MR, NE, SN, TD, TG				
AU	200186909	A	20020313	AU 2001-86909	20010829
US	2002183342	A1	20021205	US 2001-941812	20010829
US	6753429	B2	20040622		
EP	1334083	A2	20030813	EP 2001-966389	20010829
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
	IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP	2004524266	T	20040812	JP 2002-522697	20010829
CN	1543452	A	20041103	CN 2001-814832	20010829
BR	2001013445	A	20050412	BR 2001-13445	20010829
HU	2005000470	A2	20050829	HU 2005-470	20010829
HU	2005000470	A3	20051128		
US	2003207894	A1	20031106	US 2003-353471	20030129
US	7247756	B2	20070724		
ZA	2003001173	A	20040816	ZA 2003-1173	20030212
IN	2003MN00233	A	20050304	IN 2003-MN233	20030217
MX	2003PA01537	A	20030606	MX 2003-PA1537	20030220
IN	2007MN00073	A	20070810	IN 2007-MN73	20070117
PRAI	US 2000-229701P	P	20000901		
	US 2001-277203P	P	20010320		
	US 2001-941812	A3	20010829		
	WO 2001-US26962	W	20010829		
	IN 2003-MN233	A3	20030217		
OS	MARPAT 136:228356				
IT	402745-00-0P 402745-01-1P				
	RL: AGR (Agricultural use); SPN (Synthetic preparation); BIOL (Biological				
	study); PREP (Preparation); USES (Uses)				
	(preparation as insecticide)				
RN	402745-00-0 CAPLUS				
CN	1,4'-Bipiperidine, 1'-[4-[(5,6-dichloro-1-naphthalenyl)oxy]methyl]phenyl]-				
	(CA INDEX NAME)				



RN 402745-01-1 CAPLUS
 CN Piperidine, 1-[4-[[[(5,6-dichloro-1-naphthalenyl)oxy]methyl]phenyl]-4-(1-pyrrolidinyl)]- (CA INDEX NAME)

10/574,087

PAGE 1-A



PAGE 2-A



10/574,087

L4 ANSWER 83 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2002:122956 CAPLUS

DN 136:167363

TI Preparation of fused bicyclic amide compounds and use as remedies for various autoimmune diseases

IN Ushio, Hiroyuki; Naito, Youichiro; Sugiyama, Naoki; Kawaguchi, Takafumi; Ohtsuki, Makio; Chiba, Kenji

PA Welfide Corporation, Japan

SO PCT Int. Appl., 120 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002012189	A1	20020214	WO 2001-JP6852	20010809
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 200177731	A	20020218	AU 2001-77731	20010809
	EP 1310488	A1	20030514	EP 2001-955619	20010809
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 2003203909	A1	20031030	US 2003-344261	20030429
	US 7112594	B2	20060926		
PRAI	JP 2000-241934	A	20000809		
	WO 2001-JP6852	W	20010809		

OS MARPAT 136:167363


IT 398137-07-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzofurancarboxamides, benzothiophencarboxamides, and pyridinothiophencarboxamides and use as remedies for various autoimmune diseases)

RN 398137-07-0 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(4-[1,4'-bipiperidin]-1'-yl-3-cyanophenyl)- (CA INDEX NAME)



IT 288252-12-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of benzofurancarboxamides, benzothiophencarboxamides, and pyridinothiophencarboxamides and use as remedies for various autoimmune diseases)

RN 288252-12-0 CAPLUS

10/574,087

CN Benzonitrile, 5-amino-2-[1,4'-bipiperidin]-1'-yl- (CA INDEX NAME)



RE.CNT 206 THERE ARE 206 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 84 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2001:798188 CAPLUS

DN 135:344379

TI Pyrrolidine and piperidine derivatives with NMDA receptor blocking activity and their use for the treatment of neurodegenerative disorders

IN Alanine, Alexander; Buettelmann, Bernd; Heitz Neidhart, Marie-Paule; Jaeschke, Georg; Pinard, Emmanuel; Wyler, Rene

PA F. Hoffmann-La Roche A.-G., Switz.

SO PCT Int. Appl., 64 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001081303	A1	20011101	WO 2001-EP4171	20010411
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CO, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2404464	A1	20011101	CA 2001-2404464	20010411
	EP 1278728	A1	20030129	EP 2001-940321	20010411
	EP 1278728	B1	20040825		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001010112	A	20030211	BR 2001-10112	20010411
	JP 2003531190	T	20031021	JP 2001-578398	20010411
	AT 274494	T	20040915	AT 2001-940321	20010411
	PT 1278728	T	20041029	PT 2001-940321	20010411
	ES 2225553	T3	20050316	ES 2001-1940321	20010411
	US 2001047031	A1	20011129	US 2001-833450	20010412
	US 6451819	B2	20020917		
	ZA 2002008015	A	20040210	ZA 2002-8015	20021004
	MX 2002PA10261	A	20030425	MX 2002-PA10261	20021017
PRAI	EP 2000-108610	A	20000420		
	WO 2001-EP4171	W	20010411		
OS	MARPAT 135:344379				
IT	371239-85-9P, (RS)-4-[1-(1-Phenylpiperidin-4-yl)pyrrolidin-3-ylsulfonyl]phenol				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(drug candidate; preparation of pyrrolidine and piperidine derivs. for the treatment of neurodegenerative disorders)				
RN	371239-85-9 CAPLUS				
CN	Phenol, 4-[[1-(1-phenyl-4-piperidinyl)-3-pyrrolidinyl]sulfonyl]- (CA INDEX NAME)				

10/574,087



RE.CNT 5

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/574,087

L4 ANSWER 85 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2001:731369 CAPLUS
DN 135:288778
TI Preparation of indeno[1,2-c]pyrazol-4-ones as inhibitors of cyclin dependent kinases
IN Nugiel, David A.; Carini, David J.; Dimeo, Susan V.; Yue, Eddy W.
PA Bristol-Myers Squibb Pharma Company, USA
SO U.S. Pat. Appl. Publ., 104 pp., Cont.-in-part of U.S. Ser. No. 639,618.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2001027195	A1	20011004	US 2000-731304	20001206
	US 6407103	B2	20020618		
	US 6413957	B1	20020702	US 2000-639618	20000815
	CA 2420164	A1	20020502	CA 2000-2420164	20001020
	AU 200112168	A	20020506	AU 2001-12168	20001020
	EP 1414804	A1	20040506	EP 2000-973682	20001020
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
	JP 2004524277	T	20040812	JP 2002-537713	20001020
PRAI	US 1998-82476P	P	19980421		
	US 1999-295078	B1	19990420		
	US 2000-639618	A2	20000815		
	WO 2000-US28952	W	20001020		


OS MARPAT 135:288778

IT 364735-10-4P 364735-11-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of indeno[c]pyrazolones as inhibitors of cyclin dependent kinases)

RN 364735-10-4 CAPLUS

CN Urea, N-[3-(4-[1,4'-bipiperidin]-1'-ylphenyl)-2,4-dihydro-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl- (CA INDEX NAME)




RN 364735-11-5 CAPLUS

CN Urea, N-[2,4-dihydro-4-oxo-3-[4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]indeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl- (CA INDEX NAME)

10/574,087


NAME)



10/574,087

L4 ANSWER 86 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2001:565041 CAPLUS
DN 135:152818
TI Preparation of 2-amino-8H-pyrido[2,3-d]pyrimidin-7-ones as cyclin
dependent kinase inhibitors for treatment of neurodegenerative disease
IN Booth, Richard John; Chatterjee, Arindam; Malone, Thomas Charles
PA Warner-Lambert Company, USA
SO PCT Int. Appl., 232 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001055148	A1	20010802	WO 2000-US32572	20001130
	W: AE, AG, AL, AU, BA, BB, BG, BR, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, MZ, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2394525	A1	20010802	CA 2000-2394525	20001130
	BR 2000017075	A	20021105	BR 2000-17075	20001130
	EP 1255755	A1	20021113	EP 2000-980883	20001130
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	HU 2002003803	A2	20030228	HU 2002-3803	20001130
	JP 2003523358	T	20030805	JP 2001-561007	20001130
	US 2004224958	A1	20041111	US 2002-181866	20021112
PRAI	US 2000-178400P	P	20000127		
	WO 2000-US32572	W	20001130		
OS	MARPAT 135:152818				
IT	211247-61-9P				
	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)				
	(intermediate; preparation of 2-amino-8H-pyrido[2,3-d]pyrimidinones as cyclin-dependent kinase inhibitors by cyclization of 3-[2-(methylsulfinyl)-4-aminopyrimidin-5-yl]acrylates or acrylonitriles)				
RN	211247-61-9 CAPLUS				
CN	1,4'-Bipiperidine, 1'-(4-nitrophenyl)- (CA INDEX NAME)				




RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/574,087

L4 ANSWER 87 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2001:526050 CAPLUS
DN 135:107149
TI Synthesis, antibacterial activity and RNA polymerase inhibition of
phenylamidine derivs.
IN Li, Leping; Chen, Xiaoqui; Fan, Pingchen; Mihalic, Jeffrey Thomas; Cutler,
Serena
PA Tularik Inc., USA
SO PCT Int. Appl., 104 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001051456	A2	20010719	WO 2001-US1219	20010112
	WO 2001051456	A3	20011220		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	CA 2397575	A1	20010719	CA 2001-2397575	20010112
	US 2002045749	A1	20020418	US 2001-759633	20010112
	US 6780858	B2	20040824		
	EP 1246795	A2	20021009	EP 2001-914329	20010112
	EP 1246795	B1	20071031		
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	JP 2003519676	T	20030624	JP 2001-551838	20010112
	AT 376996	T	20071115	AT 2001-914329	20010112
	US 2004235911	A1	20041125	US 2004-877408	20040625
	US 7053234	B2	20060530		
	US 2006270651	A1	20061130	US 2006-344111	20060201
	US 7148259	B1	20061212		
PRAI	US 2000-175892P	P	20000113		
	US 2001-759633	A1	20010112		
	WO 2001-US1219	W	20010112		
	US 2004-877408	A3	20040625		
OS	MARPAT 135:107149				
IT	350487-04-6P				
	RL:	BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)			
		(synthesis, antibacterial activity and RNA polymerase inhibition of phenyl- and heterocyclylhydroxyamidine derivs.)			
RN	350487-04-6 CAPLUS				
CN	Benzenecarboximidamide, N-hydroxy-N'-phenyl-4-[4-(1-pyrrolidinyl)-1-piperidinyl]-3-(trifluoromethyl)- (CA INDEX NAME)				

10/574,087




L4 ANSWER 88 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2001:396661 CAPLUS
 DN 135:19547
 TI Preparation of sulfonamides and sulfinamides as NPY Y5 antagonists
 IN Kawanishi, Yasuyuki; Takenaka, Hideyuki; Hanasaki, Kohji; Okada, Tetsuo
 PA Shionogi & Co., Ltd., Japan
 SO PCT Int. Appl., 273 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001037826	A1	20010531	WO 2000-JP8197	20001121
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2389681	A1	20010531	CA 2000-2389681	20001121
	AU 200114186	A	20010604	AU 2001-14186	20001121
	AU 780790	B2	20050414		
	BR 2000015843	A	20020827	BR 2000-15843	20001121
	EP 1249233	A1	20021016	EP 2000-976387	20001121
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	HU 2003002969	A2	20031229	HU 2003-2969	20001121
	HU 2003002969	A3	20050530		
	NZ 519070	A	20050826	NZ 2000-519070	20001121
	RU 2264810	C2	20051127	RU 2002-117021	20001121
	NZ 540351	A	20060526	NZ 2000-540351	20001121
	JP 3910446	B2	20070425	JP 2001-539441	20001121
	TW 246514	B	20060101	TW 2000-89124916	20001123
	ZA 2002003306	A	20030425	ZA 2002-3306	20020425
	US 6699891	B1	20040302	US 2002-111981	20020501
	MX 2002PA04985	A	20031014	MX 2002-PA4985	20020517
	NO 2002002481	A	20020726	NO 2002-2481	20020524
	US 2004176462	A1	20040909	US 2003-747034	20031230
	US 2004180964	A1	20040916	US 2003-747359	20031230
	US 7265130	B2	20070904		
	US 2007015762	A1	20070118	US 2006-520772	20060914
PRAI	JP 1999-336469	A	19991126		
	JP 1999-353786	A	19991214		
	NZ 2000-519070	A1	20001121		
	WO 2000-JP8197	W	20001121		
	US 2002-111981	A3	20020501		
	US 2003-747034	A3	20031230		
OS	MARPAT 135:19547				
IT	342574-30-5P				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of sulfonamides and sulfinamides as NPY Y5 antagonists)				
RN	342574-30-5 CAPLUS				
CN	Cyclohexanecarboxamide, N-(4-[1,4'-bipiperidin]-1'-ylphenyl)-4-[[[(1,1-dimethylethyl)sulfonyl]amino]-, trans- (CA INDEX NAME)				

10/574,087

Relative stereochemistry.



RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/574,087

L4 ANSWER 89 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2001:338520 CAPLUS
DN 134:340521
TI Preparation of naphthalenes, piperidines, imidazoles, and quinazolines as
calcitonin gene-related peptide receptor antagonists.
IN Rudolf, Klaus; Eberlein, Wolfgang; Engel, Wolfhard; Doods, Henri;
Hallermayer, Gerhard; Bauer, Eckhart
PA Boehringer Ingelheim Pharma K.-G., Germany
SO PCT Int. Appl., 212 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001032649	A1	20010510	WO 2000-EP10463	20001024
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	DE 19952146	A1	20010607	DE 1999-19952146	19991029
	CA 2387613	A1	20010510	CA 2000-2387613	20001024
	EP 1228060	A1	20020807	EP 2000-977432	20001024
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	JP 2003513088	T	20030408	JP 2001-534800	20001024
	MX 2002PA04271	A	20021031	MX 2002-PA4271	20020429
	US 7230001	B1	20070612	US 2003-110347	20030107
	US 2007208036	A1	20070906	US 2007-743393	20070502
PRAI	DE 1999-19952146	A	19991029		
	WO 2000-EP10463	W	20001024		
	US 2003-110347	A3	20030107		

OS MARPAT 134:340521


IT 337911-87-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of naphthalenes, piperidines, imidazoles, and quinazolines as medicaments)

RN 337911-87-2 CAPLUS

CN Piperidine, 1-[4-(4-[1,4'-bipiperidin]-1'-yl-3-bromophenyl)-1,4-dioxobutyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (9CI) (CA INDEX NAME)




RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD

10/574,087

ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/574,087

L4 ANSWER 90 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2001:16846 CAPLUS
DN 134:207571
TI Aromatic aminations by heterogeneous Ni0/C catalysis
AU Lipshutz, Bruce H.; Ueda, Hiroshi
CS Department of Chemistry, University of California, Santa Barbara, CA,
93106, USA
SO Angewandte Chemie, International Edition (2000), 39(24), 4492-4494
CODEN: ACIEF5; ISSN: 1433-7851
PB Wiley-VCH Verlag GmbH
DT Journal
LA English
OS CASREACT 134:207571
IT 128504-77-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(aromatic aminations via heterogeneous Ni/C catalysis)
RN 128504-77-8 CAPLUS
CN Benzonitrile, 4-[4-(1-pyrrolidinyl)-1-piperidinyl]- (CA INDEX NAME)




RE.CNT 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/574,087

L4 ANSWER 91 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2000:874145 CAPLUS
DN 134:49131
TI Oxonol compound, light-sensitive material and process for the synthesis of
oxonol compound
IN Nishigaki, Junji; Deguchi, Yasuaki
PA Fuji Photo Film Co., Ltd., Japan
SO U.S., 72 pp., Cont.-in-part of U.S. Ser. No. 896,064, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 6159673	A	20001212	US 1999-233444	19990120
	JP 10036691	A	19980210	JP 1996-206527	19960717
	JP 3846937	B2	20061115		
	JP 10060293	A	19980303	JP 1996-235893	19960819
	JP 3796302	B2	20060712		
	JP 10251532	A	19980922	JP 1997-55315	19970310
PRAI	JP 1996-206527	A	19960717		
	JP 1996-235893	A	19960819		
	JP 1997-55315	A	19970310		
	US 1997-896064	B2	19970717		
OS	MARPAT 134:49131				
IT	202482-38-0P				
	RL: NUU (Other use, unclassified); SPN (Synthetic preparation); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses) (preparation of methine dyes for oxonol as light-sensitive dye in silver halide photog. papers)				
RN	202482-38-0	CAPLUS			
CN	Pyridinium, 1-(2,4-dinitrophenyl)-4-(2,5-dioxo-1-pyrrolidinyl)-, chloride (9CI) (CA INDEX NAME)				



● Cl⁻

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 92 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2000:725609 CAPLUS
 DN 133:296281
 TI Preparation of 2- or 4-(phenylthio)cinnamides as cell adhesion-inhibiting
 antiinflammatory and immune-suppressive compounds
 IN Link, James; Liu, Gang; Pei, Zhonghua; Von Geldern, Thomas W.; Winn,
 Martin; Xin, Zhili; Wang, Sheldon; Boyd, Steven A.; Zhu, Gui-Dong;
 Freeman, Jennifer C.; Gunawardana, Indrani W.; Staeger, Michael A.; Jae,
 Hwan-soo; Lynch, John K.
 PA Abbott Laboratories, USA
 SO PCT Int. Appl., 476 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000059880	A1	20001012	WO 2000-US8895	20000403
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR,				
	CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,				
	ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,				
	LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE,				
	SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,				
	DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,				
	CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6878700	B1	20050412	US 2000-541795	20000331
	CA 2369238	A1	20001012	CA 2000-2369238	20000403
	AU 200041944	A	20001023	AU 2000-41944	20000403
	AU 774564	B2	20040701		
	EP 1165505	A1	20020102	EP 2000-921654	20000403
	EP 1165505	B1	20040908		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
	IE, SI, LT, LV, FI, RO				
	BR 2000009426	A	20020409	BR 2000-9426	20000403
	HU 2002002031	A2	20021028	HU 2002-2031	20000403
	EE 200100513	A	20021216	EE 2001-513	20000403
	JP 2004513063	T	20040430	JP 2000-609392	20000403
	AT 275543	T	20040915	AT 2000-921654	20000403
	NZ 515237	A	20041126	NZ 2000-515237	20000403
	MX 2001PA09766	A	20020621	MX 2001-PA9766	20010927
	NO 2001004767	A	20011130	NO 2001-4767	20011001
	BG 106029	A	20020531	BG 2001-106029	20011018
	HR 2001000776	A1	20021231	HR 2001-776	20011023
	HR 2001000776	B1	20060228		
	ZA 2001008944	A	20030702	ZA 2001-8944	20011030
	HK 1040985	A1	20050218	HK 2002-102655	20020409
	AU 2004205260	A1	20040923	AU 2004-205260	20040825
PRAI	US 1999-286645	A	19990402		
	US 1999-474517	A	19991229		
	US 2000-541795	A	20000331		
	US 1998-114097P	P	19981229		
	WO 2000-US8895	W	20000403		

OS MARPAT 133:296281

IT 301179-03-3P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of (phenylthio)cinnamides as cell adhesion inhibitors by coupling of thiophenols with halobenzaldehydes, conversion to cinnamic

10/574,087


acids, amidation, and optional derivatization)
RN 301179-03-3 CAPLUS
CN 2-Propenamide, 3-[2,3-dichloro-4-[[3-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]thio]phenyl]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]-, (2E)-
(CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 93 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2000:608722 CAPLUS

DN 133:193079

TI Preparation of arylsulfonylheterocyclylhydroxamic acids and related compounds as matrix metalloprotease inhibitors

IN Barta, Thomas E.; Becker, Daniel P.; Bedell, Louis J.; Boehm, Terri L.; Carroll, Jeffery N.; De Crescenzo, Gary A.; Fobian, Yvette M.; Freskos, John N.; Getman, Daniel P.; McDonald, Joseph J.; Hanson, Gunnar J.; Hockerman, Susan L.; Howard, Susan C.; Kolodziej, Steve A.; Li, Hui; Mischke, Deborah A.; Rico, Joseph G.; Stehle, Nathan W.; Tollefson, Michael B.; Vernier, William F.; Villamil, Clara I.; Rao, Shashidhar N.

PA G.D. Searle and Co., USA

SO PCT Int. Appl., 851 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000050396	A1	20000831	WO 2000-US2518	20000222
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 2001039287	A1	20011108	US 1999-256948	19990224
	CA 2371876	A1	20000831	CA 2000-2371876	20000222
	AU 200034785	A	20000914	AU 2000-34785	20000222
	HU 2002000239	A2	20020629	HU 2002-239	20000222
	HU 2002000239	A3	20030428		
	EP 1230219	A1	20020814	EP 2000-913317	20000222
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	BR 2000008491	A	20020917	BR 2000-8491	20000222
	JP 2002537378	T	20021105	JP 2000-600979	20000222
	NZ 513648	A	20040227	NZ 2000-513648	20000222
	NO 2001003963	A	20011023	NO 2001-3963	20010815
	ZA 2001006780	A	20020816	ZA 2001-6780	20010816
	IN 2001CN01174	A	20050304	IN 2001-CN1174	20010821
	MX 2001PA08568	A	20020408	MX 2001-PA8568	20010823
	US 2002177588	A1	20021128	US 2001-954451	20010917
	US 6750233	B2	20040615		
PRAI	US 1999-256948	A	19990224		
	US 1997-66007P	P	19971114		
	US 1998-95347P	P	19980804		
	US 1998-95501P	P	19980806		
	US 1998-101080P	P	19980918		
	WO 2000-US2518	W	20000222		
OS	MARPAT 133:193079				
IT	226390-92-7P 226391-18-0P				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of arylsulfonylheterocyclylhydroxamic acids and related compds. as matrix metalloprotease inhibitors)				
RN	226390-92-7 CAPLUS				
CN	2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[4-(1-pyrrolidinyl)-1-				


10/574,087

piperidinyl]phenyl]sulfonyl]-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 226390-91-6


CMF C21 H31 N3 O5 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 226391-18-0 CAPLUS


CN 2H-Pyran-4-carboxamide, 4-[(4-[1,4'-bipiperidin]-1'-yl)phenyl]sulfonyl]tetrahydro-N-hydroxy-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 226391-17-9


CMF C22 H33 N3 O5 S

10/574,087



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RE.CNT 7

THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 94 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2000:573775 CAPLUS

DN 133:177164

TI Preparation of pyrazolecarboxamides and pyrrolecarboxamides as inhibitors of the proliferation of activated lymphocytes and as remedies for autoimmune disease.

IN Ushio, Hiroyuki; Ishibuchi, Seigo; Naito, Youichiro; Sugiyama, Naoki; Kawaguchi, Takafumi; Chiba, Kenji; Ohtsuki, Makio; Naka, Yoichi

PA Yoshitomi Pharmaceutical Industries, Ltd., Japan

SO PCT Int. Appl., 315 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000047558	A1	20000817	WO 2000-JP767	20000210
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2362381	A1	20000817	CA 2000-2362381	20000210
	NZ 514095	A	20010928	NZ 2000-514095	20000210
	EP 1176140	A1	20020130	EP 2000-902925	20000210
	EP 1176140	B1	20041229		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 2000008173	A	20021022	BR 2000-8173	20000210
	JP 3419395	B2	20030623	JP 2000-598479	20000210
	JP 2003176273	A	20030624	JP 2002-375683	20000210
	AT 286026	T	20050115	AT 2000-902925	20000210
	ES 2234564	T3	20050701	ES 2000-902925	20000210
	MX 2001PA08142	A	20030721	MX 2001-PA8142	20010810
	US 7015218	B1	20060321	US 2001-913260	20011119
PRAI	JP 1999-33367	A	19990210		
	JP 1999-198473	A	19990713		
	JP 2000-598479	A3	20000210		
	WO 2000-JP767	W	20000210		

OS MARPAT 133:177164

IT 288250-09-9P 288250-87-3P 288251-22-9P

288251-37-6P 288251-38-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of pyrazolecarboxamides and pyrrolecarboxamides as inhibitors of the proliferation of activated lymphocytes and as remedies for autoimmune disease.)

RN 288250-09-9 CAPLUS


CN 1H-Pyrazole-4-carboxamide, N-(4-[1,4'-bipiperidin]-1'-yl-3-cyanophenyl)-1-(4-fluorophenyl)-5-methyl- (CA INDEX NAME)

10/574,087

PAGE 1-A




PAGE 2-A




RN 288250-87-3 CAPLUS
CN 1H-Pyrazole-4-carboxamide, N-(4-[1,4'-bipiperidin]-1'-yl-3-cyanophenyl)-1-(4-chlorophenyl)-5-methyl- (CA INDEX NAME)

10/574,087

PAGE 1-A




PAGE 2-A




RN 288251-22-9 CAPLUS
CN 1H-Pyrazole-4-carboxamide, 1-(4-chlorophenyl)-N-[3-cyano-4-(4-hydroxy[1,4'-bipiperidin]-1'-yl)phenyl]-5-methyl- (CA INDEX NAME)

10/574,087

PAGE 1-A





PAGE 2-A





RN 288251-37-6 CAPLUS

CN 1H-Pyrazole-4-carboxamide, 1-(4-chlorophenyl)-N-[3-cyano-4-(4-methoxy[1,4'-bipiperidin]-1'-yl)phenyl]-5-methyl- (CA INDEX NAME)




RN 288251-38-7 CAPLUS
 CN 1H-Pyrazole-4-carboxamide, 1-(4-chlorophenyl)-N-[3-cyano-4-(4-oxo[1,4'-bipiperidin]-1'-yl)phenyl]-5-methyl- (CA INDEX NAME)




IT 288252-12-0P 288252-13-1P 288252-48-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of pyrazolecarboxamides and pyrrolecarboxamides as inhibitors
 of the proliferation of activated lymphocytes and as remedies for
 autoimmune disease.)
 RN 288252-12-0 CAPLUS
 CN Benzonitrile, 5-amino-2-[1,4'-bipiperidin]-1'-yl- (CA INDEX NAME)

10/574,087




RN 288252-13-1 CAPLUS

CN Benzonitrile, 2-[1,4'-bipiperidin]-1'-yl-5-nitro- (CA INDEX NAME)



RN 288252-48-2 CAPLUS

CN Benzonitrile, 5-amino-2-(4-hydroxy[1,4'-bipiperidin]-1'-yl)- (CA INDEX NAME)



RE.CNT 9

THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/574,087

L4 ANSWER 95 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2000:534991 CAPLUS
DN 133:135229
TI Preparation of cyclic amino-substituted N-aryl or N-heteroaryl cyclic
amines as antidepressants
IN Poss, Michael A.; Tortolani, David R.; Mattson, Ronald J.; Yevich, Joseph
P.
PA Bristol-Myers Squibb Company, USA
SO PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000044376	A1	20000803	WO 1999-US30501	19991221
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2360683	A1	20000803	CA 1999-2360683	19991221
	US 6225324	B1	20010501	US 1999-467957	19991221
	BR 9916618	A	20011023	BR 1999-16618	19991221
	EP 1146871	A1	20011024	EP 1999-968927	19991221
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	TR 200101939	T2	20020521	TR 2001-1939	19991221
	JP 2002535365	T	20021022	JP 2000-595679	19991221
	AU 771234	B2	20040318	AU 2000-27122	19991221
	MX 2001PA07462	A	20020208	MX 2001-PA7462	20010724
PRAI	US 1999-117651P	P	19990128		
	WO 1999-US30501	W	19991221		
OS	MARPAT 133:135229				
IT	286466-78-2P 286466-80-6P 286466-86-2P 286466-88-4P 286466-96-4P 286466-97-5P 286467-02-5P 286467-04-7P 286467-10-5P 286467-12-7P 286467-18-3P 286467-20-7P 286467-22-9P 286467-27-4P 286467-32-1P 286467-35-4P 286467-38-7P 286467-39-8P 286467-41-2P 286467-45-6P 286467-49-0P 286467-51-4P 286467-52-5P 286467-54-7P 286467-55-8P 286467-56-9P 286467-62-7P 286467-67-2P 286467-68-3P 286467-69-4P 286467-70-7P 286467-71-8P 286467-72-9P 286467-73-0P 286467-74-1P 286467-75-2P 286467-76-3P 286467-77-4P 286467-78-5P 286467-79-6P 286467-80-9P 286467-81-0P 286467-97-8P 286467-98-9P 286467-99-0P 286468-00-6P 286468-01-7P 286468-02-8P 286468-03-9P 286468-04-0P 286468-05-1P 286468-06-2P 286468-07-3P 286468-08-4P 286468-09-5P 286468-10-8P 286468-11-9P 286468-12-0P 286468-13-1P 286468-14-2P 286468-15-3P 286468-16-4P 286468-17-5P 286468-18-6P 286468-19-7P 286468-37-9P 286468-39-1P 286468-41-5P 286468-43-7P				

10/574,087


286468-45-9P 286468-47-1P 286469-06-5P
286469-07-6P 286469-20-3P 286469-22-5P
286469-23-6P 286469-24-7P 286469-25-8P
286469-31-6P 286469-32-7P 286469-33-8P
286469-34-9P 286469-36-1P 286469-37-2P
286469-38-3P 286469-39-4P 286469-40-7P
286469-41-8P 286469-43-0P 286469-44-1P
286469-47-4P 286469-48-5P 286469-49-6P
286469-50-9P 286469-51-0P 286469-52-1P
286469-53-2P 286469-97-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of cyclic amino-substituted N-aryl or N-heteroaryl cyclic amines as antidepressants)


RN 286466-78-2 CAPLUS

CN 1,4'-Bipiperidine, 4-[(2,5-dichlorophenyl)methyl]-1'-(3,4-dimethoxyphenyl)-
(CA INDEX NAME)



RN 286466-80-6 CAPLUS


CN 1,4'-Bipiperidine, 4-[(2,5-dichlorophenyl)methyl]-1'-(3-fluoro-4-methoxyphenyl)-
(CA INDEX NAME)



RN 286466-86-2 CAPLUS


CN 1,4'-Bipiperidine, 4-[(2,5-difluorophenyl)methyl]-1'-(3,4-dimethoxyphenyl)-
(CA INDEX NAME)

10/574,087




RN 286466-88-4 CAPLUS

CN 1,4'-Bipiperidine, 4-[(2,5-difluorophenyl)methyl]-1'-(3-fluoro-4-methoxyphenyl)- (CA INDEX NAME)



RN 286466-96-4 CAPLUS


CN 1,4'-Bipiperidine, 4-[(2-bromophenyl)methyl]-1'-(3,4-dimethoxyphenyl)- (CA INDEX NAME)



RN 286466-97-5 CAPLUS


CN 1,4'-Bipiperidine, 4-[(2-bromophenyl)methyl]-1'-(3-fluoro-4-methoxyphenyl)- (CA INDEX NAME)

10/574,087




RN 286467-02-5 CAPLUS

CN 1,4'-Bipiperidine, 4-[(2,5-difluorophenyl)methyl]-1'-(2-methoxyphenyl)-
(CA INDEX NAME)



RN 286467-04-7 CAPLUS


CN 1,4'-Bipiperidine, 4-[(2,5-difluorophenyl)methyl]-1'-(2,5-dimethoxyphenyl)-
(CA INDEX NAME)



RN 286467-10-5 CAPLUS


CN 1,4'-Bipiperidine, 4-[(2-bromophenyl)methyl]-1'-(2-methoxyphenyl)- (CA
INDEX NAME)

10/574,087




RN 286467-12-7 CAPLUS

CN 1,4'-Bipiperidine, 4-[(2-bromophenyl)methyl]-1'-(2,5-dimethoxyphenyl)-
(CA INDEX NAME)




RN 286467-18-3 CAPLUS

CN 1,4'-Bipiperidine, 4-[(2-chlorophenyl)methyl]-1'-(2-methoxyphenyl)- (CA
INDEX NAME)



RN 286467-20-7 CAPLUS


CN 1,4'-Bipiperidine, 4-[(2-chlorophenyl)methyl]-1'-(2,5-dimethoxyphenyl)-
(CA INDEX NAME)



10/574,087


RN 286467-22-9 CAPLUS

CN 1,4'-Bipiperidine, 4-[(2-chlorophenyl)methyl]-1'-(2,4-dimethoxyphenyl)-
(CA INDEX NAME)




RN 286467-27-4 CAPLUS

CN 1,4'-Bipiperidine, 4-[(2-chlorophenyl)methyl]-1'-(3-fluoro-4-methoxyphenyl)- (CA INDEX NAME)




RN 286467-32-1 CAPLUS

CN 1,4'-Bipiperidine, 1'-(2,5-dimethoxyphenyl)-4-[(3-methoxyphenyl)methyl]-
(CA INDEX NAME)



RN 286467-35-4 CAPLUS


CN 1,4'-Bipiperidine, 1'-(3,4-dimethoxyphenyl)-4-[(3-methoxyphenyl)methyl]-
(CA INDEX NAME)



10/574,087


RN 286467-38-7 CAPLUS

CN 1,4'-Bipiperidine, 1'-(3-fluoro-4-methoxyphenyl)-4-[(3-methoxyphenyl)methyl]- (CA INDEX NAME)




RN 286467-39-8 CAPLUS

CN 1,4'-Bipiperidine, 4-[(2-bromo-5-fluorophenyl)methyl]-1'-(2-methoxyphenyl)- (CA INDEX NAME)



RN 286467-41-2 CAPLUS


CN 1,4'-Bipiperidine, 4-[(2-bromo-5-fluorophenyl)methyl]-1'-(2,5-dimethoxyphenyl)- (CA INDEX NAME)



RN 286467-45-6 CAPLUS


CN 1,4'-Bipiperidine, 4-[(2-bromo-5-fluorophenyl)methyl]-1'-(3-fluoro-4-methoxyphenyl)- (CA INDEX NAME)

10/574,087




RN 286467-49-0 CAPLUS

CN 1,4'-Bipiperidine, 1'-(2,5-dimethoxyphenyl)-4-[(2-fluoro-5-methoxyphenyl)methyl]- (CA INDEX NAME)



RN 286467-51-4 CAPLUS


CN 1,4'-Bipiperidine, 1'-(3,4-dimethoxyphenyl)-4-[(2-fluoro-5-methoxyphenyl)methyl]- (CA INDEX NAME)



RN 286467-52-5 CAPLUS


CN 1,4'-Bipiperidine, 1'-(3-fluoro-4-methoxyphenyl)-4-[(2-fluoro-5-methoxyphenyl)methyl]- (CA INDEX NAME)

10/574,087




RN 286467-54-7 CAPLUS

CN 1,4'-Bipiperidine, 4-[(2-bromo-5-methoxyphenyl)methyl]-1'-(2-methoxyphenyl)- (CA INDEX NAME)



RN 286467-55-8 CAPLUS


CN 1,4'-Bipiperidine, 4-[(2-bromo-5-methoxyphenyl)methyl]-1'-(2,5-dimethoxyphenyl)- (CA INDEX NAME)



RN 286467-56-9 CAPLUS


CN 1,4'-Bipiperidine, 4-[(2-bromo-5-methoxyphenyl)methyl]-1'-(2,4-dimethoxyphenyl)- (CA INDEX NAME)

10/574,087




RN 286467-62-7 CAPLUS

CN 1,4'-Bipiperidine, 4-[(2-bromo-5-methoxyphenyl)methyl]-1'-(3,4-dimethoxyphenyl)- (CA INDEX NAME)



RN 286467-67-2 CAPLUS


CN 1,4'-Bipiperidine, 4-[(2-chlorophenyl)methyl]-1'-(2,3-dimethoxyphenyl)- (CA INDEX NAME)



RN 286467-68-3 CAPLUS


CN 1,4'-Bipiperidine, 4-[(2-bromophenyl)methyl]-1'-(2,3-dimethoxyphenyl)- (CA INDEX NAME)

10/574,087




RN 286467-69-4 CAPLUS

CN 1,4'-Bipiperidine, 4-[(2-bromo-5-fluorophenyl)methyl]-1'-(3-fluoro-2-methoxyphenyl)- (CA INDEX NAME)



RN 286467-70-7 CAPLUS


CN 1,4'-Bipiperidine, 4-[(2,5-dichlorophenyl)methyl]-1'-(2-methoxyphenyl)- (CA INDEX NAME)



RN 286467-71-8 CAPLUS


CN 1,4'-Bipiperidine, 4-[(2,5-dichlorophenyl)methyl]-1'-(2,5-dimethoxyphenyl)- (CA INDEX NAME)

10/574,087




RN 286467-72-9 CAPLUS

CN 1,4'-Bipiperidine, 4-[(2,5-dichlorophenyl)methyl]-1'-(2,4-dimethoxyphenyl)-
(CA INDEX NAME)



RN 286467-73-0 CAPLUS


CN 1,4'-Bipiperidine, 4-[(2,5-dichlorophenyl)methyl]-1'-(2,3-dimethoxyphenyl)-
(CA INDEX NAME)



RN 286467-74-1 CAPLUS


CN 1,4'-Bipiperidine, 1'-(3-chloro-4-fluorophenyl)-4-[(2-chlorophenyl)methyl]-
(CA INDEX NAME)

10/574,087




RN 286467-75-2 CAPLUS

CN 1,4'-Bipiperidine, 1'-(3-chloro-4-fluorophenyl)-4-[(2,5-difluorophenyl)methyl]- (CA INDEX NAME)




RN 286467-76-3 CAPLUS

CN 1,4'-Bipiperidine, 4-[(2-bromophenyl)methyl]-1'-(3-chloro-4-fluorophenyl)- (CA INDEX NAME)



RN 286467-77-4 CAPLUS


CN 1,4'-Bipiperidine, 1'-(3-chloro-4-fluorophenyl)-4-[(3-methoxyphenyl)methyl]- (CA INDEX NAME)



10/574,087


RN 286467-78-5 CAPLUS

CN 1,4'-Bipiperidine, 4-[(2-bromo-5-fluorophenyl)methyl]-1'-(3-chloro-4-fluorophenyl)- (CA INDEX NAME)




RN 286467-79-6 CAPLUS

CN 1,4'-Bipiperidine, 1'-(3-chloro-4-fluorophenyl)-4-[(2-fluoro-5-methoxyphenyl)methyl]- (CA INDEX NAME)



RN 286467-80-9 CAPLUS


CN 1,4'-Bipiperidine, 4-[(2-bromo-5-methoxyphenyl)methyl]-1'-(3-chloro-4-fluorophenyl)- (CA INDEX NAME)



RN 286467-81-0 CAPLUS


CN 1,4'-Bipiperidine, 1'-(3-chloro-4-fluorophenyl)-4-[(2,5-dichlorophenyl)methyl]- (CA INDEX NAME)

10/574,087




RN 286467-97-8 CAPLUS

CN Benzonitrile, 3-[4-[(2-chlorophenyl)methyl][1,4'-bipiperidin]-1'-yl]- (CA INDEX NAME)



RN 286467-98-9 CAPLUS


CN Benzonitrile, 3-[4-[(2,5-difluorophenyl)methyl][1,4'-bipiperidin]-1'-yl]- (CA INDEX NAME)




RN 286467-99-0 CAPLUS

CN Benzonitrile, 3-[4-[(2-bromophenyl)methyl][1,4'-bipiperidin]-1'-yl]- (CA INDEX NAME)


10/574,087




RN 286468-00-6 CAPLUS
CN Benzonitrile, 3-[4-[(3-methoxyphenyl)methyl][1,4'-bipiperidin]-1'-yl]-
(CA INDEX NAME)



RN 286468-01-7 CAPLUS
CN Benzonitrile, 3-[4-[(2-bromo-5-fluorophenyl)methyl][1,4'-bipiperidin]-1'-
yl]- (CA INDEX NAME)




RN 286468-02-8 CAPLUS
CN Benzonitrile, 3-[4-[(2-fluoro-5-methoxyphenyl)methyl][1,4'-bipiperidin]-1'-
yl]- (CA INDEX NAME)




RN 286468-03-9 CAPLUS
CN Benzonitrile, 3-[4-[(2-bromo-5-methoxyphenyl)methyl][1,4'-bipiperidin]-1'-
yl]- (CA INDEX NAME)


10/574,087



RN 286468-04-0 CAPLUS
CN Benzonitrile, 3-[4-[(2,5-dichlorophenyl)methyl][1,4'-bipiperidin]-1'-yl]-
(CA INDEX NAME)




RN 286468-05-1 CAPLUS
CN Benzonitrile, 4-[4-[(2-chlorophenyl)methyl][1,4'-bipiperidin]-1'-yl]- (CA
INDEX NAME)




RN 286468-06-2 CAPLUS
CN Benzonitrile, 4-[4-[(2,5-difluorophenyl)methyl][1,4'-bipiperidin]-1'-yl]-
(CA INDEX NAME)


10/574,087




RN 286468-07-3 CAPLUS
CN Benzonitrile, 4-[4-[(2-bromophenyl)methyl][1,4'-bipiperidin]-1'-yl]- (CA INDEX NAME)



RN 286468-08-4 CAPLUS
CN Benzonitrile, 4-[4-[(3-methoxyphenyl)methyl][1,4'-bipiperidin]-1'-yl]- (CA INDEX NAME)




RN 286468-09-5 CAPLUS
CN Benzonitrile, 4-[4-[(2-bromo-5-fluorophenyl)methyl][1,4'-bipiperidin]-1'-yl]- (CA INDEX NAME)



RN 286468-10-8 CAPLUS


10/574,087

CN Benzonitrile, 4-[4-[(2-fluoro-5-methoxyphenyl)methyl][1,4'-bipiperidin]-1'-yl]- (CA INDEX NAME)




RN 286468-11-9 CAPLUS

CN Benzonitrile, 4-[4-[(2,5-dichlorophenyl)methyl][1,4'-bipiperidin]-1'-yl]- (CA INDEX NAME)



RN 286468-12-0 CAPLUS


CN Benzonitrile, 2-chloro-4-[4-[(2-chlorophenyl)methyl][1,4'-bipiperidin]-1'-yl]- (CA INDEX NAME)




RN 286468-13-1 CAPLUS

CN Benzonitrile, 2-chloro-4-[4-[(2,5-difluorophenyl)methyl][1,4'-bipiperidin]-1'-yl]- (CA INDEX NAME)


10/574,087



RN 286468-14-2 CAPLUS
CN Benzonitrile, 4-[4-[(2-bromophenyl)methyl][1,4'-bipiperidin]-1'-yl]-2-chloro- (CA INDEX NAME)




RN 286468-15-3 CAPLUS
CN Benzonitrile, 2-chloro-4-[4-[(3-methoxyphenyl)methyl][1,4'-bipiperidin]-1'-yl]- (CA INDEX NAME)




RN 286468-16-4 CAPLUS
CN Benzonitrile, 4-[4-[(2-bromo-5-fluorophenyl)methyl][1,4'-bipiperidin]-1'-yl]-2-chloro- (CA INDEX NAME)


10/574,087



RN 286468-17-5 CAPLUS
CN Benzonitrile, 2-chloro-4-[4-[(2-fluoro-5-methoxyphenyl)methyl][1,4'-bipiperidin]-1'-yl]- (CA INDEX NAME)




RN 286468-18-6 CAPLUS
CN Benzonitrile, 4-[4-[(2-bromo-5-methoxyphenyl)methyl][1,4'-bipiperidin]-1'-yl]-2-chloro- (CA INDEX NAME)




RN 286468-19-7 CAPLUS
CN Benzonitrile, 2-chloro-4-[4-[(2,5-dichlorophenyl)methyl][1,4'-bipiperidin]-1'-yl]- (CA INDEX NAME)

10/574,087




RN 286468-37-9 CAPLUS

CN 1,4'-Bipiperidine, 4-[(2-chlorophenyl)methyl]-1'-(2,6-dimethoxyphenyl)-
(CA INDEX NAME)



RN 286468-39-1 CAPLUS


CN 1,4'-Bipiperidine, 4-[(2,5-difluorophenyl)methyl]-1'-(2,6-dimethoxyphenyl)-
(CA INDEX NAME)



RN 286468-41-5 CAPLUS


CN 1,4'-Bipiperidine, 4-[(2-bromophenyl)methyl]-1'-(2,6-dimethoxyphenyl)-
(CA INDEX NAME)

10/574,087




RN 286468-43-7 CAPLUS

CN 1,4'-Bipiperidine, 4-[(2-bromo-5-fluorophenyl)methyl]-1'-(2,6-dimethoxyphenyl)- (CA INDEX NAME)



RN 286468-45-9 CAPLUS


CN 1,4'-Bipiperidine, 4-[(2-bromo-5-methoxyphenyl)methyl]-1'-(2,6-dimethoxyphenyl)- (CA INDEX NAME)



RN 286468-47-1 CAPLUS


CN 1,4'-Bipiperidine, 4-[(2,5-dichlorophenyl)methyl]-1'-(2,6-dimethoxyphenyl)- (CA INDEX NAME)

10/574,087




RN 286469-06-5 CAPLUS

CN 1,4'-Bipiperidine, 4-[(2-bromo-5-fluorophenyl)methyl]-1'-(5-chloro-2-methoxyphenyl)- (CA INDEX NAME)



RN 286469-07-6 CAPLUS


CN 1,4'-Bipiperidine, 4-[(2-bromo-5-fluorophenyl)methyl]-1'-(2,4,6-trimethoxyphenyl)- (CA INDEX NAME)



RN 286469-20-3 CAPLUS


CN 1H-Azepine, 4-[(2-bromophenyl)methyl]-1-[1-(2,6-dimethoxyphenyl)-4-piperidinyl]hexahydro- (CA INDEX NAME)

10/574,087




RN 286469-22-5 CAPLUS

CN 1,4'-Bipiperidine, 4-[(2,5-difluorophenyl)methyl]-1'-(4,5-dimethoxy-2-methylphenyl)- (CA INDEX NAME)



RN 286469-23-6 CAPLUS


CN 1,4'-Bipiperidine, 4-[(2-bromo-5-fluorophenyl)methyl]-1'-(4,5-dimethoxy-2-methylphenyl)- (CA INDEX NAME)



RN 286469-24-7 CAPLUS


CN 1,4'-Bipiperidine, 4-[(2,5-dichlorophenyl)methyl]-1'-(4,5-dimethoxy-2-methylphenyl)- (CA INDEX NAME)

10/574,087




RN 286469-25-8 CAPLUS

CN 1,4'-Bipiperidine, 4-[(2-bromophenyl)methyl]-1'-(2,4-dimethoxy-6-methylphenyl)- (CA INDEX NAME)



RN 286469-31-6 CAPLUS


CN Benzonitrile, 3-[4-[(2,5-dichlorophenyl)methyl][1,4'-bipiperidin]-1'-yl]-4-methoxy- (CA INDEX NAME)




RN 286469-32-7 CAPLUS

CN Benzonitrile, 4-methoxy-3-[4-[(3-methoxyphenyl)methyl][1,4'-bipiperidin]-1'-yl]- (CA INDEX NAME)


10/574,087




RN 286469-33-8 CAPLUS
CN Benzonitrile, 3-[4-[(2-bromo-5-fluorophenyl)methyl][1,4'-bipiperidin]-1'-yl]-4-methoxy- (CA INDEX NAME)



RN 286469-34-9 CAPLUS
CN 1,4'-Bipiperidine, 4-[(2,5-dichlorophenyl)methyl]-1'-(2,4,5-trimethoxyphenyl)- (CA INDEX NAME)




RN 286469-36-1 CAPLUS
CN 1H-Indole-5-carbonitrile, 3-[1'-(2,3-dimethoxyphenyl)[1,4'-bipiperidin]-4-yl]- (CA INDEX NAME)



10/574,087


RN 286469-37-2 CAPLUS

CN 1H-Indole, 3-[1'-(2,4-dimethoxyphenyl)[1,4'-bipiperidin]-4-yl]-5-fluoro-
(CA INDEX NAME)




RN 286469-38-3 CAPLUS

CN 1H-Indole-5-carbonitrile, 3-[1'-(2,4-dimethoxyphenyl)[1,4'-bipiperidin]-4-yl]-
(CA INDEX NAME)




RN 286469-39-4 CAPLUS

CN 1H-Indole, 3-[1'-(2,5-dimethoxyphenyl)[1,4'-bipiperidin]-4-yl]-5-fluoro-
(CA INDEX NAME)



RN 286469-40-7 CAPLUS


CN 1H-Indole-5-carbonitrile, 3-[1'-(2,5-dimethoxyphenyl)[1,4'-bipiperidin]-4-yl]-
(CA INDEX NAME)



10/574,087


RN 286469-41-8 CAPLUS

CN 1H-Indole-5-carbonitrile, 3-[1'-(2,6-dimethoxyphenyl)[1,4'-bipiperidin]-4-yl]- (CA INDEX NAME)




RN 286469-43-0 CAPLUS

CN 1H-Indole, 5-fluoro-3-[1'-(2-methoxyphenyl)[1,4'-bipiperidin]-4-yl]- (CA INDEX NAME)




RN 286469-44-1 CAPLUS

CN 1H-Indole-5-carbonitrile, 3-[1'-(2-methoxyphenyl)[1,4'-bipiperidin]-4-yl]- (CA INDEX NAME)



RN 286469-47-4 CAPLUS


CN 1H-Indole-5-carbonitrile, 3-[1'-(3-chloro-4-cyanophenyl)[1,4'-bipiperidin]-4-yl]- (CA INDEX NAME)



RN 286469-48-5 CAPLUS


10/574,087

CN Benzonitrile, 3-[4-(5-fluoro-1H-indol-3-yl)[1,4'-bipiperidin]-1'-yl]- (CA INDEX NAME)




RN 286469-49-6 CAPLUS

CN 1H-Indole-5-carbonitrile, 3-[1'-(3-cyanophenyl)[1,4'-bipiperidin]-4-yl]- (CA INDEX NAME)




RN 286469-50-9 CAPLUS

CN 1H-Indole-5-carbonitrile, 3-[1'-(3-fluoro-4-methoxyphenyl)[1,4'-bipiperidin]-4-yl]- (CA INDEX NAME)



RN 286469-51-0 CAPLUS


CN 1H-Indole, 5-fluoro-3-[1'-(3-fluoro-4-methoxyphenyl)[1,4'-bipiperidin]-4-yl]- (CA INDEX NAME)



RN 286469-52-1 CAPLUS


10/574,087

CN Benzonitrile, 4-[4-(5-fluoro-1H-indol-3-yl)[1,4'-bipiperidin]-1'-yl]- (CA INDEX NAME)




RN 286469-53-2 CAPLUS

CN 1H-Indole-5-carbonitrile, 3-[1'-(4-cyanophenyl)[1,4'-bipiperidin]-4-yl]- (CA INDEX NAME)



RN 286469-97-4 CAPLUS

CN Benzonitrile, 3-[4-[(2,5-difluorophenyl)methyl][1,4'-bipiperidin]-1'-yl]-4-methoxy- (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/574,087

L4 ANSWER 96 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2000:532245 CAPLUS

DN 133:281562

TI Solution-Phase Synthesis of a 1,5-Dialkylamino-2,4-dinitrobenzene Library and the Identification of Novel Antibacterial Compounds from This Library

AU Liu, Gang; Fan, Yemei; Carlson, James R.; Zhao, Zhan-Gong; Lam, Kit S.

CS Department of Internal Medicine UC Davis Cancer Center and Department of Pathology, UC Davis Medical Center, Sacramento, CA, 95817, USA

SO Journal of Combinatorial Chemistry (2000), 2(5), 467-474

CODEN: JCCHFF; ISSN: 1520-4766

PB American Chemical Society

DT Journal

LA English

OS CASREACT 133:281562

IT 299899-39-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)


(solution-phase preparation of dinitrobenzenediamine combinatorial library

and

identification of antibacterial compds.)

RN 299899-39-1 CAPLUS

CN Benzenamine, N-[4-[(4-amino-3-methylcyclohexyl)methyl]-2-methylcyclohexyl]-2,4-dinitro-5-[4-(1-pyrrolidinyl)-1-piperidinyl]- (CA INDEX NAME)



RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 97 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2000:314677 CAPLUS

DN 132:321860

TI Preparation of 2-phenylbenzimidazoles as poly(ADP-ribose) polymerase inhibitors.

IN Lubisch, Wilfried; Kock, Michael; Hoger, Thomas

PA BASF Aktiengesellschaft, Germany

SO PCT Int. Appl., 75 pp.

CODEN: PIXXD2

DT Patent


LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000026192	A1	20000511	WO 1999-EP8169	19991028
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2349227	A1	20000511	CA 1999-2349227	19991028
	BR 9915013	A	20010807	BR 1999-15013	19991028
	EP 1127052	A1	20010829	EP 1999-955894	19991028
	EP 1127052	B1	20041208		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	TR 200101239	T2	20011121	TR 2001-1239	19991028
	TR 200200972	T2	20020722	TR 2002-972	19991028
	JP 2002528531	T	20020903	JP 2000-579581	19991028
	HU 2002000312	A2	20021128	HU 2002-312	19991028
	HU 2002000312	A3	20021228		
	AU 765224	B2	20030911	AU 2000-12665	19991028
	EP 1391457	A1	20040225	EP 2003-24899	19991028
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY				
	AT 284392	T	20041215	AT 1999-955894	19991028
	PT 1127052	T	20050429	PT 1999-955894	19991028
	ES 2234318	T3	20050616	ES 1999-955894	19991028
	NO 2001002158	A	20010626	NO 2001-2158	20010502
	MX 2001PA04442	A	20020108	MX 2001-PA4442	20010503
	ZA 2001003558	A	20020503	ZA 2001-3558	20010503
	IN 2001CN00619	A	20050304	IN 2001-CN619	20010503
	BG 105515	A	20011231	BG 2001-105515	20010516
	JP 2007024902	A	20070201	JP 2006-211209	20060802
PRAI	DE 1998-19850709	A	19981103		
	DE 1998-19852801	A	19981116		
	DE 1999-19908733	A	19990301		
	EP 1999-955894	A3	19991028		
	JP 2000-579581	A3	19991028		
	WO 1999-EP8169	W	19991028		
OS	MARPAT 132:321860				
IT	266993-57-1P				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of 2-phenylbenzimidazoles as PARP inhibitors)				
RN	266993-57-1 CAPLUS				

10/574,087


CN 1H-Benzimidazole-4-carboxamide, 2-(4-[1,4'-bipiperidin]-1'-ylphenyl)-
(9CI) (CA INDEX NAME)




RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/574,087


L4 ANSWER 98 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2000:215045 CAPLUS
DN 132:334117
TI Stepwise versus Direct Long-Range Charge Separation in Molecular Triads
AU Willemse, R. J.; Piet, J. J.; Warman, J. M.; Hartl, F.; Verhoeven, J. W.;
Brouwer, A. M.
CS Contribution from the Institute of Molecular Chemistry, University of
Amsterdam, Amsterdam, 1018 WS, Neth.
SO Journal of the American Chemical Society (2000), 122(15), 3721-3730
CODEN: JACSAT; ISSN: 0002-7863
PB American Chemical Society
DT Journal
LA English
IT 267428-40-0P 267428-43-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(Wadsworth-Emmons; stepwise vs. direct long-range photoinduced charge
separation in trichromophoric donor-donor-acceptor mols.)
RN 267428-40-0 CAPLUS
CN [1,4'-Bipiperidin]-4-one, 1'-(4-methoxyphenyl)- (CA INDEX NAME)



RN 267428-43-3 CAPLUS
CN [1,4'-Bipiperidin]-4-one, 1'-(4-cyclohexylphenyl)- (CA INDEX NAME)




IT 147328-62-9P
RL: PEP (Physical, engineering or chemical process); PRP (Properties); SPN
(Synthetic preparation); PREP (Preparation); PROC (Process)
(crystallog.; stepwise vs. direct long-range photoinduced charge separation
in trichromophoric donor-donor-acceptor mols.)
RN 147328-62-9 CAPLUS
CN 1-Naphthalenecarbonitrile, 4-[[1'-(4-methoxyphenyl)[1,4'-bipiperidin]-4-
ylidene]methyl]- (CA INDEX NAME)



IT 147328-61-8
 RL: PEP (Physical, engineering or chemical process); PRP (Properties);
 PROC (Process)
 (stepwise vs. direct long-range photoinduced charge separation in
 trichromophoric donor-donor-acceptor mols.)
 RN 147328-61-8 CAPLUS
 CN 1-Naphthalenecarbonitrile, 4-[(1'-phenyl[1,4'-bipiperidin]-4-
 ylidene)methyl]- (CA INDEX NAME)

10/574,087




IT 166043-76-1P

RL: PEP (Physical, engineering or chemical process); PRP (Properties); SPN (Synthetic preparation); PREP (Preparation); PROC (Process)
(stepwise vs. direct long-range photoinduced charge separation in trichromophoric donor-donor-acceptor mols.)

RN 166043-76-1 CAPLUS


CN 1-Naphthalenecarbonitrile, 4-[[1'-(4-cyclohexylphenyl)[1,4'-bipiperidin]-4-ylidene]methyl]- (CA INDEX NAME)

PAGE 1-A



10/574,087

PAGE 2-A




RE.CNT 72 THERE ARE 72 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/574,087


L4 ANSWER 99 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1999:581736 CAPLUS
DN 132:146936
TI N-(3-iodophenyl)trozamicol (IPHT) and related inhibitors of vesicular
acetylcholine transport: synthesis and preliminary biological
characterization
AU Khare, A. B.; Langason, R. B.; Parsons, S. M.; Mach, R. H.; Efange, S. M.
N.
CS Medicinal Chemistry and Neurosurgery, Departments of Radiology, University
of Minnesota, Minneapolis, MN, USA
SO Nuclear Medicine and Biology (1999), 26(6), 609-617
CODEN: NMBIEO; ISSN: 0969-8051
PB Elsevier Science Inc.
DT Journal
LA English
IT 258284-30-9P 258284-31-0P 258284-32-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(N-(3-iodophenyl)trozamicol (IPHT) and related inhibitors of vesicular
acetylcholine transport, their synthesis and preliminary biol.
characterization)
RN 258284-30-9 CAPLUS
CN [1,4'-Bipiperidin]-3'-ol, 1'-(2-bromo-4-nitrophenyl)-4-phenyl-,
(3'R,4'R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 258284-31-0 CAPLUS
CN [1,4'-Bipiperidin]-3'-ol, 1'-(5-bromo-2-nitrophenyl)-4-phenyl-,
(3'R,4'R)-rel- (CA INDEX NAME)

Relative stereochemistry.




10/574,087

RN 258284-32-1 CAPLUS

CN [1,4'-Bipiperidin]-3'-ol, 1'-(4-bromo-2-nitrophenyl)-4-phenyl-,
(3'R,4'R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RE.CNT 55 THERE ARE 55 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/574,087

L4 ANSWER 100 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1999:350651 CAPLUS

DN 131:18929

TI Preparation of arylsulfonylheterocyclylhydroxamic acids and related compounds as matrix metalloprotease inhibitors

IN Barta, Thomas E.; Becker, Daniel P.; Boehm, Terri L.; De Crescenzo, Gary A.; Villamil, Clara I.; McDonald, Joseph J.; Freskos, John N.; Getman, Daniel P.

PA G.D. Searle and Co., USA

SO PCT Int. Appl., 840 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 9925687	A1	19990527	WO 1998-US23242	19981112
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2306460	A1	19990527	CA 1998-2306460	19981112
	AU 9913732	A	19990607	AU 1999-13732	19981112
	AU 756150	B2	20030102		
	BR 9814643	A	20001003	BR 1998-14643	19981112
	EP 1042290	A1	20001011	EP 1998-957485	19981112
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
	JP 2001523662	T	20011127	JP 2000-521071	19981112
	NZ 503485	A	20021025	NZ 1998-503485	19981112
	RU 2250105	C2	20050420	RU 2000-115948	19981112
	ZA 9810412	A	19991209	ZA 1998-10412	19981113
	US 2001014688	A1	20010816	US 1998-191129	19981113
	NO 2000002469	A	20000712	NO 2000-2469	20000512
	MX 2000PA04660	A	20010930	MX 2000-PA4660	20000512
	US 6541489	B1	20030401	US 2000-554082	20000731
	US 2002177588	A1	20021128	US 2001-954451	20010917
	US 6750233	B2	20040615		
	US 2004048852	A1	20040311	US 2003-337942	20030107
	US 6890937	B2	20050510		
	US 2006084688	A1	20060420	US 2005-46645	20050128
PRAI	US 1997-66007P	P	19971114		
	US 1998-95347P	P	19980804		
	US 1998-95501P	P	19980806		
	US 1998-101080P	P	19980918		
	WO 1998-US23242	W	19981112		
	US 1999-256948	B3	19990224		
	US 2000-554082	A3	20000731		
	US 2003-337942	A3	20030107		
OS	MARPAT 131:18929				
IT	226390-92-7P 226391-18-0P				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of arylsulfonylheterocyclylhydroxamic acids and related compds. as matrix metalloprotease inhibitors)				
RN	226390-92-7 CAPLUS				


10/574,087

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]sulfonyl]-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 226390-91-6


CMF C21 H31 N3 O5 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 226391-18-0 CAPLUS


CN 2H-Pyran-4-carboxamide, 4-[(4-[1,4'-bipiperidin]-1'-yl)phenyl]sulfonyl]tetrahydro-N-hydroxy-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 226391-17-9


CMF C22 H33 N3 O5 S

10/574,087



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RE.CNT 6

THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/574,087


L4 ANSWER 101 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1999:9703 CAPLUS
DN 130:81404
TI Piperidinylazacycloalkylmethylureas as α 1A adrenergic receptor
antagonists
IN Patane, Michael A.; Bock, Mark G.
PA Merck & Co., Inc., USA
SO PCT Int. Appl., 143 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9857640	A1	19981223	WO 1998-US12672	19980618
	W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GW, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	EP 1019052	A1	20000719	EP 1998-931353	19980617
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
	US 6143750	A	20001107	US 1998-98780	19980617
	CA 2294346	A1	19981223	CA 1998-2294346	19980618
	AU 9881501	A	19990104	AU 1998-81501	19980618
	JP 2002508764	T	20020319	JP 1999-504780	19980618
PRAI	US 1997-50960P	P	19970618		
	GB 1998-231	A	19980106		
	WO 1998-US12672	W	19980618		
OS	MARPAT 130:81404				
IT	218430-11-6P 218430-12-7P 218430-21-8P 218430-22-9P 218430-23-0P 218430-24-1P 218430-59-2P				
	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation of piperidinylazacycloalkylmethylureas as α 1A adrenergic receptor antagonists)				
RN	218430-11-6 CAPLUS				
CN	Carbamic acid, [[1'-(2-cyanophenyl)[1,4'-bipiperidin]-4-yl]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)				




RN 218430-12-7 CAPLUS
CN Benzonitrile, 2-[4-(aminomethyl)[1,4'-bipiperidin]-1'-yl]- (CA INDEX NAME)


10/574,087




RN 218430-21-8 CAPLUS
CN Benzonitrile, 2-[3-(hydroxymethyl)[1,4'-bipiperidin]-1'-yl]- (CA INDEX NAME)



RN 218430-22-9 CAPLUS
CN Benzonitrile, 2-[3-[[[(4-methylphenyl)sulfonyl]oxy]methyl][1,4'-bipiperidin]-1'-yl]- (CA INDEX NAME)




RN 218430-23-0 CAPLUS
CN Benzonitrile, 2-[3-(azidomethyl)[1,4'-bipiperidin]-1'-yl]- (CA INDEX NAME)



RN 218430-24-1 CAPLUS
CN Benzonitrile, 2-[3-(aminomethyl)[1,4'-bipiperidin]-1'-yl]- (CA INDEX NAME)


10/574,087



RN 218430-59-2 CAPLUS

CN 3-Oxazolidinecarboxamide, N-[(3R)-1-[1-(2-cyanophenyl)-4-piperidinyl]-3-pyrrolidinyl]-4-(3,4-difluorophenyl)-2-oxo-5-[[tetrahydro-2H-pyran-2-yl]oxy]methyl-, (4S,5R)- (CA INDEX NAME)

Absolute stereochemistry.



IT 218430-13-8P 218430-14-9P 218430-26-3P
218430-28-5P 218430-29-6P 218430-30-9P
218430-38-7P 218430-39-8P 218430-40-1P
218430-41-2P 218430-42-3P 218430-43-4P
218430-44-5P 218430-45-6P 218430-46-7P
218430-52-5P 218430-54-7P 218430-55-8P
218430-60-5P 218430-61-6P 218430-62-7P
218430-73-0P 218430-74-1P 218430-75-2P
218430-76-3P 218430-77-4P 218430-78-5P
218430-79-6P 218430-80-9P 218430-81-0P
218430-82-1P 218430-83-2P 218430-84-3P
218430-85-4P 218430-86-5P 218430-90-1P
218430-91-2P 218430-92-3P 218430-93-4P
218430-94-5P 218430-95-6P 218430-96-7P
218430-97-8P 218430-98-9P


RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of piperidinylazacycloalkylmethylureas as α 1A adrenergic receptor antagonists)

RN 218430-13-8 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 1-[[[1'-(2-cyanophenyl)[1,4'-bipiperidin]-4-yl]methyl]amino]carbonyl]-6-(3,4-difluorophenyl)-1,2,3,6-tetrahydro-4-(methoxymethyl)-2-oxo-, methyl ester, (6S)- (CA INDEX NAME)

Absolute stereochemistry.

10/574,087




RN 218430-14-9 CAPLUS
CN 5-Pyrimidinecarboxylic acid, 1-[[[1'-(2-cyanophenyl)[1,4'-bipiperidin]-4-yl]methyl]amino]carbonyl]-6-(3,4-difluorophenyl)-1,2,3,6-tetrahydro-4-(methoxymethyl)-2-oxo-, methyl ester, (6S)-, trifluoroacetate (5:7) (9CI) (CA INDEX NAME)

CM 1

CRN 218430-13-8
CMF C33 H38 F2 N6 O5

Absolute stereochemistry.




CM 2

CRN 76-05-1

10/574,087

CMF C2 H F3 O2



RN 218430-26-3 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 1-[[[1'-(2-cyanophenyl)[1,4'-bipiperidin]-3-yl]methyl]amino]carbonyl]-6-(3,4-difluorophenyl)-1,2,3,6-tetrahydro-4-(methoxymethyl)-2-oxo-, methyl ester, (6S)-, trifluoroacetate (10:17) (9CI) (CA INDEX NAME)

CM 1

CRN 218430-25-2

CMF C33 H38 F2 N6 O5


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 218430-28-5 CAPLUS


CN 3-Oxazolidinecarboxamide, N-[[1'-(2-cyanophenyl)[1,4'-bipiperidin]-3-yl]methyl]-4-(3,4-difluorophenyl)-2-oxo-, (4S)-, trifluoroacetate (10:13) (9CI) (CA INDEX NAME)

CM 1

10/574,087


CRN 218430-27-4
CMF C28 H31 F2 N5 O3

Absolute stereochemistry.




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 218430-29-6 CAPLUS
CN 3-Oxazolidinecarboxamide, N-[[1'-(2-cyanophenyl)[1,4'-bipiperidin]-4-yl]methyl]-4-(3,4-difluorophenyl)-2-oxo-, (4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 218430-30-9 CAPLUS
CN 3-Oxazolidinecarboxamide, N-[[1'-(2-cyanophenyl)[1,4'-bipiperidin]-4-yl]methyl]-4-(3,4-difluorophenyl)-2-oxo-, (4S)-, trifluoroacetate (10:19) (9CI) (CA INDEX NAME)


10/574,087

CM 1

CRN 218430-29-6

CMF C28 H31 F2 N5 O3


Absolute stereochemistry.



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 218430-38-7 CAPLUS


CN Carbamic acid, [1'-(2-cyanophenyl)[1,4'-bipiperidin]-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 218430-39-8 CAPLUS

CN Benzonitrile, 2-(3-amino[1,4'-bipiperidin]-1'-yl)-, hydrochloride (5:12) (CA INDEX NAME)

10/574,087




●12/5 HCl

RN 218430-40-1 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 1-[[[(3R)-1'-(2-cyanophenyl)[1,4'-bipiperidin]-3-yl]amino]carbonyl]-6-(3,4-difluorophenyl)-1,2,3,6-tetrahydro-4-(methoxymethyl)-2-oxo-, methyl ester, (6S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 218430-41-2 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 1-[[[(3S)-1'-(2-cyanophenyl)[1,4'-bipiperidin]-3-yl]amino]carbonyl]-6-(3,4-difluorophenyl)-1,2,3,6-tetrahydro-4-(methoxymethyl)-2-oxo-, methyl ester, (6S)- (CA INDEX NAME)


Absolute stereochemistry.

10/574,087



RN 218430-42-3 CAPLUS

CN Benzeneacetamide, N-[1'-(2-cyanophenyl)[1,4'-bipiperidin]-3-yl]-3,4-difluoro-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 218430-43-4 CAPLUS

CN Carbamic acid, [(3S)-1-[1-(2-cyanophenyl)-4-piperidinyl]-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/574,087



RN 218430-44-5 CAPLUS

CN Benzonitrile, 2-[4-[(3S)-3-amino-1-pyrrolidinyl]-1-piperidinyl]-, trihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.





●3 HCl

RN 218430-45-6 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 1-[[[1-[1-(2-cyanophenyl)-4-piperidinyl]-3-pyrrolidinyl]amino]carbonyl]-6-(3,4-difluorophenyl)-1,2,3,6-tetrahydro-4-(methoxymethyl)-2-oxo-, methyl ester, (6S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 218430-46-7 CAPLUS
 CN Benzeneacetamide, N-[(3S)-1-[1-(2-cyanophenyl)-4-piperidinyl]-3-pyrrolidinyl]-3,4-difluoro-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/574,087




● HCl

RN 218430-52-5 CAPLUS

CN 5-Oxazolidinecarboxylic acid, 4-(3,4-difluorophenyl)-3-[[[(3R)-1-[1-[4-fluoro-2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]-4-piperidinyl]-3-pyrrolidinyl]amino]carbonyl]-2-oxo-, methyl ester, dihydrochloride, (4S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




● 2 HCl

RN 218430-54-7 CAPLUS
 CN 5-Oxazolidinecarboxylic acid, 4-(3,4-difluorophenyl)-3-[[[(3R)-1-[1-(4-fluoro-2-methoxyphenyl)-4-piperidinyl]-3-pyrrolidinyl]amino]carbonyl]-2-oxo-, methyl ester, (4S,5R)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 218430-53-6
 CMF C28 H31 F3 N4 O6

Absolute stereochemistry.



CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 218430-55-8 CAPLUS
 CN 5-Oxazolidinecarboxylic acid, 3-[[[(3R)-1-[1-(2-cyanophenyl)-4-piperidinyl]-3-pyrrolidinyl]amino]carbonyl]-4-(3,4-difluorophenyl)-2-oxo-, methyl ester, monohydrochloride, (4S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/574,087



● HCl

RN 218430-60-5 CAPLUS
CN 3-Oxazolidinecarboxamide, N-[(3R)-1-[1-(2-cyanophenyl)-4-piperidinyl]-3-pyrrolidinyl]-4-(3,4-difluorophenyl)-5-(hydroxymethyl)-2-oxo-, monohydrochloride, (4S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 218430-61-6 CAPLUS
CN 3,5-Oxazolidinedicarboxamide, N3-[(3R)-1-[1-(2-cyanophenyl)-4-piperidinyl]-3-pyrrolidinyl]-4-(3,4-difluorophenyl)-2-oxo-, monohydrochloride, (4S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/574,087



● HCl

RN 218430-62-7 CAPLUS
CN 3,5-Oxazolidinedicarboxamide, 4-(3,4-difluorophenyl)-N3-[(3R)-1-[1-(4-fluoro-2-methoxyphenyl)-4-piperidinyl]-3-pyrrolidinyl]-2-oxo-, (4S,5R)-
(CA INDEX NAME)


Absolute stereochemistry.



RN 218430-73-0 CAPLUS
CN Benzeneacetamide, 3,4-difluoro-N-[(3R)-1-[1-(2-nitrophenyl)-4-piperidinyl]-3-pyrrolidinyl]-, hydrochloride (4:7) (CA INDEX NAME)

Absolute stereochemistry.

10/574,087




● 7/4 HCl

RN 218430-74-1 CAPLUS

CN Benzeneacetamide, 3,4-difluoro- α -(1-methylethyl)-N-[(3R)-1-[1-(2-nitrophenyl)-4-piperidinyl]-3-pyrrolidinyl]-, hydrochloride (5:7) (CA INDEX NAME)

Absolute stereochemistry.




● 7/5 HCl

RN 218430-75-2 CAPLUS

CN Benzeneacetamide, N-[(3R)-1-[1-(2-cyanophenyl)-4-piperidinyl]-3-pyrrolidinyl]-3,4-difluoro- α -(1-methylethyl)-, (α S)- (CA INDEX NAME)


Absolute stereochemistry.

10/574,087



RN 218430-76-3 CAPLUS
CN Benzeneacetamide, N-[(3R)-1-[1-(2-cyanophenyl)-4-piperidinyl]-3-pyrrolidinyl]-3,4-difluoro- α -(1-methylethyl)-, (α R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 218430-77-4 CAPLUS
CN 3-Oxazolidinecarboxamide, 4-(3,4-difluorophenyl)-N-[(3R)-1-[1-(2-nitrophenyl)-4-piperidinyl]-3-pyrrolidinyl]-2-oxo-, hydrochloride (3:4), (4S)- (CA INDEX NAME)

Absolute stereochemistry.


10/574,087



●4/3 HCl

RN 218430-78-5 CAPLUS
CN 3-Oxazolidinecarboxamide, 4-(3,4-difluorophenyl)-N-[(3R)-1-[1-[2-[[(methylamino)carbonyl]amino]phenyl]-4-piperidinyl]-3-pyrrolidinyl]-2-oxo-, hydrochloride (5:11), (4S)- (CA INDEX NAME)

Absolute stereochemistry.




●11/5 HCl

RN 218430-79-6 CAPLUS
CN 3-Oxazolidinecarboxamide, 4-(3,4-difluorophenyl)-N-[(3R)-1-[1-[2-[[(dimethylamino)sulfonyl]amino]phenyl]-4-piperidinyl]-3-pyrrolidinyl]-2-oxo-, hydrochloride (10:19), (4S)- (CA INDEX NAME)

Absolute stereochemistry.


10/574,087



●19/10 HCl

RN 218430-80-9 CAPLUS
CN 3-Oxazolidinecarboxamide, 4-(3,4-difluorophenyl)-N-[(3R)-1-[1-[2-[(methylsulfonyl)amino]phenyl]-4-piperidinyl]-3-pyrrolidinyl]-2-oxo-, dihydrochloride, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 218430-81-0 CAPLUS
CN 3-Oxazolidinecarboxamide, N-[(3R)-1-[1-[2-(acetamino)phenyl]-4-piperidinyl]-3-pyrrolidinyl]-4-(3,4-difluorophenyl)-2-oxo-, (4S)- (CA INDEX NAME)

Absolute stereochemistry.

10/574,087





RN 218430-82-1 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 6-(3,4-difluorophenyl)-1,2,3,6-tetrahydro-4-(methoxymethyl)-1-[[[(3R)-1-[1-(2-nitrophenyl)-4-piperidinyl]-3-pyrrolidinyl]amino]carbonyl]-2-oxo-, methyl ester, (6S)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A







RN 218430-83-2 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 6-(3,4-difluorophenyl)-1,2,3,6-tetrahydro-4-(methoxymethyl)-1-[[[(3R)-1-[1-[2-[(methylamino)carbonyl]amino]phenyl]-4-piperidinyl]-3-pyrrolidinyl]amino]carbonyl]-2-oxo-, methyl ester, (6S)- (CA INDEX NAME)

Absolute stereochemistry.




10/574,087

RN 218430-84-3 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 6-(3,4-difluorophenyl)-1-[[[(3R)-1-[1-[2-[[[(dimethylamino)sulfonyl]amino]phenyl]-4-piperidinyl]-3-pyrrolidinyl]amino]carbonyl]-1,2,3,6-tetrahydro-4-(methoxymethyl)-2-oxo-, methyl ester, hydrochloride (10:21), (6S)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A





●21/10 HCl

RN 218430-85-4 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 1-[[[(3R)-1-[1-[2-(acetylamino)phenyl]-4-piperidinyl]-3-pyrrolidinyl]amino]carbonyl]-6-(3,4-difluorophenyl)-1,2,3,6-tetrahydro-4-(methoxymethyl)-2-oxo-, methyl ester, (6S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 218430-86-5 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 6-(3,4-difluorophenyl)-1,2,3,6-tetrahydro-4-(methoxymethyl)-1-[[[(3R)-1-[1-[2-[(methoxymethyl)amino]phenyl]-4-piperidinyl]-3-pyrrolidinyl]amino]carbonyl]-2-oxo-, methyl ester, (6S)- (CA INDEX NAME)


Absolute stereochemistry.

10/574,087

PAGE 1-A




PAGE 2-A



RN 218430-90-1 CAPLUS
CN 3-Oxazolidinecarboxamide, N-[[1-[1-(2-cyanophenyl)-4-piperidinyl]-3-pyrrolidinyl]methyl]-4-(3,4-difluorophenyl)-2-oxo-, (4S)- (CA INDEX NAME)

Absolute stereochemistry.

10/574,087




RN 218430-91-2 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 1-[[[(3S)-1-[1-(2-cyanophenyl)-4-piperidinyl]-3-pyrrolidinyl]methyl]amino]carbonyl]-6-(3,4-difluorophenyl)-1,2,3,6-tetrahydro-4-(methoxymethyl)-2-oxo-, methyl ester, (6S)- (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



10/574,087


PAGE 2-A




RN 218430-92-3 CAPLUS
CN 5-Pyrimidinecarboxylic acid, 1-[[[(3R)-1-[1-(2-cyanophenyl)-4-piperidinyl]-3-pyrrolidinyl]methyl]amino]carbonyl]-6-(3,4-difluorophenyl)-1,2,3,6-tetrahydro-4-(methoxymethyl)-2-oxo-, methyl ester, (6S)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




10/574,087

RN 218430-93-4 CAPLUS

CN 3-Oxazolidinecarboxamide, N-[[[(3S)-1'-(2-cyanophenyl)[1,4'-bipiperidin]-3-yl]methyl]-4-(3,4-difluorophenyl)-2-oxo-, (4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 218430-94-5 CAPLUS

CN 3-Oxazolidinecarboxamide, N-[[[(3R)-1'-(2-cyanophenyl)[1,4'-bipiperidin]-3-yl]methyl]-4-(3,4-difluorophenyl)-2-oxo-, (4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 218430-95-6 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 1-[[[[(3S)-1'-(2-cyanophenyl)[1,4'-bipiperidin]-3-yl]methyl]amino]carbonyl]-6-(3,4-difluorophenyl)-1,2,3,6-tetrahydro-4-(methoxymethyl)-2-oxo-, methyl ester, (6S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 218430-96-7 CAPLUS

10/574,087

CN 5-Pyrimidinecarboxylic acid, 1-[[[(3R)-1'-(2-cyanophenyl)[1,4'-bipiperidin]-3-yl]methyl]amino]carbonyl]-6-(3,4-difluorophenyl)-1,2,3,6-tetrahydro-4-(methoxymethyl)-2-oxo-, methyl ester, (6S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 218430-97-8 CAPLUS

CN Benzoic acid, 2-[4-[(3R)-3-[[[(4S,5S)-4-(3,4-difluorophenyl)-5-methyl-2-oxo-3-oxazolidinyl]carbonyl]amino]-1-pyrrolidinyl]-1-piperidinyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 218430-98-9 CAPLUS

CN 5-Oxazolidinecarboxylic acid, 4-(3,4-difluorophenyl)-3-[[[(3R)-1-[1-[2-(methoxycarbonyl)phenyl]-4-piperidinyl]-3-pyrrolidinyl]amino]carbonyl]-2-oxo-, methyl ester, hydrochloride (10:21), (4S,5R)- (CA INDEX NAME)

Absolute stereochemistry.

10/574,087



●21/10 HCL

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/574,087

L4 ANSWER 102 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1998:724203 CAPLUS
DN 130:38288
TI Preparation of condensed ring aromatic compounds and dopamine receptor D4
antagonists containing the compounds for treatment of schizophrenia
IN Takada, Susumu; Fukui, Kiichi; Sasatani, Takashi
PA Shionogi and Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 91 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 10298180	A	19981110	JP 1997-108832	19970425
PRAI	JP 1997-108832		19970425		
OS	MARPAT 130:38288				
IT	216489-04-2P				


RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of condensed ring aromatic compds. as dopamine D4 receptor antagonists for treatment of schizophrenia)

RN 216489-04-2 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(3S)-1-[1-(4-fluorophenyl)-4-piperidinyl]-3-pyrrolidinyl]-4-methoxy-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.




10/574,087

L4 ANSWER 103 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1998:543072 CAPLUS
DN 129:161569
TI Preparation of pyrido[2,3-d]pyrimidines and 4-aminopyrimidines as
inhibitors of cellular proliferation
IN Boschelli, Diane Harris; Dobrusin, Ellen Myra; Doherty, Annette Marian;
Fattacy, Ali; Fry, David W.; Barvian, Mark R.; Kallmeyer, Susanne Trumpp;
Wu, Zhipei
PA Warner Lambert Company, USA
SO PCT Int. Appl., 170 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	WO 9833798	A2	19980806	WO 1998-US1343	19980126
	WO 9833798	A3	19981105		
	W: AL, AU, BA, BB, BG, BR, CA, CN, CZ, EE, GE, HU, ID, IL, IS, JP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2271157	A1	19980806	CA 1998-2271157	19980126
	AU 9866480	A	19980825	AU 1998-66480	19980126
	AU 749750	B2	20020704		
	EP 964864	A2	19991222	EP 1998-908442	19980126
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 9807305	A	20000502	BR 1998-7305	19980126
	NZ 335666	A	20001027	NZ 1998-335666	19980126
	JP 2001509805	T	20010724	JP 1998-532971	19980126
	EP 1806348	A2	20070711	EP 2007-105377	19980126
	EP 1806348	A3	20080102		
	R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, AL, LT, LV, MK, RO, SI				
	ZA 9800914	A	19981109	ZA 1998-914	19980204
	US 6498163	B1	20021224	US 1999-355681	19990802
PRAI	US 1997-37220P	P	19970205		
	US 1997-69743P	P	19971216		
	EP 1998-908442	A3	19980126		
	WO 1998-US1343	W	19980126		
OS	MARPAT 129:161569				
IT	211247-61-9P				
	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)				
	(preparation of pyrido[2,3-d]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation)				
RN	211247-61-9 CAPLUS				
CN	1,4'-Bipiperidine, 1'-(4-nitrophenyl)- (CA INDEX NAME)				

10/574,087



10/574,087

L4 ANSWER 104 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1998:133560 CAPLUS

DN 128:160936

TI Oxonol compound, silver halide photographic material, and process for synthesis of oxonol compound

IN Nishigaki, Junji; Deguchi, Yasuaki

PA Fuji Photo Film Co., Ltd., Japan

SO Eur. Pat. Appl., 116 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	EP 819977	A1	19980121	EP 1997-112271	19970717
	EP 819977	B1	20060104		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 10036691	A	19980210	JP 1996-206527	19960717
	JP 3846937	B2	20061115		
	JP 10060293	A	19980303	JP 1996-235893	19960819
	JP 3796302	B2	20060712		
	JP 10251532	A	19980922	JP 1997-55315	19970310
	EP 1473330	A1	20041103	EP 2004-18506	19970717
	EP 1473330	B1	20070214		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				

PRAI JP 1996-206527 A 19960717

JP 1996-235893 A 19960819

JP 1997-55315 A 19970310

EP 1997-112271 A3 19970717

OS MARPAT 128:160936

IT 202482-38-0P


RL: RCT (Reactant); SPN (Synthetic preparation); TEM (Technical or engineered material use); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation and reaction in preparing oxonol dye for silver halide photog. materials)

RN 202482-38-0 CAPLUS

CN Pyridinium, 1-(2,4-dinitrophenyl)-4-(2,5-dioxo-1-pyrrolidinyl)-, chloride (9CI) (CA INDEX NAME)

10/574,087



● Cl⁻

RE.CNT 7

THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/574,087

L4 ANSWER 105 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1997:140310 CAPLUS

DN 126:157403

TI Preparation of benzamidoxime derivatives as cell adhesion inhibitors

IN Honda, Tadashi; Goto, Hiroyuki; Tsuji, Hiroyuki

PA Japan Tobacco Inc., Japan

SO PCT Int. Appl., 98 pp.


CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 9702245	A1	19970123	WO 1996-JP1861	19960705
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, KE, KG, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML				
	AU 9663188	A	19970205	AU 1996-63188	19960705
	JP 09071564	A	19970318	JP 1996-195544	19960705
	IN 1996CN00615	A	20050304	IN 1996-CN615	19960913
PRAI	JP 1995-195932	A	19950706		
	WO 1996-JP1861	W	19960705		
OS	MARPAT 126:157403				
IT	186650-22-6P 186650-31-7P 186650-33-9P 186650-64-6P				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of benzamidoxime derivs. as cell adhesion inhibitors)				
RN	186650-22-6 CAPLUS				
CN	Benzenecarboximidamide, 4-[1,4'-bipiperidin]-1'-yl-N-hydroxy- (CA INDEX NAME)				



RN 186650-31-7 CAPLUS

CN Benzenecarboximidamide, 4-[1,4'-bipiperidin]-1'-yl-N-hydroxy-, trihydrochloride (9CI) (CA INDEX NAME)


10/574,087



●3 HCl

RN 186650-33-9 CAPLUS

CN Benzenecarboximidamide, N-hydroxy-4-[4-(1-pyrrolidinyl)-1-piperidinyl]-, trihydrochloride (9CI) (CA INDEX NAME)




●3 HCl

RN 186650-64-6 CAPLUS


CN Benzenecarboximidamide, 4-[1,4'-bipiperidin]-1'-yl-3-bromo-N-hydroxy-, dihydrochloride (9CI) (CA INDEX NAME)

10/574,087




● 2 HCl

IT 128504-77-8P 179163-14-5P 186650-99-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of benzamidoxime derivs. as cell adhesion inhibitors)
RN 128504-77-8 CAPLUS
CN Benzonitrile, 4-[4-(1-pyrrolidinyl)-1-piperidinyl]- (CA INDEX NAME)




RN 179163-14-5 CAPLUS
CN Benzonitrile, 4-[1,4'-bipiperidin]-1'-yl- (CA INDEX NAME)



RN 186650-99-7 CAPLUS
CN Benzonitrile, 4-[1,4'-bipiperidin]-1'-yl-3-bromo- (CA INDEX NAME)

10/574,087



10/574,087

L4 ANSWER 106 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1997:55 CAPLUS

DN 126:47237

TI Preparation of N-[(acylamidino)phenyl]oxazolidinones and analogs as
adhesion receptor antagonists

IN Gante, Joachim; Juraszyk, Horst; Raddatz, Peter; Wurziger, Hanns;
Bernotat-Danielowski, Sabine; Melzer, Guido

PA Merck Patent Gmbh, Germany

SO Eur. Pat. Appl., 48 pp.

CODEN: EPXXDW

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	EP 741133	A2	19961106	EP 1996-106423	19960424
	EP 741133	A3	19970129		
	EP 741133	B1	20040128		
	R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	DE 19516483	A1	19961107	DE 1995-19516483	19950505
	TW 378205	B	20000101	TW 1996-85103612	19960326
	AT 258548	T	20040215	AT 1996-106423	19960424
	PT 741133	T	20040630	PT 1996-106423	19960424
	ES 2213758	T3	20040901	ES 1996-106423	19960424
	IN 1996CA00767	A	20050304	IN 1996-CA767	19960426
	RU 2162086	C2	20010120	RU 1996-108122	19960429
	AU 9651969	A	19961114	AU 1996-51969	19960430
	AU 708813	B2	19990812		
	PL 187000	B1	20040430	PL 1996-314044	19960430
	JP 08301857	A	19961119	JP 1996-134137	19960502
	ZA 9603535	A	19960808	ZA 1996-3535	19960503
	CA 2175767	A1	19961106	CA 1996-2175767	19960503
	NO 9601813	A	19961106	NO 1996-1813	19960503
	CN 1138037	A	19961218	CN 1996-106225	19960503
	CN 1134422	B	20040114		
	BR 9602150	A	19980630	BR 1996-2150	19960503
	HU 9601176	A2	19980728	HU 1996-1176	19960503
	US 6455529	B1	20020924	US 1996-642268	19960503
	CZ 291621	B6	20030416	CZ 1996-1295	19960503
	SK 282563	B6	20021008	SK 1996-573	19960506
PRAI	DE 1995-19516483	A	19950505		

OS MARPAT 126:47237


IT 184634-48-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-[(acylamidino)phenyl]oxazolidinones and analogs as
adhesion receptor antagonists)

RN 184634-48-8 CAPLUS

CN [1,4'-Bipiperidine]-4-carboxylic acid, 1'-[4-[(benzoylamino)iminomethyl]ph
enyl]-, ethyl ester (CA INDEX NAME)

10/574,087



L4 ANSWER 107 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1996:462227 CAPLUS

DN 125:115150

TI Cyclic hexapeptides having antibiotic activity

IN Ohki, Hidenori; Tomishima, Masaki; Yamada, Akira; Takasugi, Hisashi

PA Fujisawa Pharmaceutical Co., Ltd., Japan

SO PCT Int. Appl., 273 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9611210	A1	19960418	WO 1995-JP1983	19950929
	W: AU, CA, CN, FI, HU, JP, KR, MX, NO, RU, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2202058	A1	19960418	CA 1995-2202058	19950929
	CA 2202058	C	20071106		
	AU 9535780	A	19960502	AU 1995-35780	19950929
	AU 696949	B2	19980924		
	EP 788511	A1	19970813	EP 1995-932935	19950929
	EP 788511	B1	20021211		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	CN 1168675	A	19971224	CN 1995-196643	19950929
	JP 10507174	T	19980714	JP 1995-512472	19950929
	JP 2897427	B2	19990531		
	HU 77736	A2	19980728	HU 1998-338	19950929
	JP 10324695	A	19981208	JP 1998-136756	19950929
	JP 3518665	B2	20040412		
	RU 2165423	C2	20010420	RU 1997-107338	19950929
	AT 229541	T	20021215	AT 1995-932935	19950929
	PT 788511	T	20030430	PT 1995-932935	19950929
	ES 2187575	T3	20030616	ES 1995-932935	19950929
	IL 115484	A	20000716	IL 1995-115484	19951002
	ZA 9508458	A	19960507	ZA 1995-8458	19951006
	BR 9504791	A	19961022	BR 1995-4791	19951006
	TW 562808	B	20031121	TW 1995-84110544	19951006
	IN 1995MA01286	A	20050225	IN 1995-MA1286	19951006
	FI 9701397	A	19970527	FI 1997-1397	19970404
	NO 9701544	A	19970604	NO 1997-1544	19970404
	US 6107458	A	20000822	US 1997-809723	19970521
	HK 1004136	A1	20050826	HK 1998-103576	19980428
	US 6265536	B1	20010724	US 1999-248267	19990211
PRAI	GB 1994-20425	A	19941007		
	GB 1995-8745	A	19950428		
	JP 1996-512472	A3	19950929		
	WO 1995-JP1983	W	19950929		
	US 1997-809723	A3	19970521		

OS MARPAT 125:115150

IT 179163-14-5P 179163-79-2P 179164-29-5P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of cyclic hexapeptides active against fungi and Pneumocystis carinii)

RN 179163-14-5 CAPLUS


CN Benzonitrile, 4-[1,4'-bipiperidin]-1'-yl- (CA INDEX NAME)

10/574,087




RN 179163-79-2 CAPLUS

CN Benzoic acid, 4-[1,4'-bipiperidin]-1'-yl- (CA INDEX NAME)



RN 179164-29-5 CAPLUS

CN 1H-Benzotriazole, 1-(4-[1,4'-bipiperidin]-1'-ylbenzoyl)-, 3-oxide (9CI)
(CA INDEX NAME)



IT 179166-13-3P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of cyclic hexapeptides active against fungi and *Pneumocystis carinii*)

RN 179166-13-3 CAPLUS


CN Proline, N2-(4-[1,4'-bipiperidin]-1'-ylbenzoyl)-4,5-dihydroxyornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfoxy)phenyl]threonyl-3-hydroxyglutaminy-3-hydroxy-4-methyl-, cyclic (6→1)-peptide, monosodium salt (9CI) (CA INDEX NAME)

10/574,087

L4 ANSWER 108 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1996:251789 CAPLUS
DN 124:302279
TI Photoinduced electron transfer in isolated bichromophoric and solvated
trichromophoric systems
AU Verhoeven, J. W.; Wegewijs, B.; Hermant, R. M.; Willemse, R. J.; Brouwer,
A. M.
CS Laboratory of Organic Chemistry, University of Amsterdam, Nieuwe
Achtergracht 129, 1018 WS, Amsterdam, Neth.
SO Journal of Photochemistry and Photobiology, A: Chemistry (1996), 95(1),
3-6
CODEN: JPPCEJ; ISSN: 1010-6030
PB Elsevier
DT Journal
LA English
IT 147328-61-8 147328-62-9 166043-76-1
RL: PEP (Physical, engineering or chemical process); PRP (Properties);
PROC (Process)
(photoinduced electron transfer in isolated bichromophoric and solvated
trichromophoric systems)
RN 147328-61-8 CAPLUS
CN 1-Naphthalenecarbonitrile, 4-[(1'-phenyl[1,4'-bipiperidin]-4-
ylidene)methyl]- (CA INDEX NAME)




RN 147328-62-9 CAPLUS
CN 1-Naphthalenecarbonitrile, 4-[[1'-(4-methoxyphenyl)[1,4'-bipiperidin]-4-
ylidene)methyl]- (CA INDEX NAME)




RN 166043-76-1 CAPLUS
 CN 1-Naphthalenecarbonitrile, 4-[[1'-(4-cyclohexylphenyl)[1,4'-bipiperidin]-4-ylidene]methyl]- (CA INDEX NAME)

10/574,087

PAGE 1-A



PAGE 2-A



10/574,087

L4 ANSWER 109 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1995:846650 CAPLUS

DN 123:256532

TI Preparation of [(4-aminopiperidino)benzoyl]guanidines as Na⁺/H⁺ antiporter inhibitors

IN Gericke, Rolf; Beumgarth, Manfred; Dorsch, Dieter; Beier, Norbert; Minck, Klaus-Otto; Lues, Ingeborg

PA Merck Patent G.m.b.H., Germany

SO Eur. Pat. Appl., 16 pp.

CODEN: EPXXDW

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 667341	A1	19950816	EP 1995-101575	19950207
	EP 667341	B1	20010829		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	DE 4404183	A1	19950817	DE 1994-4404183	19940210
	AU 9511571	A	19950817	AU 1995-11571	19950206
	AU 693496	B2	19980702		
	CN 1112550	A	19951129	CN 1995-101910	19950207
	CN 1082948	B	20020417		
	SK 281721	B6	20010710	SK 1995-157	19950207
	AT 204864	T	20010915	AT 1995-101575	19950207
	ES 2161789	T3	20011216	ES 1995-101575	19950207
	PT 667341	T	20011228	PT 1995-101575	19950207
	CA 2142070	A1	19950811	CA 1995-2142070	19950208
	CZ 286681	B6	20000614	CZ 1995-327	19950208
	NO 9500485	A	19950811	NO 1995-485	19950209
	ZA 9501059	A	19951013	ZA 1995-1059	19950209
	US 5461066	A	19951024	US 1995-385790	19950209
	HU 72306	A2	19960429	HU 1995-396	19950209
	HU 215601	B	19990128		
	RU 2140412	C1	19991027	RU 1995-101843	19950209
	PL 179255	B1	20000831	PL 1995-307190	19950209
	JP 07267926	A	19951017	JP 1995-22475	19950210
	GR 3036839	T3	20020131	GR 2001-401701	20011009
PRAI	DE 1994-4404183	A	19940210		

OS MARPAT 123:256532

IT 168767-82-6P 168767-83-7P 168767-92-8P

168767-95-1P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of [(4-aminopiperidino)benzoyl]guanidines as Na⁺/H⁺ antiporter inhibitors)

RN 168767-82-6 CAPLUS


CN Benzamide, N-(aminoiminomethyl)-3-(methylsulfonyl)-4-[4-(1-pyrrolidinyl)-1-piperidinyl]- (CA INDEX NAME)

10/574,087




RN 168767-83-7 CAPLUS

CN Benzamide, N-(aminoiminomethyl)-4-[1,4'-bipiperidin]-1'-yl-3-(methylsulfonyl)- (CA INDEX NAME)



RN 168767-92-8 CAPLUS

CN Benzamide, N-(aminoiminomethyl)-4-[1,4'-bipiperidin]-1'-yl-3-(methylsulfonyl)-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 168767-95-1 CAPLUS


CN Benzamide, N-(aminoiminomethyl)-3-(methylsulfonyl)-4-[4-(1-pyrrolidinyl)-1-piperidinyl]-, dihydrochloride (9CI) (CA INDEX NAME)

10/574,087




●2 HCl

IT 168768-08-9 168768-09-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of [(4-aminopiperidino)benzoyl]guanidines as Na⁺/H⁺ antiporter inhibitors)
RN 168768-08-9 CAPLUS
CN Benzoic acid, 3-(methylsulfonyl)-4-[4-(1-pyrrolidinyl)-1-piperidinyl]-, methyl ester (CA INDEX NAME)




RN 168768-09-0 CAPLUS
CN Benzoic acid, 4-[1,4'-bipiperidin]-1'-yl-3-(methylsulfonyl)-, methyl ester (CA INDEX NAME)

10/574,087




10/574,087

L4 ANSWER 110 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1995:495397 CAPLUS
DN 123:127286
TI Reversible Charge Migration in the Excited State of an Electron
Donor-Donor-Acceptor System Detected via Delayed Charge Transfer
Fluorescence
AU Willemse, R. J.; Verhoeven, J. W.; Brouwer, A. M.
CS Amsterdam Institute of Molecular Studies, University of Amsterdam,
Amsterdam, 1018 WS, Neth.
SO Journal of Physical Chemistry (1995), 99(16), 5753-6
CODEN: JPCHAX; ISSN: 0022-3654
PB American Chemical Society
DT Journal
LA English
IT 147328-61-8 147328-62-9 166043-76-1
RL: PEP (Physical, engineering or chemical process); PROC (Process)
(photoinduced reversible intramol. electron transfer in trichromophoric
electron donor-donor-acceptor compds.)
RN 147328-61-8 CAPLUS
CN 1-Naphthalenecarbonitrile, 4-[(1'-phenyl[1,4'-bipiperidin]-4-
ylidene)methyl]- (CA INDEX NAME)




RN 147328-62-9 CAPLUS
CN 1-Naphthalenecarbonitrile, 4-[[1'-(4-methoxyphenyl)[1,4'-bipiperidin]-4-
ylidene)methyl]- (CA INDEX NAME)




RN 166043-76-1 CAPLUS
 CN 1-Naphthalenecarbonitrile, 4-[[1'-(4-cyclohexylphenyl)[1,4'-bipiperidin]-4-ylidene]methyl]- (CA INDEX NAME)

10/574,087

PAGE 1-A




PAGE 2-A




10/574,087

L4 ANSWER 111 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1994:323213 CAPLUS
DN 120:323213
TI Synthesis and exploratory photophysical investigation of
donor-bridge-acceptor systems derived from N-substituted 4-piperidones
AU Scherer, T.; Hielkema, W.; Krijnen, B.; Hermant, R. M.; Eijkelhoff, C.;
Kerkhof, F.; Ng, A. K. F.; Verleg, R.; van der Tol, E. B.; et al.
CS Lab. Org. Chem., Univ. Amsterdam, Amsterdam, 1018 WS, Neth.
SO Recueil des Travaux Chimiques des Pays-Bas (1993), 112(10), 535-48
CODEN: RTCPA3; ISSN: 0165-0513
DT Journal
LA English
OS CASREACT 120:323213
IT 154912-91-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(intermediate in preparation of donor-bridge-acceptor systems derived from
N-substituted piperidones)
RN 154912-91-1 CAPLUS
CN [1,4'-Bipiperidin]-4-one, 1'-phenyl- (CA INDEX NAME)



IT 147328-61-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation and catalytic hydrogenation of)
RN 147328-61-8 CAPLUS
CN 1-Naphthalenecarbonitrile, 4-[(1'-phenyl[1,4'-bipiperidin]-4-
ylidene)methyl]- (CA INDEX NAME)

10/574,087




IT 154913-12-9P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 154913-12-9 CAPLUS

CN 1-Naphthalenecarbonitrile, 4-[(1'-phenyl[1,4'-bipiperidin]-4-yl)methyl]-
(CA INDEX NAME)




10/574,087

L4 ANSWER 112 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1994:244687 CAPLUS
DN 120:244687
TI Preparation of 3-(4-phenylpiperidino)-4-piperidinols (azavesamicols) as
anticholinergics
IN Efange, Simon Mbua Ngale; Parsons, Stanley M.
PA University of Minnesota, USA
SO PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9324457	A1	19931209	WO 1993-US5209	19930527
	W: AU, CA, JP, KR				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 5338852	A	19940816	US 1992-893129	19920603
	AU 9345264	A	19931230	AU 1993-45264	19930527
	AU 670306	B2	19960711		
	EP 643696	A1	19950322	EP 1993-915180	19930527
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 07507547	T	19950824	JP 1993-500839	19930527
	US 5789420	A	19980804	US 1993-122159	19930917
	US 5876694	A	19990302	US 1997-905636	19970804
PRAI	US 1992-893129	A	19920603		
	WO 1993-US5209	A	19930527		
	US 1993-122159	A3	19930917		
OS	MARPAT 120:244687				
IT	153969-63-2P 153969-64-3P				
	RL: SPN (Synthetic preparation); PREP (Preparation)				
	(preparation of, as anticholinergic)				
RN	153969-63-2 CAPLUS				
CN	[1,4'-Bipiperidin]-3'-ol, 1'-(4-nitrophenyl)-4-phenyl-, trans- (9CI) (CA INDEX NAME)				


Relative stereochemistry.



RN 153969-64-3 CAPLUS
CN [1,4'-Bipiperidin]-3'-ol, 1'-(4-nitrophenyl)-4-phenyl-, monohydrochloride,
trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.


10/574,087



10/574,087


L4 ANSWER 113 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1993:408659 CAPLUS
DN 119:8659
TI Nonsymmetrical bipiperidyls as inhibitors of vesicular acetylcholine storage
AU Efange, S. M. N.; Khare, A.; Parsons, S. M.; Bau, R.; Metzenthin, T.
CS Dep. Radiol., Univ. Minnesota, Minneapolis, MN, 55455, USA
SO Journal of Medicinal Chemistry (1993), 36(8), 985-9
CODEN: JMCMAR; ISSN: 0022-2623
DT Journal
LA English
IT 153969-63-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and vesicular acetylcholine storage inhibitory activity of)
RN 153969-63-2 CAPLUS
CN [1,4'-Bipiperidin]-3'-ol, 1'-(4-nitrophenyl)-4-phenyl-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



10/574,087


L4 ANSWER 114 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1993:233400 CAPLUS
DN 118:233400
TI Two-step sequential light-induced electron transfer in a simple
trichromophoric donor-donor-acceptor system
AU Brouwer, A. M.; Eijkelhoff, C.; Willemse, R. J.; Verhoeven, J. W.;
Schuddeboom, W.; Warman, J. M.
CS Lab. Org. Chem., Univ. Amsterdam, Amsterdam, 1018 WS, Neth.
SO Journal of the American Chemical Society (1993), 115(7), 2988-9
CODEN: JACSAT; ISSN: 0002-7863
DT Journal
LA English
IT 147328-61-8
RL: PRP (Properties)
(fluorescence of, solvent effect on)
RN 147328-61-8 CAPLUS
CN 1-Naphthalenecarbonitrile, 4-[(1'-phenyl[1,4'-bipiperidin]-4-
ylidene)methyl]- (CA INDEX NAME)



IT 147328-62-9
RL: PRP (Properties)
(sequential photochem. electron transfer in)
RN 147328-62-9 CAPLUS
CN 1-Naphthalenecarbonitrile, 4-[[1'-(4-methoxyphenyl)[1,4'-bipiperidin]-4-
ylidene)methyl]- (CA INDEX NAME)

10/574,087

PAGE 1-A




PAGE 2-A



10/574,087

L4 ANSWER 115 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1993:22147 CAPLUS
DN 118:22147
TI Preparation of 1-phenyl-4-amino-piperidines and analogs as antiarrhythmics
and psychotropics
IN Lubisch, Wilfried; Schult, Sabine; Behl, Berthold; Kirchengast, Michael
PA BASF A.-G., Germany
SO Eur. Pat. Appl., 21 pp.
CODEN: EPXXDW
DT Patent
LA German
FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	EP 503411	A1	19920916	EP 1992-103514	19920229
	EP 503411	B1	19951129		
	R: AT, BE, CH, DE, DK, FR, GB, IT, LI, NL, SE				
	DE 4117904	A1	19921203	DE 1991-4117904	19910531
	AT 130851	T	19951215	AT 1992-103514	19920229
	US 5296485	A	19940322	US 1992-849250	19920311
	CA 2063030	A1	19920915	CA 1992-2063030	19920313
	CA 2063030	C	20020326		
	JP 05078316	A	19930330	JP 1992-55006	19920313
	JP 3058746	B2	20000704		
PRAI	DE 1991-4108184	A	19910314		
	DE 1991-4117904	A	19910531		
OS	MARPAT 118:22147				
IT	144872-20-8P 144872-22-0P 144872-23-1P				
	144872-29-7P 145088-96-6P				
	RL: SPN (Synthetic preparation); PREP (Preparation)				
	(preparation of, as antiarrhythmic and psychotropic)				
RN	144872-20-8 CAPLUS				
CN	[1,4'-Bipiperidin]-4-ol, 4-(4-chlorophenyl)-1'-(4-nitrophenyl)- (CA INDEX NAME)				



10/574,087


RN 144872-22-0 CAPLUS

CN 1,4'-Bipiperidine, 1'-(4-nitrophenyl)-4-phenyl- (CA INDEX NAME)



RN 144872-23-1 CAPLUS


CN Benzenamine, 4-(4-phenyl[1,4'-bipiperidin]-1'-yl)- (CA INDEX NAME)



RN 144872-29-7 CAPLUS

CN 1,4'-Bipiperidine, 1'-(4-chlorophenyl)-4-phenyl- (CA INDEX NAME)

10/574,087




RN 145088-96-6 CAPLUS

CN Pyridine, 4-(4-fluorophenyl)-1,2,3,6-tetrahydro-1-[1-(4-nitrophenyl)-4-piperidinyl]-, (2E)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 145088-95-5

CMF C22 H24 F N3 O2




CM 2

CRN 110-17-8

CMF C4 H4 O4


10/574,087

Double bond geometry as shown.



10/574,087


L4 ANSWER 116 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1991:523604 CAPLUS
DN 115:123604
TI Charge separation in the excited state of electron donor-acceptor
compounds containing the piperazine moiety
AU Brouwer, A. M.; Mout, R. D.; Maassen van den Brink, P. H.; Van Ramesdonk,
H. J.; Verhoeven, J. W.; Warman, J. M.; Jonker, S. A.
CS Lab. Org. Chem., Univ. Amsterdam, Amsterdam, 1018 WS, Neth.
SO Chemical Physics Letters (1991), 180(6), 556-62
CODEN: CHPLBC; ISSN: 0009-2614
DT Journal
LA English
IT 135804-40-9
RL: PRP (Properties)
(optical absorption spectrum of, charge-separation in excited state of
electron donor-acceptor compds. containing piperazine group in relation to)
RN 135804-40-9 CAPLUS
CN 1,4'-Bipiperidine, 1'-phenyl-, radical ion(1+) (9CI) (CA INDEX NAME)



10/574,087


L4 ANSWER 117 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1990:478169 CAPLUS
DN 113:78169
TI Preparation of 1-substituted-4-pyrrolidinopiperidines as inhibitors of
interleukin 1
IN Skotnicki, Jerauld S.
PA American Home Products Corp., USA
SO U.S., 5 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 4902800	A	19900220	US 1988-233187	19880817
PRAI	US 1988-233187		19880817		
OS	CASREACT 113:78169; MARPAT 113:78169				
IT	128504-77-8P 128504-78-9P				
	RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of, as antiinflammatory)				
RN	128504-77-8 CAPLUS				
CN	Benzonitrile, 4-[4-(1-pyrrolidinyl)-1-piperidinyl]- (CA INDEX NAME)				



RN 128504-78-9 CAPLUS
CN Piperidine, 1-[4-(methylsulfonyl)phenyl]-4-(1-pyrrolidinyl)- (CA INDEX NAME)

10/574,087



10/574,087

L4 ANSWER 118 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1976:543094 CAPLUS

DN 85:143094

OREF 85:22940h,22941a

TI Trialkylsilyl esters of 6-(substituted amino)phenyl-1, dihydro-2-oxonicotinic acid and conversion to the corresponding acid chlorides

IN Goel, Om P.

PA Parke, Davis and Co., USA

SO U.S., 9 pp.


CODEN: USXXAM

DT Patent

LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 3951982	A	19760420	US 1974-526017	19741121
PRAI	US 1974-526017	A	19741121		
IT	56915-99-2P 56916-03-1P				
	RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)				
RN	56915-99-2 CAPLUS				
CN	3-Pyridinecarbonitrile, 6-(4-[1,4'-bipiperidin]-1'-ylphenyl)-1,2-dihydro-2-oxo- (CA INDEX NAME)				



RN 56916-03-1 CAPLUS


CN 3-Pyridinecarbonitrile, 1,2-dihydro-2-oxo-6-[4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]- (CA INDEX NAME)



10/574,087

L4 ANSWER 119 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1976:508683 CAPLUS
DN 85:108683
OREF 85:17452h,17453a
TI Antibacterial amide compounds
IN Doub, Leonard; Kaltenbronn, James S.; Schweiss, Dieter
PA Parke, Davis and Co., USA
SO U.S., 27 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 3954734	A	19760504	US 1974-534031	19741223
	ZA 7500046	A	19760825	ZA 1975-46	19750102
	BE 824579	A1	19750515	BE 1975-152538	19750120
	SE 7500570	A	19750722	SE 1975-570	19750120
	NL 7500645	A	19750723	NL 1975-645	19750120
	JP 50106995	A	19750822	JP 1975-8596	19750120
	DK 7500149	A	19750922	DK 1975-149	19750120
	FR 2263764	A1	19751010	FR 1975-1608	19750120
	AT 7500364	A	19760915	AT 1975-364	19750120
	AT 336788	B	19770525		
	GB 1464525	A	19770216	GB 1975-2461	19750120
	ES 433981	A1	19770301	ES 1975-433981	19750120
	AU 7577676	A	19760729	AU 1975-77676	19750129
	US 4053470	A	19771011	US 1976-650098	19760119
	AT 7602182	A	19770215	AT 1976-2182	19760325
	AT 339482	B	19771025		
	ES 448721	A1	19770716	ES 1976-448721	19760610
PRAI	US 1974-434763	A2	19740121		
	US 1974-534031	A3	19741223		
	AT 1975-364	A	19750120		
IT	60282-97-5				
	RL: RCT (Reactant); RACT (Reactant or reagent) (acylation by, of ampicillins)				
RN	60282-97-5 CAPLUS				
CN	3-Pyridinecarbonyl chloride, 6-(4-[1,4'-bipiperidin]-1'-ylphenyl)-1,2-dihydro-2-oxo-, monohydrochloride (9CI) (CA INDEX NAME)				



● HCl

IT 56915-21-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

10/574,087


(preparation and bactericidal activity of)

RN 56915-21-0 CAPLUS

CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[[[6-(4-[1,4'-bipiperidin]-1'-ylphenyl)-1,2-dihydro-2-oxo-3-pyridinyl]carbonyl]amino]phenylacetyl]amino]-3,3-dimethyl-7-oxo-, monosodium salt, [2S-[2 α ,5 α ,6 β (S*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



● Na

PAGE 1-B

— Me

... CO₂H

IT 56915-99-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and hydrolysis of)

RN 56915-99-2 CAPLUS


CN 3-Pyridinecarbonitrile, 6-(4-[1,4'-bipiperidin]-1'-ylphenyl)-1,2-dihydro-2-oxo- (CA INDEX NAME)

N#Cc1ccc(cc1C2=CN(C(=O)N2)c3ccc(cc3)N4CCCCC4)N5CCCCC5

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[[[6-(4-[1,4'-bipiperidin]-1'-ylphenyl)-1,2-dihydro-2-oxo-3-pyridinyl]carbonyl]amino]phenyl]acetyl]amino]-3,3-dimethyl-7-oxo-, [2S-[2 α ,5 α ,6 β (S*)]]- (9CI) (CA INDEX NAME)

PAGE 1-A




— Me

 CO_2H


10/574,087

L4 ANSWER 120 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1975:564214 CAPLUS
DN 83:164214
OREF 83:25775a,25778a
TI Modified antibiotics
IN Doub, Leonard; Kaltenbronn, James S.; Schweiss, Dieter
PA Parke, Davis and Co., USA
SO Ger. Offen., 86 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 2


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2502119	A1	19750724	DE 1975-2502119	19750120
	ZA 7500046	A	19760825	ZA 1975-46	19750102
	BE 824579	A1	19750515	BE 1975-152538	19750120
	SE 7500570	A	19750722	SE 1975-570	19750120
	NL 7500645	A	19750723	NL 1975-645	19750120
	JP 50106995	A	19750822	JP 1975-8596	19750120
	DK 7500149	A	19750922	DK 1975-149	19750120
	FR 2263764	A1	19751010	FR 1975-1608	19750120
	AT 7500364	A	19760915	AT 1975-364	19750120
	AT 336788	B	19770525		
	GB 1464525	A	19770216	GB 1975-2461	19750120
	ES 433981	A1	19770301	ES 1975-433981	19750120
	AU 7577676	A	19760729	AU 1975-77676	19750129
	AT 7602182	A	19770215	AT 1976-2182	19760325
	AT 339482	B	19771025		
	ES 448721	A1	19770716	ES 1976-448721	19760610
PRAI	US 1974-434763	A	19740121		
	AT 1975-364	A	19750120		
IT	56915-99-2P 56916-03-1P				
	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)				
	(preparation and hydrolysis of)				
RN	56915-99-2 CAPLUS				
CN	3-Pyridinecarbonitrile, 6-(4-[1,4'-bipiperidin]-1'-ylphenyl)-1,2-dihydro-2-oxo- (CA INDEX NAME)				



RN 56916-03-1 CAPLUS
CN 3-Pyridinecarbonitrile, 1,2-dihydro-2-oxo-6-[4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]- (CA INDEX NAME)



IT	56915-19-6P RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation and reaction of, with penicillin and cephalosporin derivs.)
RN	56915-19-6 CAPLUS
CN	3-Pyridinecarbonyl chloride, 6-(4-[1,4'-bipiperidin]-1'-ylphenyl)-1,2- dihydro-2-oxo-, hydrochloride (9CI) (CA INDEX NAME)




```

IT      56915-20-9P 56915-21-0P
        RL: SPN (Synthetic preparation); PREP (Preparation)
          (preparation of)
RN      56915-20-9  CAPLUS
CN      4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[[[6-(4-[1,4'-
        bipiperidin]-1'-ylphenyl)-1,2-dihydro-2-oxo-3-
        pyridinyl]carbonyl]amino]phenyl]acetyl]amino]-3,3-dimethyl-7-oxo-,
        [2S-[2 $\alpha$ ,5 $\alpha$ ,6 $\beta$ (S*)]]- (9CI) (CA INDEX NAME)

```

PAGE 1-A



10/574,087

PAGE 1-B

— Me


... CO₂H

RN 56915-21-0 CAPLUS

CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[[[6-(4-[1,4'-bipiperidin]-1'-ylphenyl)-1,2-dihydro-2-oxo-3-pyridinyl]carbonyl]amino]phenylacetyl]amino]-3,3-dimethyl-7-oxo-, monosodium salt, [2S-[2 α ,5 α ,6 β (S*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



● Na


PAGE 1-B

— Me


... CO₂H

10/574,087

L4 ANSWER 121 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1944:516 CAPLUS
DN 38:516
OREF 38:100i,101a-i,102a-c
TI Substituted 4-aminopiperidines. III
AU Hahn, V.; Cerkovnikov, E.; Prelog, V.
SO Helvetica Chimica Acta (1943), 26, 1132-42
CODEN: HCACAV; ISSN: 0018-019X
DT Journal
LA Unavailable
OS CASREACT 38:516
IT 855253-86-0, 1,4'-Bipiperidine, 1'-p-tolyl-
(and derivs.)
RN 855253-86-0 CAPLUS
CN 1,4'-Bipiperidine, 1'-p-tolyl- (4CI) (CA INDEX NAME)



IT 855253-87-1, 1,4'-Bipiperidine, 1'-(p-hydroxyphenyl)-
(derivs.)
RN 855253-87-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




IT 861019-48-9P, Picrolonic acid, compound with 1'-(2,4-xylyl)-1,4'-
bipiperidine
RL: PREP (Preparation)
(preparation of)
RN 861019-48-9 CAPLUS
CN Picrolonic acid, compd. with 1'-(2,4-xylyl)-1,4'-bipiperidine (4CI) (CA
INDEX NAME)

CM 1

CRN 861019-47-8
CMF C18 H28 N2


10/574,087



CM 2


CRN 550-74-3

CMF C10 H8 N4 O5




10/574,087

L4 ANSWER 122 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1943:37801 CAPLUS
DN 37:37801
OREF 37:6033a-e
TI Pharmacology of N-phenyl-4-dimethylaminopiperidine and related compounds
AU Stern, Pavao
SO Archiv fuer Experimentelle Pathologie und Pharmakologie (1942), 199,
251-64
CODEN: AEXPBL; ISSN: 0365-2041
DT Journal
LA Unavailable
IT 876611-69-7P, 1,4'-Bipiperidine, 1'-phenyl-
RL: PREP (Preparation)
(preparation of)
RN 876611-69-7 CAPLUS
CN 1,4'-Bipiperidine, 1'-phenyl- (CA INDEX NAME)



10/574,087

L4 ANSWER 123 OF 123 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1943:588 CAPLUS
DN 37:588
OREF 37:126h-i,127a-d
TI A new series of spasmolytic compounds. The substituted 4-aminopiperidines.
II
AU Hahn, Viktor; Cerkovnikov, Eugen; Prelog, Vlado
SO Berichte der Deutschen Chemischen Gesellschaft [Abteilung] B: Abhandlungen
(1941), 74B, 1658-60
CODEN: BDCBAD; ISSN: 0365-9488
DT Journal
LA Unavailable
IT 876611-69-7, 1,4'-Bipiperidine, 1'-phenyl-
(and derivs.)
RN 876611-69-7 CAPLUS
CN 1,4'-Bipiperidine, 1'-phenyl- (CA INDEX NAME)



10/574,087

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

462.69

641.72

STN INTERNATIONAL LOGOFF AT 09:44:53 ON 21 JAN 2008